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Abstract

DEVELOPMENT OF IRREVERSIBLE SUBSTRATE COMPETITIVE PROBES FOR PKA
ACTIVITY
By Robert A. Coover, Ph.D.
A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor of
Philosophy at Virginia Commonwealth University.
Virginia Commonwealth University, 2015.
Major Director: Keith C. Ellis Assistant Professor, Department of Medicinal Chemistry

The current environment for drug discovery and disease treatment relies heavily on
genomic analysis, structural biology and chemical biology techniques. With the enormous
advances in genomic analysis and structural biology, the use of and desire for targeted therapies
has increased. However, as more genomic data for cancer disease state pathology becomes
available we must ask increasingly difficult questions and even produce new technologies, such
as activity-based probes, to answer these questions.
In particular, targeted kinase inhibitors for the treatment of cancer has become a mainstay
for drug development for both industry and academia, but it is evident that the genomic data is
not always indicative of protein expression. Additionally, protein expression alone does not
completely characterize functional activity. Therefore, in order to more accurately validate drug
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targets and predict drug efficacy, we must not only identify possible targets but also determine
their activity in vivo.
The goal of this work was to develop a probe for Protein Kinase A that would act by
alkylating a conserved cysteine in the substrate-binding pocket of the enzyme. We hypothesized
that by targeting the substrate-binding pocket we could effectively utilize the natural substrate
selectivity filters as well as take into account multiple endogenous regulatory mechanisms. We
produced probes utilizing portions of the pseudosubstrate inhibitor PKI that demonstrate the
ability to label the catalytic subunit of Protein Kinase A in an activity-dependent manner, thus
making it an important first step in a new class of activity-based probes for the kinome.
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Chapter 1: Introduction
1.1: Proteomics
The sequencing of the human genome has yielded a complete image of the possible
products of gene expression in the body.1 As the technology has advanced, sequencing has been
increasingly used to characterize disease states with fascinating results. However, the genomic
data does not always directly correlate to the phenotype.2,3 Which is partly due to the genotype
not always being indicative of the cellular environment, especially the post-translational
modifications that may occur.2 This is particularly true in human malignancies, where multiple
genetics mutations may provide phenotypes with increased survival advantages that result from
downstream effects.4
In general, the field of proteomics seeks to determine actual protein amounts and general
characteristics of the phenotype.5 Proteomic data can be acquired in a multitude of ways, ranging
from qualitative to quantitative analysis.6,7 Important tools and technologies available for
proteomic analysis are continuously improved upon and invented. However, some mainstay
technologies and techniques are: molecular probes, gel electrophoresis, chromatography, mass
spectrometry, and immunochemistry. It is only through the appropriate execution of these
experiments and expert interpretation that the data obtained gains significant value.
Proteomics has influenced oncology for many decades, with examples dating back to the
early twentieth century where researchers analyzed blood plasma by gel electrophoresis to link
increased protein expression with the cancer phenotype.8 Since early publication such as this,
proteomics has been utilized in various ways to delineate the cancer disease state.8,9 While this
information is very useful, it does not have the level of detail required to link protein activity
with expression. This disconnect has provided a new frontier for characterizing phenotypic
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function in diseased states thus expanding traditional proteomics to include a new area known as
chemical proteomics.10
1.2: Chemical Proteomics
In the field of proteomics, the gap of data between protein levels and functions has
formed a specialized application. That is, activity-based proteomics, or chemical proteomics.
Activity-based proteomics utilizes small molecules, known as activity-based probes (ABPs), to
selectively react with a residue only in the active form of an enzyme.11-13 This selective reactivity
enables tagging of enzymes exclusively in their active state for analysis. This direct measurement
technique allows the quantification of aberrantly active enzymes and can help to identify novel
drug targets, inhibitors, and relevant pathways. Clarifying the relationship of expression and
activity is the major task of activity-based proteomics, the process of conducting such
experiments with an ABP is known as activity-based protein profiling (ABPP).14-17
1.2.1: Activity-Based Probes
To conduct ABPP, an activity-based probe must be developed, and there are many
criteria and factors to consider. Activity based probes (ABPs) must be covalent inhibitors and
selective for the active form of the enzyme. For different classes of enzyme, there are different
approaches to achieve this type of selectivity.18-21 Identifying a mechanism of action that will
allow a probe to label in an activity-dependent manner is the first step. With some enzyme
classes, this challenge is more obvious than with others. The cysteine proteases, for example,
have a nucleophilic cysteine in the active-site that is critical for activity. This active site not only
serves as an important location to target, but by its nature will yield an inhibitor that behaves in
an activity dependent manner.20 In general, kinases do not utilize a nucleophilic amino acid for
phosphoryl transfer, this in turn provides a challenge for developing an activity-based probe. The
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few examples of known ABPs in the kinome target a cysteine that is found in the ATP-binding
pocket. While these cysteines do not directly participate in catalysis, their alkylation causes
inhibition of the enzyme. It is also suggested that by binding in the nucleotide binding site they
are acting in an activity-dependent manner. While this approach has proved valuable for
developing ABPs and irreversible inhibitors for a number of kinases, the bulk of the kinome
remains without such probes.17 This is in part due to the conservation of nucleotide binding
pockets across not only the kinome but the entire proteome. Therefore, we set out to develop a
new strategy to target kinases in an activity-dependent manner that does not rely on targeting the
ATP-binding site (see Chapter 3).

Tag

Linker

Warhead

Figure 1: Major components of an activity-based probe (ABP).

ABPs consist of three major components (Figure 1). First, there is a reactive moiety
(electrophile) i.e., warhead, for selective covalent modification of the desired residue. These
electrophiles can range from moieties geared towards specific side chains containing nitrogen,
sulfur, or oxygen to actual substrates that become covalently attached when the enzyme acts
upon it (Table 1). Selection of the electrophile is an important decision when designing a probe.
Some of the major considerations one should factor is whether their goal is to produce a family
selective or a target selective probe. If the goal is to develop a family selective probe, the
warhead is selected solely on selective reactivity. The acyloxymethylketone (AOMK) moiety is a
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prime example of a reactive moiety being selected to produce a family selective ABP. It is a very
selective electrophile, and inherently only weakly electrophilic. Only by placement in close
proximity to the nucleophilic residue does the reaction occur (in biological systems). The
halomethylketone moieties have seen widespread application, their reactivity can be attenuated
significantly by the leaving group halogen. Iodomethyl ketone for example is not an ideal
electrophile for developing a selective ABP because it is very reactive towards cysteine (and
other nucleophilic residues). However, iodomethyl ketone has been appended onto a generic
scaffold and used in conjunction with click chemistry to characterize the cysteinome. Similarly,
the bromomethyl ketone is generally too reactive for the development of a selective ABP. The
chloromethyl ketone can be utilized in a variety of different applications. For instance,
chloromethyl ketones are a primary ingredient in protease inhibitor cocktails. In contrast to the
iodo- bromo- and chloromethyl ketone is the fluoromethyl ketone which has a significantly
reduced reactivity profile.
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Table 1: Representative selective electrophiles

F

O
R

O

R

O
Acyloxymethylketone

O

R

Epoxide

R

S

Methylvinylsulfone

O
O
F
Phenoxymethylketone

O

O

R

R

O

O
S

O
R

Fluorophosphonate

X

F
Sulfonate-ester

O
R

R

N
H
Acrylamide

Halomethylketone

R

R

O
N

O
Maleimide

Vinylketone

X

N
H

Chloro/Iodoacetamides

O

O

O

O

F

O
P F
O

R
Propargyl Ketone

Second, there must be a linker, or recognition sequence, to connect the warhead and tag.
The difference between the two can be reduced to whether your probe is selective for a family of
proteins or a single target. In general, a generic hydrocarbon linker is chosen when the purpose is
to develop a family selective ABP (Figure 2, FP-biotin). With a linker the most important
variables are length and desired physical properties (if required for solubility/cell permeability).
The recognition sequence provides the greatest selectivity as it serves as the primary scaffold and
can have the greatest variability and this is utilized when the desired outcome is a target selective
ABP (Figure 2, fmk-pa).10 The scaffold can and should be optimized to have greater affinity and
selectivity than a simple linker.22 Common examples of recognition sequences include small
molecules, peptide substrate sequences (proteases), and adenosine triphosphate (ATP) analogues
(kinases).
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Recognition Scaffold
Linker
NH 2

O
F P

Warhead

O

N
N

Tag

Biotin N
H
Tag

F

N
O

N
H

Warhead
fmk-pa

FP-biotin

Figure 2: Activity-based probes with different linker styles, family and target selective.

The final requirement is a detectable tag for quantification. Selection of a tag is generally
limited to fluorescent, affinity, and click based tags (Figure 3, 4). There are many fluorescent
options available and are quite often dependent on the selected system. For example, when
examining isolated proteins or lysates by gel electrophoresis, one does not need to consider cell
permeability or background fluorescence. In such a case, generic rhodamine or rhodamine
derivative is acceptable. However, if the probe is destined for use in vivo, a fluorophore such a
BODIPY should be considered due to its physical properties allowing for cell permeability.
Additional probes with varying absorption and emission properties are commercially available,
allowing a researcher to select Stoke shift values, wavelengths, and quantum yields. Having
appropriately tailored fluororphores is particularly important when FRET based applications are
to be considered.
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OH
O

N

O

N

N
F

B

N
F

BODIPY

Rhodamine

Click

Figure 3. Representative fluorophores and a click handle.

Affinity tags can also vary greatly. Deciding on an affinity tag relies heavily on the
application. For small molecule/probe development, biotin is the most commonly used affinity
handle (Figure 4). This is due to its favorable size and known high affinity for streptavidin.
Biotin is also easily appended onto a peptide or small molecule by simple chemical
transformations and its solubility can be attenuated for different labeling applications. Other
affinity tags may take the form as short peptides and quite often are used on the target itself and
not the probe: histidine (His tag), Myc tag, human influenza hemagglutinin (HA tag), and etc.
(see Figure 4). These may be appended by chemical or biological methods and offer high
selectivity; however, size/steric bulk becomes an issue when attempting to use the peptide-based
affinity tags.
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O
HN
H
HHHHHH

EQKLISEEDL

NH
H
OH

S
O

Histidine Tag

C-Myc Tag

D-biotin

Click

Figure 4: Representative affinity labels and click handle.

1.3: Irreversible Inhibitors of the Kinome
The beginnings of an activity-based probe lay within the development of irreversible
inhibitors. The development of selective irreversible inhibitors is a critical first step in the
production of an activity-based probe, because one of the requirements for ABPP is that the ABP
be irreversible. The kinome is one of the most numerous and varied class of enzymes found in
nature. Kinases catalyze the transfer of a phosphate group from a nucleotide to a substrate. This
post-translational modification has significant effects on cell signaling, phenotype, and disease
state. This central role to the basic foundations of life have caused many kinases to be the center
of drug discovery efforts.17 The vast majority of kinase inhibitors are competitive inhibitors of
the ATP-binding pocket, which is highly conserved.23 Because of this conserved binding site and
mechanism of action by the inhibitors, off-target activity is always a consideration. There is a
concerted effort to develop selective inhibitors by capitalizing on different mechanisms of action
for inhibition. Of particular interest is the focus on the irreversible targeting of cysteines in the
kinome.
Targeting cysteines for the regulation of kinase activity has long been used, if not well
understood. Numerous examples exist dating back long before their binding mechanisms were
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fully developed. These range from allosteric to orthosteric cysteine alkylating compounds. The
solution of many crystal structures has enabled a structure-based design push for selective kinase
inhibitors. The interest in irreversible kinase inhibitors has increased, and the most prevalent
approach in the literature utilizing a nucleophilic cysteine is a strategy that targets the ATPbinding site (Table 2). Through the use of multiple selectivity filters, residue binding
interactions, gatekeeper interactions, and location of the target cysteines, a significant number of
irreversible inhibitors for the kinome, many with clinical relevance, have been produced. Indeed,
many screening platforms have been developed to determine off-target activity/selectivity for the
kinome. However, the development of selective kinase inhibitors has only been completed for a
small fraction of the kinome.
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Table 2: Examples of irreversible kinase inhibitors (green are natural products, blue have been
further developed into ABPs, and black are generic Type I irreversible inhibitors).

O

N
HO

N

HN

OH O
O

H
N

O

N

H
N
O

N
H

PD168393

O

O

JH295
F

OH O
OHO

OHO
O

O

O

O
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Cl

HN

N
H

OH

OH

HO
Hypothemycin

N
H

N

JNK-IN-8

OH O

OH O

N
H
O

HN

N

O
Lactoquinomycin

N

O

Br

O

O

O

HN

5Z-7-oxozeaenol

N

O
O

OH

E6201

N

O

N

Cl-1033

Cl
O

S

HN

O

N

N

O
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O
Berberine
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HN

O

HN

N

O

O
N
H

N
H

O

O
N
H

Cl

O

Br

N

O

S

O

N

GSK-3b inhibitor (compound 5)

VEGFR inhibitor (compound 1)

c-Src inhibitor (compound 8)

Cl

Br

O
Cl
N

O

O

NH 2

N

HO

N

NH 2

N

OH

N

N
N

N
O

OH

F

PGA 1

FMK

O

HN

N
H

N
N

N

O
O

Cl

O

H
N
O

NEt 2
PCI-32765

FIIN-1

The prevailing strategy for the development of irreversible kinase inhibitors is producing
a number of Type I inhibitors. Many reversible inhibitors that bind in the ATP-binding pocket
with a known cysteine in close proximity have been altered with medicinal chemistry techniques
to produce irreversible inhibitors. This successful approach has resulted in major efforts to
develop new strategies for producing irreversible kinase inhibitors. The current set of cysteines
being actively targeted reside in four distinct positions within the ATP-binding pocket: roof
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region, DFG region, glycine-rich loop region, and the hinge binding region. Each of these
regions has examples of being targeted by irreversible kinase inhibitors; however, some are more
effective than others. This set of irreversible kinase inhibitors that bind exclusively to the ATPbinding pocket, and are competitive with ATP, are known as Type I binding inhibitors.
Diverse examples exist in the literature of type I cysteine modifying inhibitors of the
kinome that target each of the four cysteines. Dual specificity mitogen-activated protein kinase 7
(MAP2K7) is involved in mitochondrial cell death and its inhibition has been of interest. The
inhibitor 5Z-7-Oxozeaenol (5Z7O, Table 2) has been demonstrated to inhibit MAP2K7 in a Type
I binding mechanism by crystallography and shown to alkylate Cys218, which is located at the
outskirts of the hinge region.24 It was also pointed out that there are 11 such similar cysteines in
the kinome, i.e., this conserved cysteine is also targeted by EGFR, Nek2, KDR, IKKb, ITX,
BMX, JMK1-3, and BTK inhibitors.25 A cysteine located in the β-strand (DFG region) is
targeted by the activity-based probe “FMK” for the kinase RSK.26 Similar cysteines in the βstrand have been targeted effectively against TAK1, ERK2, GSK3b, and MEK1.27-29 Cysteines
located in the glycine-rich loop region have been effectively targeted against FGFR1-4 and have
been the subject of ABPP.30,31 A cysteine identified in the roof region has been targeted in Her2
and has shown increased efficacy over reversible inhibitors. This strategy has thus far proven
effective at producing efficacious kinase inhibitors with the potential for turning into ABPs.17
However, selectivity does continue to be an issue that requires additional binding interactions to
address.25
Much effort has since been put forth to develop Type II inhibitors. Type II inhibitors also
bind to the ATP-binding pocket and take advantage of the DFG-out configuration. It has been
demonstrated that, by utilizing the additional binding interactions from the DFG-out
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configuration as a selectivity filter, increased-kinome wide selectivity can be achieved.28 This
approach has also found applications in the production of irreversible kinase inhibitors, as Type
II inhibitors have been altered with medicinal chemistry techniques to produce cysteine
alkylating Type II inhibitors.28 These representative examples have produced highly selective
and efficacious inhibitors but their application to the kinome is limited and certainly would not
be applicable as an ABP, as the DFG-out configuration is inactive. Targeting other cysteines
outside of the ATP-binding pocket would provide a route to produce inhibitors with access to
more kinases. Type III inhibitors (allosteric inhibitors) have had sporadic success as reversible
inhibitors, and few examples (if any) exist that conclusively display irreversible inhibition that is
also saturable.32
Substrate competitive, or type IV binding, irreversible inhibitors are becoming more
prominent, as it is suggested that the natural selectivity filters involved with the substrate-binding
site will provide similarly increased selectivity in complex biological mixtures.33 Many examples
exist and a predominant case is with Protein Kinase B (PKB, or AKT). AKT has been the subject
of numerous inhibition studies for various disease implications, most notably cancer. AKT1 has
a number of solvent exposed cysteine residues that when alkylated modulate activity, most
notably Cys310 in the substrate-binding site, specifically the activation loop (or T-loop). This
particular cysteine has been demonstrated to be alkylated by peptidomimmetic compounds
(TPCK, Boc-Phe-VK), and natural products (lactoquinomycin, wortmanin, and berberine); upon
alkylation, inhibition of catalytic activity is resultant.34-36
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Figure 5: Peptide-based inactivators of PKB by a Type IV binding mechanism.

Protein Kinase A (PKA, or cAMP-dependent protein kinase) is the prototype kinase and
has been the first in many regards for various studies and is the target of this thesis. The pathway
to the development of an ABP goes through irreversible inhibitor design, and a thorough
knowledge of the available data on irreversible inhibition of your target is required to avoid
repetitious results therefore a brief overview of Type IV inhibitors of the prototype kinase is
below.
Protein Kinase A (PKA) is the prototype kinase with two cysteine residues that have been
thoroughly investigated throughout the years, and one in particular has been shown to modulate
catalytic activity: Cys199.37-41 Cys199 is located in the substrate-binding pocket, specifically the
activation loop (T-loop) and alkylating or oxidizing this residue inhibits catalytic activity.42,43
Cys199 has been shown to be nucleophilic and react with a variety of different electrophiles and
inhibitors. Taylor and colleagues demonstrated that oxidation at Cys199 by glutathione was a
endogenous regulatory mechanism.37 Additionally, in separate studies conducted by Taylor,
Cys199 was alkylated by Michael acceptors, sulfhydryl moieties, and halomethyl ketones
(Figure 6).44-46 More early (1982) work by Taylor and colleagues, produced a peptide based
affinity probe that formed a disulfide bond with Cys199; this probe contained the sequence
LRRACLG with the cysteine oxidized with Npys so that it will selectively oxidize Cys199
(Figure 7).44
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Figure 7: First designed irreversible peptide-based inactivator of PKA

A number of other groups have also taken advantage of the substrate-binding pocket and
the nucleophilic cysteine located in the activation loop. Shaltiel and colleagues used a
combination of known amino acid substrate sequences to hypothesize that: 1) both a basic and
hydrophobic moiety, 2) or only the basic moiety were important recognition elements, and that
by producing these one would develop an active site directed labeling compound.47 They
examined the inhibitory effects of Nα-tosyl-L-lysine chloromethyl ketone (TLCK) and Nα-tosylL-phenylalanine chloromethyl ketone (TPCK) to test this hypothesis (Figure 8).
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It was

determined that both labeled Cys199 and inactivated PKACα by this mechanism, and reagents
such as chloroacetamide and chloroacetic acid did not. This was important early work in
characterizing not only the promiscuity of previously thought to be selective trypsin and
chymotrypsin inhibitors, but in mapping the active site of PKA. It is important to note however,
that their labeling was greatly affected by their simulated biological conditions. Specifically, it
was noted that when MgATP was added to their labeling conditions, inactivation of PKACα was
prevented.47 In another publication it was demonstrated that this could be an additional
regulatory mechanism in which substrate specificity is altered by the immediate environment of
the cell (a type of reversible spatial regulation). Finally, the reactivity of the sulfhydryl groups in
response to these stimuli was determined, and it was indeed affected greatly.48
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Figure 8: Inhibitors used by Shaltiel et al to characterize the active site of PKA.

E. T. Kaiser (1938-1988) also pioneered significant early work with PKA and produced
multiple publications in the development of active site (Type IV) directed affinity labels for
PKACα (Figure 9). Kaiser’s work centered on peptide based affinity labels. He coauthored with
Taylor the 1982 paper that detailed disulfide bond mechanism based peptide affinity labels.44
They went on to further examine the substrate-binding pocket by synthesizing a number of
subsequent peptide based affinity labels incorporating bromoacetamides and chloroacetamides in
addition to the oxidized cysteine residues used to form the disulfide at Cys199. However, only
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the bromoacetamides showed any labeling activity. Their radiolabaled probes and trypsin
digestion experiments help form early models of the substrate-binding site (prior to crystal
structure). They hypothesized that the conserved nature of this cysteine among known kinases
(considerably fewer at the time), would provide a general strategy to develop affinity labels that
work by a similar mechanism to determine active site sequences.49 Kaiser and Miller also
produced a peptide based photoaffinity label that produced similar results when used to discover
the residues responsible for substrate recognition.50 Further they characterized a small library of
their peptide based covalent inactivators and known ones (the disulfide forming compounds
explored previously, Figure 9). Their results were particularly noteworthy in light of what we
now know in that, in addition to them further demonstrating the amino acids that play a role in
substrate recognition, their probes were prevented from covalent labeling in the presence of
physiologically relevant concentrations of MgATP.51
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Figure 9: Peptide-based active site directed affinity labels for PKA by Kaiser et al.
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Contemporary to the work of Kaiser et al., two other groups produced Type IV
irreversible inhibitor studies. Glass and colleagues produced a photoaffinity labeling peptide
based on the PKI(6-22) scaffold and show that it does label the catalytic subunit of PKA. They
cite “soon to be published” work in complex biological mixtures, but that work was never
published.52 A group at Louisiana State University published a study detailing the fluorescent
affinity labeling of the catalytic subunit with a small molecule. They propose a novel mechanism
of action in that their small molecule reacts with two residues, lysine-72 and cysteine-199, by
forming an isoindole derivative with PKACα.53 However, in a simultaneous publication they
note the similar mechanism and inhibitory activity against Protein Kinase G (cGMP-dependent
protein kinase, or PKG).54
Lawrence and colleagues attempted similar affinity labels with the aid of the now
available kinase crystal structures, and the ability to express recombinant PKACα (previous
groups had been using purchased or isolated mammalian proteins from various mammalian
sources). They essentially demonstrated the structure-based design principle of our approach by
synthesizing multiple affinity probes and performing substrate analysis. Early work was focused
on appending an oxidized cysteine at the C-terminal end of a peptide inhibitor to selectively
oxidize Cys199 (Figure 10). These peptides were effective at inhibiting PKACα by reacting
specifically with Cys199. Interesting, ATP blocked labeling of their peptide probes as well,
lending support to the hypothesis that there is a confirmation change of the cysteine in the
presence of a nucleotide.55 They state that they were continuing structure-activity relationship
studies on these series of peptides but nothing has been published with them since (although a
different strategy was used in 2011 and is discussed in chapter 2). They do note, however, that in
addition to labeling Cys199 they also labeled a similar cysteine in Protein Kinase G, PKG.56
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Selectivity between the two similar kinases was not achieved at first but they were able to tune
for PKG over PKA in a later paper.55,57 However, they moved into methods to detect PKACα
activity while not inhibiting and will be discussed in chapter 2, methods to detect PKA activity.
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Figure 10: Peptide-based affinity labels for PKA, representative peptides from Lawrence et al.

A contemporary example of peptide-based affinity labels that target the Cys199 of
PKACα in the activation loop comes from Tung et al. They utilize a mechanism-based
inactivation method that effectively is silent until it labels the free catalytic subunit of PKA
(Figure 11).58 This example is particularly interesting in that the probe was designed to remain
quenched until reacting with PKACα, effectively only reporting the amount of catalytic subunit
not bound to regulatory subunits or inhibited by any other substrate competitive mechanism.
Tung et al examine their probe in various conditions to display selectivity in biological mixtures
and quantitate levels of the protein in various ways with the hypothesis that this could be used to
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detect PKA levels in cancer patients. The mechanism and lead compound are shown below in
Figure 11. The researchers did not however publish data concerning the protective effects of
ATP (or lack thereof) against their probe.58

Arg

Arg

Phe
Ala

Arg
Arg

Cys

FAMS

TAMARA

Leu

Cys199

Phe
SH

Quenched

Cys199
SH
TAMARA

Arg
Leu

Arg
Arg

Phe
Arg

Phe

S

FAMS

S

Ala

Disulfide
exchange

Cys199
S
TAMARA

Arg
Leu

Arg
Arg

Phe
Arg

Phe
Ala

S

FAMS
HS

Figure 11: Mechanism-based quenched fluorescent probe of PKA

	
  

19	
  

1.3: Activity-Based Protein Profiling
Genomic analysis relies almost exclusively on manipulating gene expression (RNAinterference, knock-out/down, etc.) in order to determine a protein’s function and importance in a
disease state. This approach is usually coupled with a generic proteomics approach (mass
spectrometry, blotting techniques etc.) to correlate protein levels with genomic analysis.
Activity-based protein profiling (ABPP) has arisen out of a necessity to determine, in addition to
total protein amounts (proteomics), protein function in complex biological mixtures.15,59 The
successful design and implementation of a covalent ABP is a critical step to begin the process of
characterizing the active site, and activity (not always the same) of specific proteins and/or
families of proteins (discussed in section 1.2).
1.3.2: ABPP Applications
ABPP applications include, but are not limited to, molecular target identification, drug
discovery, off-target analysis, and active site characterization.14,15,60 Molecular target
identification is dominated by gel electrophoresis ABPP techniques.15 Healthy and disease state
samples are compared for aberrantly active (or inactivated) protein levels. The resulting
differences can be attributed to the disease state and warrants further examination.15,61 Drug
discovery efforts can be enhanced with an ABP.62 By competition with potential drug candidates,
a subsequent decrease in probe labeling is noted and can be interpreted in a number of different
ways. Additionally, if a family selective ABP is being utilized, off-target binding analyses can be
conducted by this competitive labeling experiment.18,20 By serendipity an ABP may identify a
novel protein that shares the mechanism of action of the target enzyme. This can enable the
identification and subsequent classification of new or old proteins with previously unknown
function(s).15,20
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1.3.3: Historical Perspective of ABPP Development
ABPP at its onset was primarily focused on protease and protease-like enzyme
families.11,18,21 This is due to the catalytic mechanism of these enzymes being well defined which
allows for a more straight-forward probe design. The serine hydrolases have seen significant
progress in ABP development and implementation in ABPP. Serine hydrolases encompass a
number of different proteins, which include lipases, proteases, esterases, and peptidases. Despite
the differing substrate specificity, the diverse proteins converge on a shared active site
mechanism of action. This catalytic mechanism utilizes a serine residue that is made nucleophilic
in the active site for subsequent attack on the carbonyl carbon of the substrate to form a
tetrahedral intermediate. Water then hydrolyzes the following acyl-enzyme intermediate to
regenerate the serine and eject the product. Targeting the transition state of an enzyme is an
effective strategy to produce inhibitors. The fluorophosphonate, and aryl phosphonate
electrophiles have been shown to be effective reactive moieties for ABPP of the serine
hydrolases.18,63-67
An effective example of ABPP applied to the serine hydrolases is from the Jessani group
using the phosphonate electrophiles as transition state mimetics that also form a covalent bond.
Their work lead to the identification of the integral membrane protein KIA1361 as an important
biological target in aggressive cancers.68 These probes have been conclusively demonstrated to
selectively react with the active form of the enzyme and not physiologically relevant inactive
forms; this makes them effective tools for ABPP. Certain other groups have developed similar
probes and have used them extensively in ABPP applications that examine the cancer
phenotype.15,69
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In a similar setting, the cysteine proteases have garnered remarkable success in ABP
development and applications in ABPP.13,19,20 However, the subtle differences in the active site,
the differing mechanism of action, the nature of the nucleophile (serine OH as compared to the
cysteine SH), and hard-soft acid base interactions allow for orthogonal targeting by electrophiles.
Of particular interest is the fluorophosphonate electrophile: it does not inactivate the cysteine
proteases. Many other cysteine selective electrophiles do covalently label the cysteine proteases
with varying efficiency and selectivity. The acyloxymethyl ketone (AOMK) electrophile
synthesis and application has been optimized and tailored to the cysteine protease family.20
AOMK has also demonstrated intrinsic selectivity for the cysteine proteases while generally not
reacting with less potent nucleophiles.70 The solid phase synthesis of AOMK containing
peptides/small molecules has been disclosed and has since spurred a large increase in ABPP of
the cysteine proteases.19,20
Many more enzyme classes have been targeted with varying degrees of success; however,
as our understanding of enzyme catalysis and active site dynamics increases, so has the pool of
potential targets for ABP development increased.17,71,72 Not only can we target new catalytic
mechanisms but new classes of enzymes. It is indeed important that more ABPs be developed to
target and characterize more disease states. The kinome has proved a bountiful source of
therapeutic targets but has mostly evaded wide spread irreversible inhibitor development and
thus the potential for ABP development.17,23
1.3.4: ABPP and the Kinome
There is a current need for ABPs for the kinome. Many kinases are implicated in various
disease states, however their immediate function is difficult to elucidate without such probes.59,7375
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BTK, and FGFR (Figure 12),26,31,76,77 all of which target the conserved cysteine in the nucleotidebinding site.17 There are also examples of non-selective ABPs, where, simply put, a known
irreversible inhibitor has been outfitted with a tag and electrophile.78 While these approaches
have yielded successful ABPs, there are many kinases with a cysteine in the ATP-binding pocket
(approximately 200), and the ATP-binding site is conserved among many enzymes and enzyme
classes.26,73 This has made it difficult to achieve the level of selectivity required for selective
enzyme activity-based protein profiling (ABPP) since more proteins than those in the kinome
utilize ATP; a significant portion of the proteome has a nucleotide binding site.17
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Figure 12: Adenine base and representative activity-based probes for the kinome.
It is generally assumed that if Type I inhibitors, ATP-competitive, can bind to a kinase
nucleotide binding site, it is in its active confirmation and therefore with the appropriate
placement of a tag can be an ABP.17,59,60,71 As a result, the ABPs available for the kinases rely on
this mechanism of action to inactivate in an activity-dependent manner. There have been a
number of examples of how one might discover irreversible inhibitors that behave in this
manner, and while they may produce ABPs Type I in nature, they are unable to, or currently are
not being used to, examine other mechanisms of action. 73
There is another binding site that has similar activity dynamics in the kinome, and in
some cases is more sensitive to active site dynamics; this site is the substrate-binding site.33 In
addition to providing the scaffold for proper orientation of a substrate for phosphoryl transfer,
the substrate-binding site is sensitive to many post-translational modifications that do not always
affect the nucleotide binding site. For example, PKACα is regulated by an endogenous inhibitor
peptide that does not prevent binding of ATP; therefore, a (theoretical) Type I ABP would not
account for such a regulatory mechanism. To date, there currently is no other general strategy to
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develop, or singular example of, an ABP that does not rely on an ATP competitive mechanism in
the kinome. Therefore, the development of a general strategy to produce ABPs for the kinome
that relies on the substrate-binding site would have significant impact on the field.
1.4: General Hypothesis
The above is the summary knowledge gained towards the development of Type IV
covalent inactivators of PKACα and their applications. Using this and the vast literature on PKA
(see chapter 2), we hypothesize that an activity-based probe can be effectively developed for the
prototype kinase that utilizes a binding pocket other than the ATP-binding pocket. But utilizing a
high affinity pseudosubstrate peptide with a known binding site (active-site directed) and
mechanism of action, we can effectively target Cys199 of PKA in an irreversible and selective
manner to produce an activity-based probe for activity-based protein profiling. We additionally
suggest that this approach can be generalized, by nature of its application to the prototype kinase
and existence of similar cysteines in other kinases, for activity-based protein profiling of the
kinome. This hypothesis was tested by synthesizing a number of peptidomimetic compounds
based on a structure-based design approach and their mechanism of action was investigated by
both various inhibition and gel electrophoresis assays (see section 3.12).
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Chapter 2: cAMP-Dependent Protein Kinase
2.1: cAMP-dependent Protein Kinase
Phosphorylation is an important regulatory post-translational modification in eukaryotes.
Phosphorylation is often responsible for regulating the dynamics of the cellular environment; at
the same time it is often reversible by enzymes known as phosphatases. Phosphorylation is the
transfer of a phosphate group to a substrate. Enzymatic proteins that catalyze the transfer of a
phosphate group are known as kinases. Common substrates include serine, threonine, and
tyrosine. Eukaryotic protein kinases (EPKs) make up a superfamily of homologous proteins.
The EPK homology region is defined by the catalytic (or kinase) domain; this domain is
approximately 250 amino acids. The catalytic domain is responsible for the catalytic activity and
is where the phospho transfer takes place. Kinases generally utilize ATP or GTP as their
phosphate source and catalyze the transfer of the terminal gamma phosphate to the substrate.79
The phosphate transfer process can be viewed as a general three-step mechanism. The first two
of which are not necessarily in this order: 1) the nucleotide binds to the nucleotide binding
pocket of the catalytic domain; 2) a substrate binds in the substrate-binding pocket of the
catalytic domain; 3) there is a transfer of the gamma-phosphate to the substrate.79 The first two
steps may not necessarily occur in that sequence and may occur in a difference sequence in
vivo.80,81 It was previously believed that a divalent cation, such as Mg2+, was required for the
phosphate transfer step. This has recently been shown to not be the case in terms of phosphate
transfer alone (for PKACα), the divalent cation plays a larger role in release of ADP which is the
rate limiting step in catalysis turnover.80 Taylor and colleagues have demonstrated phosphoryl
transfer in the absence of divalent metal cations.80
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The kinase superfamily is referred to as the kinome and accounts for ~2% of the human
genome. The kinases are broken up into eight broad classes based on the homology of their
catalytic domains: AGC; CAMK; CMGC; TK; TKL; STE; RGC; and CK1. PKA is a member of
the AGC kinase family, the AGC kinases are serine/threonine specific kinases. Because the
cAMP-dependent protein kinase (PKA) was the first crystallized, and its core residues (40-300)
are highly conserved, it is the prototype kinase.82 PKA is undoubtedly the most studied and
perhaps well understood of the protein kinases. The catalytic subunit α of PKA (PKACα) was
the first kinase crystal structure to be solved; this protein continues to be the template to which
we base general kinase structure and function on.42,83 This structure also contributed to the
initiation of a new chapter in eukaryote protein kinase (EPK) drug discovery, structure-based
drug design.84
2.2: Structure of PKA.
Specific regions of PKA are often referred to when discussing inhibition strategies, and
these regions often serve as the template for the modeling of other kinases. The main portions of
the kinase that are involved with substrate, inhibitor, or regulatory function and/or binding are
the nucleotide binding loop (51-56), hinge region (120-126), catalytic loop (162-173), E-helix
(140-159), 3rd beta strand (67-75), C-helix (85-97), activation loop (184-208), and the P+1 loop
(211-214). These regions are highlighted in Figure 13 below with the crystal structure of
PKACα, which contains the catalytic subunit with ATP, and the inhibitor peptide PKI(5-24)
(PDBID: 1ATP). Type IV inhibitors bind to the substrate-binding pocket (occupied by substrate,
white in Figure 13) made up by the activation loop (magenta) and the catalytic loop (teal). It is
important to note that affects made outside of the pocket (such as post-translational
modifications) can greatly affect the characteristics of the substrate-binding site. Cysteine-199,
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the cysteine which we focus on for this thesis, is located on the activation loop. Cysteines in the
activation loop are very common and their location is often conserved. For example, the human
kinome contains 99 kinases that share a cysteine in the same spot as PKACα (to be discussed
later). Many more cysteines exist thoughout the activation loop and their presence is an
indication of their potential to be targeted (see Chapter 3 Figure 69 for complete human kinome
activation loop sequence alignment with cysteine highlights).
The activation loop (or T-loop) is characterized by a conserved DFG (aspartic acidphenylalanine-glycine) start sequence and ends at the APE (alanine-phenylalanine-glutamic acid)
motif. This region is highly conserved in eukaryote protein kinases (EPKs) and is heavily
involved in the catalytic activity of EPKs. For most EPKs the activation loop is disordered when
the kinase is not phosphorylated at the appropriate residues (Thr 197 for PKA). This disordered
nature of the region reduces affinity of substrates and, in result, the kinase catalytic activity is
severely diminished or completely abolished. Therefore, the nature of the activation loop and by
extension the substrate-binding pocket is an important regulatory factory in the kinome (see
section 2.3 on PKA regulation below).
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Figure 13: Major regions interacting with the active-site. Image generated on pymol.

2.3: Expression and Regulation of PKA.
PKA consists of multiple subunits and splice variants produced in most mammalian cell
and tissue types. There are three catalytic subunits denoted alpha, beta, and gamma (PKACα,
PKACβ, PKACγ). The alpha and beta are the two major isoforms found in humans. The gamma
subunit is primarily expressed in the prostate. In addition to the catalytic subunits are regulatory
subunits; these regulatory subunits also have multiple isoforms: Ia, Ib, IIa, and IIb. The
regulatory subunits all have cAMP binding domains (CBDs), and have high affinity for the
second messenger. However, the different regulatory isoforms have different affinities for
cAMP.42,85,86 This allows for greater regulation of cAMP signaling, by having different amounts
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of PKA activated at different thresholds of cAMP (discussed below). However, the main focus
will remain on the alpha subunit, PKACα.
Despite the localized expression of the catalytic subunit isoforms, their regulatory
mechanisms are essentially the same. PKA is regulated by multiple endogenous regulatory
mechanisms, many of which are conserved or very similar within the kinome.84 Upon
transcription, PKA is autophosphorylated on Ser 338 and then rapidly phosphorylated on Thr
197 by PDK1.87 However, these phosphorylations are considered silent when left as is, in that
they are not dephosphorylated by known phosphatases.38 Additionally, the phosphorylation
occurs immediately during (auto) and upon transcription (PDK1).87 However, it has been
demonstrated that oxidation of Cys199 by glutathione, a physiologically relevant posttranslational modification, renders the pThr 197

and pSer 338 residues susceptible to

phosphatase activity.38 Whether or not this is a physiologically relevant event remains to be
conclusively determined. What is clear is that phosphorylation at Thr 197 causes an ordering of
the activation loop (and by extension the substrate-binding pocket as a whole), which increases
substrate-binding resulting in increased catalytic activity.87 Of particular note is that the inhibitor
peptide (PKI, IP20) binds to the dephosphorylated isoform with ~9 fold less affinity than for the
phosphorylated isoform (6.4 vs 54 nM).87
Once translated, PKACα forms the inactive holoenzyme by binding as a heterotetramer
with two regulatory subunits. These regulatory subunits bind with high affinity to the substratebinding site and occlude substrates from binding; therefore, inhibiting the catalytic activity of
PKACα.88-92 However, the second messenger cAMP binds to the regulatory subunits
cooperatively and with high affinity, which causes the release of the free, catalytically active,
enzyme.92
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The free PKACα may still remain inactive because it can bind to the endogenous
inhibitor peptide, the heat-stable protein kinase inhibitor (PKI).93,94 PKI binds selectively and
with very high affinity to the free catalytic subunits of PKA. In addition to substrate competitive
regulation, cysteine 199 can be oxidized with glutathione, which inhibits activity. The specific
residue interactions between the pseudosubstrate inhibitor PKI and the catalytic subunit are
detailed in a 2-D representation below.
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In addition to the regulatory mechanisms described above, the functional effect of PKA is
also spatially and temporally regulated by A-Kinase anchoring proteins (AKAPs), of which there
are more than fifty (when splice variants are considered).95 The regulatory subunits bind to the
AKAPs, which are clustered, and upon stimulation with cAMP, catalytically active PKACα is
released in a localized fashion. The original AKAPs were isolated as contaminants when
attempting to purify regulatory subunit.95 It is clear that PKA functional activity is not only
regulated in a dynamic nature but it is tissue specific (see Table below for a list of AKAPs and
their tissue expression). It is because of this dynamic activity that current methods to detect PKA
activity in vivo do not necessarily reflect the function of PKA in that state and no one method
available can decipher all the data.

Table 3. Selection of known A-Kinase Anchoring Proteins (AKAPs).95,96
AKAP
D-AKAP1
AKAP-KL
AKAP110
AKAP79
mAKAP
AKAP18α
AKAP18β
AKAP18γ
AKAP18δ
AKAP95
AKAP350
Isoform Yotiao
D-AKAP2
AKAP220
Gravin

	
  

Tissue Expression
Ubiquitous
Kidney, lung, thymus, cerebellum, heart
Testis
Ubiquitous
Heart, brain, skeletal muscle
Heart, brain, lung, pancreas, kidney
Kidney, brain
Heart, brain, placenta, lung, pancreas
Heart, kidney inner medulla
Nuclear matrix
Ubiquitous
Brain, heart, placenta, skeletal muscle, pancreas, testis
Ubiquitous
Testis, brain, kidney
All tissues except liver
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AKAP-Lbc
AKAP28
GSKIP
MyRIP
Rab32
SKIP
BIG2
Ezrin
WAVE-1
MAP2
Neurobeachin
MTG8
Myosin VIIA
MTG16b
Synemin
PAP7
Myospryn
SFRS17A
Merlin
Moesin
AKAP85
Pericentrin
RSK1

Ubiquitous
Lung
Ubiquitous
Ubiquitous
Ubiquitous
Heart, brain, ovary, spleen
Placenta, lung, heart, brain, kidney, pancreas
Blood cells, placenta, secretory epithelia, brain
Brain, platelets, liver
Brain, ovaries
Ubiquitous
Brain, lymphocytes
Ubiquitous
Ubiquitous
Muscle
Ubiquitous
Skeletal and heart muscle
Ubiquitous
CNS
Blood
Lymphocytes, epithelial cells
Ubiquitous
Ubiquitous

The second messenger cAMP is generated from ATP by adenylate cyclases (ACs), whose
activity can be increased by extracellular signals. Levels of cAMP are regulated by extraceullar
signals that can activate ACs through G-protein coupled receptors (GPCRs) and
phosphodieserases (PDEs) that catalyze the breakdown of cAMP.97 GPCRs can be coupled to a
variety of G protein complexes which in turn can positively or negatively effect AC activity. For
example, the Gαs protein increases AC activity and the Gαi inhibits AC activity. In a healthy
physiological state, PKA acts as the main intracellular target of cAMP. Once cAMP is generated,
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it binds to the regulatory subunits that inhibit PKA and causes the release of catalytically active
PKACα.97

Adenylyl cyclase

ATP

GPCR
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Figure 15. Schematic representation of cAMP-dependent activation of PKA.

2.4.1: PKA activity.
PKA is ubiquitously expressed and is responsible for the regulation of multiple proteins
and transcription factors via phosphorylation of many Ser/Thr residues that directly result in
increased cAMP levels (often resultant from GPCR stimulation).6 The consensus sequence for
phosphorylation by PKACα is RRXS.6 A brief sample of various protein substrates is listed
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below in Table 4.98 Taylor and colleagues have performed a quantitative mass spectrometry
based proteomic analysis to identify many proteins whose expression is effected by directly
altered by PKA.6

Table 4. Selected substrates of PKACα.
PKA Substrates
Muscle Glycogen Synthase
Phosphorylase Kinase α
Protein Phosphatase 1
CREB
Liver Tyrosine Hydroxylase
Phopholamban
USP20
PKACα (auto)
CDC25B
ABL1
NFKB1
CLDN3
RORA
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Table 5. Proteins whose expression is increased (green) or decreased (red) directly by PKA
activity.
PKA-Dependent Protein Expression
Isocitrate dehydrogenase (NAD) subunit γ
glutathione reductase
glyoxylate reductase 1 homologue
mortality factor 4-like protein 2
isoform 4 of E3 ubiquitin-protein ligase
nuclear autoantigenic sperm protein isoform 1
isoform 1 of Rab GDP dissociation inhibitor β
GTP-binding nuclear protein Ran
prostaglandin E synthase 3
translin-associated protein X
F-actin-capping protein subunit α2
(Rpsa-ps7) similar to 40S ribosomal protein SA
scavenger mRNA-decapping enzyme
exosome complex exonuclease RRP41
isoform 2 of phosphoglycerate mutase family member 5
(gm4492) similar to gag
isoform 2 of acidic leucine-rich nuclear phosphoprotein 32 family member E
peptidyl-prolyl cis-trans isomerase
Annexin A5
sinalosome complex subunit 4
leucine-rich repeat containing protein 59
isoform 1 of 36biquitin carboxyl-terminal hydrolase isozyme L5
Tnpo1 transportin-1
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The different holoenzymes play a role in PKA’s normal function as well. Type I
holoenzymes (defined by which regulatory subunit the catalytic subunit is bound, for Type I it is
RI) are typically found in the cytosol and Type 2 are generally localized to the membrane. The
dynamics of PKA signaling modulate cell cycle entry in multiple systems. PKA has also been
identified as a regulator of deubiquitinase (DUB) activity for GPCRs, thus playing a role in
receptor desensitization. PKA has also been demonstrated to have an important role in the
regulation and development of Schwann cell (SC) growth and proliferation.88
PKA signaling is closely tied to β-adrenergic stimulation. Upon stimulation of a
positively coupled to cAMP GPCR, cAMP is generated and causes the release of free,
catalytically active PKACα. A brief illustration of PKA’s role in heart muscle contractility and
energy production in the tissue is shown below in Figure 16.98 When this signaling is perturbed,
various disease states can result.96,98
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Figure 16. PKA’s role in heart contractility and energy consumption.

2.4.2: Aberrant PKA activity.
Aberrant PKA activity has been implicated in a number of cancers, with opposing affects
of both increasing and decreasing cell proliferation.99,100 For example, it has been shown that an
increase in the expression of regulatory subunit IA, which results in a decrease of PKA catalytic
subunit activity, causes increased cell proliferation in human melanoma cells.101,102 Conversely,
the cAMP response element modulator (CREB) is activated by PKA. Studies have shown that
increased levels of PKA increase CREB activity and contribute to cell proliferation in various
cancers.103 It has also been demonstrated that certain forms of cancer excrete PKACα, known as
extracellular protein kinase (ECPKA); the activity and amount of ECPKA strongly correlates
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with tumor size.104 This is a particularly interesting observation for PKA in that a probe that
selectively detects ECPKA, such as the one discussed in this thesis, could be a valuable tool in
the clinic as a detection method for a tumor biomarker.
Aberrant PKA activity has been identified and implicated the PKA pathway as a
therapeutic target in Cushing’s disease.105 This example is another prominent illustration of the
normal PKA catalytic activity being influenced by alterations in its regulatory subunit binding.105
The reduced affinity of catalytic subunit for the regulatory subunit, and therefore its ability to
form the inactive holoenzyme, cause an increased basal level of PKACα activity.105
PKA activity is, not surprisingly, implicated in a number of other endocrine disorders as
well.97,105 Instead of normal stimulation of GPCRs by endogenous hormones, mutations and/or
regulatory perturbations that increase basal levels of PKA activity lead to related disease states.
Aberrant PKA activity has been implicated in the endocrine disorders hyperthyroidism and
acromegaly.106-109 Because PKA plays such a central role to cAMP signaling and protein
expression, its involvement in various disease states is vast and diverse; therefore, methods to
detect PKA activity have often been sought.
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2.5: Current methods to detect PKA and PKACα activity.
There are numerous antibodies commercially available for Western blot detection of
many aspects of PKA, including both catalytic subunits (generally nonspecific splice variant
detection), and the regulatory subunits. Some of these antibodies are non-selective, that is they
detect all forms of PKA. There are also phosphorylation specific antibodies which only detect
catalytic subunits of PKA that have been phosphorylated at Thr 197. These phospho specific
antibodies are one current technology used to quantify active amounts of PKA. However, these
antibodies are unable to take into account the other mechanism of regulation that PKA is subject
to. Another common practice is to measure a specific substrate, or even total phosphorylation
events that could be attributed to PKA. For example, there are CREB phosphorylation specific
antibodies and by quantifying the levels of phosphorylation, it is reasoned that increased (or
decreased phosphporylation) is an indicator of PKA activity. Additionally, a common antibody
recognizes the substrate consensus sequence of PKA (RRXS/T) in its phosphorylated form
RRXpS/T and by quantifying global detection of phosphorylation (or in some cases
visualization) can be interpreted to be an indicator of PKA activity. These methods tend to fall
short of truly accurate active levels of PKA and better reflect situational specific increases in a
particular event correlated to PKA activity.
There are a variety of sophisticated kits and detailed methods to analyze substrate
turnover in complex biological mixtures and isolated protein solutions for both well and lesser
equipped laboratories. Genomic sequencing is a stand by for most biology labs, however this
does not address the phenotype. Substrate turnover is another common method, but this generally
cannot be used in vivo nor can it account for pathway redundancies, e.g., a secondary enzyme
causing additional activity due to overlapping consensus sequences (see discussion of consensus
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sequence antibody for PKA activity above). When substrate is used in vitro it is very effective.
Multiple detection methods can be employed to detect substrate turnover with isolated enzyme
including, but not limited to, radiometric analysis, UV detections, fluorescence polarization,
fluorescence-resonance energy transfer (FRET), thin-layer chromatography, and blotting
techniques. We utilized a commercially available FRET based assay to determine out PKA
activity in vitro and will be our procedures discussed in detail in the experimental section.
There are a number of examples of a substrate-based probes to measure phosphate
transfer at the source, both in whole cell and isolated enzyme assays. These probes utilize
substrates demonstrated to be selectively phosphorylated by PKACα (kemptide for example),
and a fluorophore whose emission is shifted when bound to and phosphorylated by PKACα.
Lawrence and colleagues developed such a probe utilizing a coumarin derivative tag and a
quencher dye for detection. When the probe is phosphorylated by PKA it causes a sharp increase
in the coumarin fluorophore’s emission spectra allowing for selective detection. Through
numerous peptide syntheses and various dyes, they optimized the substrate properties for
maximum signal with minimal background. This is also detectable and quantifiable in real time
so it has been used to characterize the location of PKA that is in the process of, or has very
recently, phosphorylated the substrate based probe. This allows quantification of the relative
amounts of PKA in mitochondrial microenvironments.110
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Figure 17. Substrate-based probe of PKACα catalytic activity.

Lawrence et al have also described a unique probe for detecting intracellular levels of
PKA. They utilize a portion of PKI as an active site directed scaffold. However, instead of
targeting Cys199 in the substrate-binding pocket, they target a non active-site cysteine (Cys 343)
that does not inhibit the enzyme. Once their probe has bound, they expose it to UV light and a
photoreactive moiety causes the release of PKI and only the labeled portion of the probe
covalenty bound to the auxillary cysteine remains. Here they report that their probe identifies
free and catalytically active enzyme yet does not inhibit it and thus they can tag it and follow its
activity as a result of various stimuli.111
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Figure 18. Active-site directed probe with electrophile directed towards Cys343.

Another group has developed an affinity assay based on the PKI scaffold.93 In essence,
this is the purpose of our probe but as applied in a reversible situation. PKI’s mechanism of
action is well documented and therefore this report concludes that it can be used to selectively
detect and measure amounts of free and catalytically active amounts of PKACα. They utilize
residues 5-24 of PKI and express it linked to glutathione S-transferase (GST, with a Gly5 linker):
GST-PKI(5-24). Upon generation of GST-PKI(5-24), they immobilized it onto solid glutathione
beads for use in affinity purification. They were able to pull down catalytically active PKA and
perform a number of activity-based experiments. An interesting outcome was the confirmation of
H89 (a high affinity ATP competitive inhibitor of PKA) reducing affinity of PKI for the catalytic
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subunit. However, they go on to note that the assay simply evaluates relative degrees of PKI
affinity and does not quantify PKACα activity itself.93
Imperiali and Shults have developed a generalizable strategy to apply to numerous
protein kinases and display the utility of their approach on PKACα. They append a Sox residue
to the C-terminal a PKA substrate (Ac-Leu-Arg-Arg-Ala-Ser-Leu-Pro-Sox-NH2). When the
substrate is unphosphorylated, the affinity for Mg2+ of the substrate (has an engineered β turn for
Mg2+ binding and is the lynch pin for the technique) is minimal, but upon phosphorylation the
affinity increase dramatically. This increased binding of Mg2+ causes a detectable fluorescence
signal to be generated by the Sox residue.112

SO2N(CH 3)2
O

OH

N

NH 2

OH
Sox
Figure 19. Sox residue used for selective detection of Mg2+ binding which was correlated to
phosphorylation of substrate.

Uri and coworkers have developed an easily accessible assay that utilizes thin-layer
chromatography to detect PKA substrate turnover activity.113 They appended 5-TAMRA (a
common fluorophore) to kemptide (a commonly used and commercially available PKA
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substrate) and developed TLC conditions sufficient to separate the phosphorylated and non
phosphorylated substrates, thereby allowing for selective detection and quantification.113 While
this assay is generally only applicable in situations with isolated enzyme, its simplicity and
accessibility make it noteworthy.
The mechanism based fluorescence reporter mentioned in the irreversible Type IV
inhibitors section of Chapter 1 (Figure 11) can also be included here in the review of methods to
detect PKACα activity.58 Tung and colleagues’ mechanism based fluorescence reporter
selectively reacts with Cys199 in the activation loop. Until this selective interaction occurs, the
probe they developed remains quenched. In experiments they conducted in fetal bovine serum
spiked with PKACα, they noted significant increase in fluorescence intensity in a dose
dependent manner with increasing PKACα concentration.58
PKA activity is an important indicator of cellular homeostasis and, as such, probes that
accurately detect the activity of PKACα in vivo would have diverse applications in a variety of
diseased and non-diseased systems. Here we report the efforts and resulting data towards the
production of an ABP for the cAMP-Dependent Protein Kinase A (PKA). PKA is the prototype
kinase, therefore the strategy described in the following text may serve as a general strategy to
target other kinases with a similar cysteine in the activation loop.
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Chapter 3: Development of ABPs for PKACα
Chapter 2 details the dynamic regulatory mechanism associated with PKACα catalytic
activity. These mechanisms reinforce the high degree of sensitivity associated with the substratebinding pocket. Therefore, a probe that is selective for the active conformation of the substratebinding pocket would have significant advantages in terms of monitoring more accurately the
levels of active protein available in the cell. Below is detailed the rationale for selection of the
peptide scaffold as the recognition sequence and the subsequent structure-based design used to
implement it an effort to produce an ABP.
3.1: Background on the heat-stable protein kinase inhibitor (PKI)
The heat-stable protein kinase inhibitor (PKI) is endogenously expressed as a 76 amino
acid protein (7,989 Da). It was identified by Edwin G. Krebs et al. in 1971.114 They detailed
many characteristics of PKI; most notably, it was shown to be an efficacious inhibitor of
PKACα.114 Many groups have performed subsequent structure-activity relationship studies on
the peptide scaffold to determine the amino acids critical for binding, selectivity, and effective
inhibition. Below is a brief summary of the data obtained in the context of PKI as a selective,
active-site directed, peptide inhibitor.
The expression of PKI has been shown to vary greatly between tissue types. A study done
on various rabbit tissues revealed that brain tissue had the highest levels of endogenous PKI.
Cardiac muscle and skeletal muscle had roughly equivalent amounts of PKI, at about 1/3 that of
the brain. The liver, kidney, and thymus only had a fraction of PKI as compared to brain and
muscle tissues.115 These amounts were reported as units/g and generally only serve as relative
amounts for these purposes.
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Multiple truncations of the full length PKI have been found to retain significant inhibition
activity against PKACα. Many of the initial structure-activity relationship studies relied on
isolating endogenous sources of PKI and truncating it with different proteolytic enzymes. Also, a
few synthetic peptides are included (discussed in next paragraph).114-118 Some notable fragments
that were identified are listed in Table 6 below. While these studies effectively demonstrated that
it is possible for fragments of the full-length heat-stable protein kinase inhibitor to inhibit the
catalytic activity, the peptides were limited to truncations made by their proteolytic enzymes and
therefore the studies were not exhaustive.

Table 6. Fragments of PKI and the corresponding Ki values for PKACα.
Sequence
TTYADFIASGRTGRRNAIHD
TTYADFIASGRTGRRNAIHD - NH2
TTYADFIASGRTGRRNAI - NH2
TYADFIASGRTGRRNAI - NH2
FIASGRTGRRNAIHD - NH2
IASGRTGRRNAIHD - NH2
GRTGRRNAIHD - NH2
GKTGRRNAIHD - NH2
ADFIASGRTGRRNAI - NH2
DFIASGRTGRRNAI - NH2
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Ki
0.3 nM
2.3 nM
3.1 nM
1.7 nM
73 nM
115 nM
57 nM
370 nM
90 nM
97 nM

The next round of structure-activity relationship studies performed on PKI brought in a
number of synthetic peptides. Among these is the primary example of the minimum sequence
required for maximum inhibition, PKI(14-22)-Amide, with a Ki of 36 nM along with valuable
structure-activity relationship data. PKI(14-22)-Amide, surprisingly, has an even lower Ki than
PKI(14-24)-Amide (57 nM).94,117,119 This is one of the major reasons PKI(14-22) was selected as
the “full length” ABP recognition sequence.

Table 7. Structure-activity relationship analysis by amino acid substitution.
PKI(14-22)
GRTGRRNAI - NH2
GRTGRRAAI - NH2
GRTGRRGAI - NH2
GRTLRRNAI - NH2
GRAGRRNAI - NH2
GRTGRRNAL - NH2
GRTGRRNAG - NH2

	
  

Ki
36 nM
550 nM
110 nM
390 nM
140 nM
180 nM
1400 nM
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3.2: PKI Selectivity.
Full length PKI is regarded as being very selective for PKACα in complex biological
mixtures.116,120 The selectivity of PKI(14-22)-Amide has been examined on a number of isolated
enzymes; however, a full panel of kinase inhibition has not been published.116,119,121 Proteome
selectivity of a derivative of PKI(14-22) is briefly addressed by an affinity pull-down experiment
performed with murine tissue lysates. One enzyme that in particular continues to be part of the
equation when considering PKI’s in vivo activity is the cGMP-dependent protein kinase, PKG.
The activation loop sequences of these two kinases have high similarity, and as a result the
shorter PKI sequences have activity against PKA and PKG.118,119

Table 8. Sequence alignment of DFG---APE regions of PKA and PKG.

PKA
PKG

	
  

Activation Loop Sequence alignment
DFGFAKRVKG-- RTWTLCGTPEYLAPE
DFGFAKKIGFGKKTWTFCGTPEYVAPE
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Table 9. Representative PKI fragments and their corresponding affinity for PKG.119,121
PKI Fragments
TYADFIASGRTGRRNAI - NH2
GRTGRRNAI - NH2

PKA Ki
1.7 nM
36 nM

PKG Ki
37820 nM
8000 nM

PKG/PKA
22247
222

Additionally, various derivatives of the PKI inhibitor peptide have been produced to
attenuate its activity profile. One research team has attached the DPTsh1 shuttling peptide to
PKI(5-24)-Amide to produce a selective, cell permeable, peptide-based, inhibitor of PKACα.122
Various lengths of the inhibitor peptide PKI are commercially available from many vendors.
Additionally, these peptides are available with various N-terminal modifications; one of which is
the addition of a myristyl group, which has been demonstrated to make the peptide cell
permeable while maintaining affinity (our lab determined the IC50 of commercial Myr-PKI(1422)-Amide to be 47.9 nM) .120
3.3.1: Inhibitor rationale: Structure-based design of PKI-based compounds.
The multiple crystal structures of PKACα have played vital roles in deciphering the
complex regulatory mechanisms that attenuate its catalytic activity. The first crystal structure of
PKACα was the first of any protein kinase and thus provided valuable data concerning the
makeup of the active site.83 Prior to this crystal structure, the use of active-site directed probes
and subsequent analysis was the main method to determine the residues that make up the binding
site (classical). Additionally, the first crystal structure was published as a His6 tagged
recombinant protein bound to both ATP and a portion of the heat stable protein kinase inhibitor
PKI(5-24). This particular crystal structure clearly illustrates the proximity of Cys199 to the P+1
and P+2 positions of the inhibitor peptide.
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PKI-Ile22 occupies the hydrophobic site at the P+1 position, this position has been
demonstrated to have significant effect on the binding affinity of the peptide inhibitor (see Table
4, above). From the crystal structure the distance was measured from the alpha carbon on the Cterminal end of the peptide to estimate where the electrophilic carbon of an electrophile, such as
a chloromethyl ketone, would reside. It was determined to be 7.3 Å for an Ile22 based
electrophile. At the P+2 position is a histidine residue that has numerous interactions with
surrounding residues (the specifics of which are detailed in Figure 14). From the crystal structure
(1ATP) the distance was from the alpha carbon on the C-terminus side of His23 to estimate
where an electrophile, like glycine halomethyl ketone, would reside; it was determined to be 8.3
Å (Figure 20 below).
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Figure 20. Distance analysis of relevant alpha carbons to the side chain of Cys199.

3.3.2 Activity-Based Probe Rational: Selecting PKI as the active-site recognition sequence.
Numerous inhibitors that target the ATP-binding site have been developed. Most of these,
however, show little selectivity for PKACα. This is mostly due to the conserved nature of the
nucleotide-binding site among many proteins in mammalian cells. Additionally, inhibitors of this
nature must have high affinity to compete with millimolar concentrations of intracellular ATP if
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they are to make the transfer from the lab to the clinic. While there have been some covalent
inhibitors produced for other kinases that target the ATP-binding site, PKA does not have an
appropriately placed cysteine necessary to be a target of this strategy.
PKI has been demonstrated to be highly selective for PKA in vivo. In addition to its high
selectivity, PKI (and many of its fragments) have high affinity for PKACα based on the available
information and, perhaps most importantly, the mechanism of action of pseudosubstrate
inhibitors. More specifically, by binding with the substrate-binding pocket of PKACα, PKI binds
competitively with a number of endogenous regulatory mechanisms (reviewed in Chapter 2.3).
Therefore, PKI presented itself as an ideal candidate as the recognition scaffold for the
generation of an activity-based probe of PKACα.
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Figure 21. View of critical amino acids in PKI for affinity for PKACα.
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3.4: Single Amino Acid Analogues
3.4.1: Rational and design of single amino acid analogues.
The distance between the carbonyl carbon of the P + 1 Ile22 and Cys199 in the cocrystal
structure 1ATP is 6.8 Å, the C-terminal α-carbon distance is 7.3 Å and the C-terminal α-carbon
at the P+2 position is 8.3 Å. The objective was to selectively react with this cysteine in the
activation loop by utilizing endogenous binding mechanisms and a known binding mechanism of
action. The project began by preparing a library of single amino acid analogues to capitalize on
the hydrophobic binding pocket at the P+1 binding site of PKI, and its close proximity to the
cysteine. It was hypothesized that the single amino acid, isoleucine, would maintain affinity for
the hydrophobic binding pocket such that it would position itself appropriately for an appropriate
cysteine selective electrophile. Also, this binding mechanism should be predictive of the full
length peptide, thus providing valuable data pertaining to its activity-based mechanism of action
and ability to inhibit the enzyme by alkylating Cys199.
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Figure 22. Close up on Ile22 and proximity to Cys199.

The first round of single amino acid analogues were centered around isoleucine,
phenylalanine, and glycine. It was hypothesized that the isoleucine would bind in a similar
manner to the isoleucine in PKI (Figure 23), the phenylalanine may be either able to increase
hydrophobic interactions or be too large and thus provide important selectivity data, and the
glycine would serve as a control for the backbone and/or amide in conjunction with the vinyl
ketone to demonstrate the added binding interactions of the side chains.
3.4.2: Preparation of the single amino acid analogues.
The initial electrophile selected was the vinyl ketone electrophile, this is a particularly
electrophilic moiety. Also, a vinyl ketone ensures labeling at the desired nucleophilic cysteine if
the binding hypothesis holds true. Analogues were prepared in a short two-step synthesis.
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Starting with the commercially available t-butyl carbamate (Boc) protected amino acids, a
standard coupling was performed with N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide (EDCI)
hydrochloride, 1-hydroxybenzotriazole (HOBt) hydrate, 4-methylmorpholine as the base, N,Odimethylhydroxylamine hydrochloride, and dichloromethane as the solvent at ambient
temperature for 16 hr to generate the Weinreb amide leaving group. The Weinreb amide is a
suitable leaving group for the subsequent Grignard reaction with vinylmagensium bromide in
ether at 0 °C to produce the Boc protected amino acids with a vinyl ketone electrophile at the Cterminal position. A control ethyl compound was synthesized by taking compound 2 and
reducing the vinyl group with Pd/C and hydrogen gas at 1 atm for 16 hr.
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Figure 23. Synthesis of Boc vinylketone amino acid derivatives.

The propargyloxycarbonyl (Poc) protected amino acids were synthesized in anticipation
of the utilization of ‘click’ chemistry for selective detection.34 The free base amino acids were
commercially available. To prepare the Poc protected amino acids, propargyl chloroformate was
incubated with the desired amino acid and sodium hydroxide as the base. Then a standard
coupling

was

performed

with

N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide

(EDCI)

hydrochloride, 1-hydroxybenzotriazole (HOBt) hydrate, 4-methylmorpholine as the base, N,Odimethylhydroxylamine hydrochloride, and dichloromethane as the solvent at ambient
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temperature for 16 hr to generate the Weinreb amide leaving group. Followed by a Grignard
reaction with vinylmagensium bromide in ether at 0 °C to produce the Poc protected amino acids
with a vinyl ketone electrophile at the C-terminal position.
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Figure 24. Synthesis of Poc vinylketone amino acid derivatives.

An additional set of single amino acid analogues was synthesized to explore other
electrophilic moieties with the goal of identifying the most suitable electrophile appropriate for
selective labeling of activation segment cysteine while exploring various distances of the
electrophilic group. Beginning with the commercially available Boc-protected isoleucine a
standard coupling was performed with N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide (EDCI)
hydrochloride, 1-hydroxybenzotriazole (HOBt) hydrate, 4-methylmorpholine as the base,
ethanolamine, and dichloromethane (DCM) as the solvent at ambient temperature for 16 hr. The
resultant alcohol was exposed to Appel reaction conditions to substitute the alcohol with a
halide. A halide source (I2, CBr4, or CCl4), triphenylphosphine, imidazole, and DCM and the
solvent at 0 °C for 4 hr yielded the alkyl halide electrophilic analogues 22-24.
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Figure 25. Synthesis of various amino acid—electrophile derivatives.

To produce a sulfur analogue for generating a disulfide bond with Cys199 and the Bocprotected isoleucine, a standard coupling was performed with N-(3-dimethylaminopropyl)-N′ethylcarbodiimide

(EDCI)

hydrochloride,

1-hydroxybenzotriazole

(HOBt)

hydrate,

4-

methylmorpholine as the base, cysteinamine, and dichloromethane (DCM) as the solvent at
ambient temperature for 16 hr.
To produce a maleimide analogue for covalent attachment with Cys199 and the
electrophilic maleimide group on the Boc protected isoleucine. A standard coupling was
performed with N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide (EDCI) hydrochloride, 1hydroxybenzotriazole (HOBt) hydrate, 4-methylmorpholine as the base, ethanolamine, and
dichloromethane (DCM) as the solvent at ambient temperature for 16 hr. The resultant alcohol
was purified on silica and then made into an electrophilic group with triphenylphosphine, diethyl
azodicarboxylate (DEAD), and tetrahydrofuran (THF) as the solvent at -78 °C for 4 hr for the
SN2 reaction with commercially available maleimide to produce 20.
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3.4.3 Evaluation of single amino acid analogues as PKACα and AKT inhibitors.
The first set of single amino acid analogue compounds with the vinyl ketone was tested
for their inhibitory properties in a biochemical fluorescence resonance energy transfer (FRET)
assay (Z’-LYTE kinase assay, Ser/Thr kit 1 and 6, Invitrogen, assays were run as published in
reference 34)34 using commercially available recombinant PKACα and AKT1 (Invitrogen,
P2999). This assay utilizes proprietary peptides that serve as substrates for the target enzyme and
are labeled with coumarin and fluorescein at opposite ends for FRET action. The kinase
(PKACα or AKT1) transfers a phosphate to the substrate from ATP. The reaction is halted and
the FRET signal measured. The detectable FRET signal is only from phosphorylated substrate
where the coumarin and fluorescein are still connected by the substrate scaffold.
Unphosphorylated peptide is cleaved by a proprietary protease provided in the kit. The
proteolytic action prevents FRET from occurring with the unphosphorylated substrate.
Therefore, a decrease in FRET signaling is indicative of decreased enzymatic action. The
compounds added that decrease FRET signaling can be interpreted as inhibitors of PKACα or
AKT1. However, whether these are ATP or substrate competitive inhibitors is, generally, not
discernable from these data.
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Figure 26. PKACα inhibition graphs.

Table 10. PKACα IC50’s by Z’Lyte Assay
PKACα IC50 (μM)
Compound
3
56.2a
6
>100
9
>100
10
>100
18
>100
Table 10. a: value obtained from reference 24.34
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3.4.4: Results of Single Amino Acid Analogues
The four compounds were tested against PKACα in triplicate. These compounds did not
show any inhibition at concentrations up to 100 μM. This observation could be attributed to a
number of factors. It is possible the vinyl ketone Michael acceptor is too reactive and is
essentially used up non-specifically before it can alkylate a residue that inhibits the enzyme. It is
also possible that the cysteine is not as accessible when the full length peptide is not present and
therefore the electrophile cannot reach the cysteine, although previous attempts with single
amino acid analogues by other groups were successful (see Chapter 1). Another possibility that
more closely matches previously published results is that the reactivity of Cys199 towards
external electrophiles is significantly reduced in the presence of ATP (at various physiologically
relevant concentrations, see chapter 1 Type IV inhibitors of PKACα, section 1.3); therefore, the
inhibitory effect seen by alkylation of Cys199 would not have occurred and the amino acids
alone would not have sufficient binding affinity to inhibit activity.
Three of the single amino acid analogues were also tested against AKT1 in triplicate
using the Z’Lyte assay. The purpose of testing against AKT1, another AGC kinase, was to
provide valuable selectivity data. AKT1’s hydrophobic pocket at the P+1 position has been
demonstrated to be better suited for aromatic moieties and it was hypothesized that we could
obtain selectivity both for and against AKT1 via this mechanism. AKT1 was selected due to both
its similar consensus sequence with PKACα (RXRXXSF and RRXS respectively) and its
availability in our lab. The results are displayed below.
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Compound
AKT1 IC50 (μM)
95% Confidence Int PKACα IC50 (μM)
a
3
0.58
.46-.75
56.2a
6
1.56
1.36-1.78
>100
9
12.32
9.89-15.35
>100
10
>100
14
2.44
1.23-2.76
18
>100
Table 11. Summary information of AKT1 and PKACα inhibition.
Table 11. a: value obtained from reference 24.34

6

9

14

Figure 27. AKT1 inhibition.
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In all cases, compounds that were tested against both enzymes (3, 6, 9) indicated they
were more potent inhibitors of AKT1 than PKACα. Compounds 3, 14, 9, and 6 had 0.58, 2.44,
12.32, and 1.56 mM activity, respectively. It was not unexpected that the phenylalanine
analogues would have better activity than the glycine analogues. This is particularly true when
considering that the available data for TPCK, a phenylalanine based chloromethyl ketone
commercially available and commonly used as a protease inhibitor, was demonstrated to have
selectivity for AGC kinase cysteines in the activation loop that have a phenylalanine
hydrophobic pocket adjacent to the cysteine of interest.35
3.4.5: Discussion of the Single Amino Acid Analogue Results
After review of the data and available literature it was determined that, first, the single
amino acid residues would not provide the desired properties to reliably target Cys199. Second,
the single amino acid analogues would not provide the selectivity required for activity-based
protein profiling on either a family or target selective scale (for the kinome). Third, that the vinyl
ketone is too reactive of an electrophile to be reliably used and stored under mild conditions for
extended periods of time (a logistical consideration). Lastly, it appears reactivity of Cys199 is
not as robust as indicated with pure enzyme and it is necessary to increase the amount of time the
electrophile is in proximity of the thiol side chain for adequate alkylation to occur. Therefore, a
new hypothesis was needed to address issues of reactivity, selectivity, and binding action.
3.5 Production and Evaluation of Longer Peptide Probes
By returning to the original structure-based design approach of PKI complexed with
PKACα it was concluded that there are a minimum number of amino acids from the inhibitor
peptide required for the preparation of an activity based probe with the necessary properties. It
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was also hypothesized that there was a need for more stable electrophiles and that, despite their
weaker reactivity, the appropriate placement by the PKI scaffold would be enough for sufficient
labeling at Cys199. Additionally, new assays were required to address the need to determine if
labeling was occurring in addition to the inhibitory properties. Therefore the Z’Lyte assay was
no longer sufficient for the purposes of characterization (as a stand alone indicator), and a new
method to assist in determining the mechanism of action was required.
3.5.1 Experimental design.
It was decided that gel electrophoresis techniques would allow for a more mechanistic
characterization of new probes (as compared to the FRET assay). The initial experiments focused
on fluorescence detection techniques using compounds tagged with rhodamine and different
electrophiles. To perform these experiments, sufficient amounts of probe and a large scale source
of protein were required. As a result, manual solid phase peptide synthesis to produce the peptide
scaffold for the probe, solution phase organic synthesis to produce large quantities of a reactive
rhodamine derivative, solution phase organic synthesis to produce the electrophiles, and
recombinant protein expression for the preparation of PKACα presented themselves as solutions
to the problem.
The general strategy selected for the production of probe involved a combination of
synthetic steps that took place both on solid phase and in the solution phase with a (necessary)
two-phase purification work up. The peptide was to be synthesized on a super acid-sensitive
resin. The final N-terminal deprotection was to be done on the resin, then a tag could be placed
on the N-terminus while still on solid phase using basic SN2 conditions. The use of a super acidsensitive resin is critical to the successful synthesis of these probes. The super acid-sensitive
resin allows for orthogonal deprotection from the resin while maintaining the side chain
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protecting groups on the amino acids. The side chain protecting groups prevent undesired
coupling at later stages in the synthesis, not just for the Fmoc-based solid phase synthesis.
The 2-chloryltrityl chloride (2-CTC) resin was selected to be the solid support system for
our Fmoc-based peptide chemistry. The 2-CTC resin has a number of desirable properties. It has
been proven effective in Fmoc-based peptide syntheses.123 The cleaved alcohol resin can be
regenerated with thionylchloride to produce the original 2-CTC species, if desired.124 It is not
patent protected and is generally cheaply commercially available from multiple vendors in
various preparations. Perhaps most importantly, it is super acid-sensitive, which means we can
use a <3% TFA solution in dichloromethane to remove the peptide from the resin.123 These
weakly acidic conditions will preserve the side chains of the amino acids necessary as part of the
PKI scaffold and allow for subsequent orthogonal chemistry.
The fluorescent tag rhodamine was selected for the development of the first round of
peptide-based probes. Many derivatives of rhodamine are available, as it is a common
fluorophore. However, we needed relatively large quantities of a reactive rhodamine derivative
to synthesize our probes and commercially available analogues were generally cost prohibitive.
Therefore, the synthesis began with the generic rhodamine B which is very economical. For a
linker, N-methylamino butyric acid was coupled. This route was adapted from a previously
reported synthesis and improved upon it to prepare our rhodamine-NHS ester in large
quantities.125,126
The electrophile was reevaluated and based on available data it was determined to move
forward with the chloromethyl ketone. The chloromethyl ketone has a variety of pros and cons
for its usage in ABPP. Very much in its favor is its selectivity for cysteine over other amino
acids. It is also relatively small and can be incorporated into various scaffolds. Conversely, its
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synthesis it difficult and requires the use of a potentially explosive diazomethane intermediate.
As a result the first priority was to identify a different route to the chloromethyl ketone that did
not require diazomethane.
3.5.2 Preparation of the Chloromethyl Ketone
In an attempt to avoid using diazomethane as the intermediate to the production of
chloromethyl ketone, a new synthetic route was explored that would allow the production of
glycine chloromethyl ketone without the need for the specialized equipment to produce
diazomethane. The initial starting materials benzylamine and epichlorohydrin are commercially
available. Mixing benzylamine and epichlorohydrin in cyclohexane at ambient temperature for
16 hrs produces 25. Followed by addition of the Boc protecting group, this is important if one
desires to acid deprotect in the end and produce the stable HCl salt. The Boc group was added
using Boc anhydride in dichloromethane at ambient temperature for 16 hr to produce 26. The
alcohol was oxidized to a ketone by Swern oxidation conditions to produce the doubly protected
chloromethyl ketone (27). Finally the benzyl group was removed with Pd(OH)/C in ethanol
(Pd/C was not effective at removing this group), and hydrogen at 1 atm for 16 hr. While this did
produce the desired chloromethyl ketone in quantities to move forward, we would need large
quantities and the yield was relatively poor at this time (conditions were not optimized).
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Figure 28. Alternative route to glycine chloromethyl ketone.

As a result, the use of diazomethane chemistry to produce the selected chloromethyl
ketone moiety for incorporation into our probe was necessary. To produce the diazomethane
intermediate, the mixed anhydride of the Boc-protected amino acid must be produced.127 This is
done by incubating the Boc-protected amino acid with isobutyl chloroformate in tetrahydrofuran
with N-methylmorpholine as the base at -20 °C for 0.5 hr. Diazomethane is prepared from a
stable, commercially available, derivative: Diazald. Diazald is broken down into diazomethane
with KOH, the resulting diazomethane is then distilled with ether into a separate flask and kept
cool in an ice bath. The diazomethane ether solution is poured directly into the mixed aldehyde
produced in the previous steps and allowed to react for 4 hr, while the remaining diazomethane is
quenched. The Boc protected amino acid with the diazomethane moiety is stable enough for
purification. This product is treated with 4 N HCl in dioxane and monitored by TLC until
completion. The resulting HCl salt can be crashed out by triturating with ether allowing for easy
isolation without the need for column chromatography (Figure 29).127
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Figure 29. Diazomethane route to chloromethyl ketone formation.

3.5.3: Preparation of Rhodamine-NHS Ester.
The need for an abundant source of fluorophore led to an extensive search of the
literature for a method to rapidly access large quantities of a reactive rhodamine derivative. What
was found was a derivative of rhodamine B that would provide a linker and the ability to make
the NHS ester for nucleophilic substitution onto the N-terminal of the peptide.125,126 Starting with
rhodamine B, a standard coupling was performed with N-(3-dimethylaminopropyl)-N′ethylcarbodiimide (EDCI), N-hydroxysuccinimide, and dichloromethane (DCM) as the solvent
at ambient temperature for 16 hr. The resulting NHS ester 35 is ideal for the SN2 chemistry we
employed to attached the N-methylamino butyric acid. The secondary amine is critical for the
rhodamine to maintain its fluorescent characteristics; if it were not a secondary amine it would
be subject to intramolecular lactam formation and subsequent quenching of the fluorescent
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character. The resulting acid 34 is then exposed to a second round of standard coupling
conditions,

although

this

time

with

N,N′-dicyclohexylcarbodiimide

(DCC),

N-

hydroxysuccinimide, and dichloromethane (DCM) as the solvent at ambient temperature for 16
hr. The final product was crashed out of solution with ether and collected as a viscous resin.
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Figure 30. Synthesis of Rhodamine-NHS ester.
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3.5.4: Preparation of Peptide Scaffold.
The traditional approach to large scale peptide synthesis relies on the use of solidphase Fmoc based chemistry.123 The super acid sensitive 2-chlorotrityl chloride (2-CTC) resin
was selected as the solid phase support system. It was hypothesized that incorporating the amino
acids

18

RRNA21 onto the single amino acid Ile(22) (RRNAI) would be adequate for

demonstrating the feasibility of the probe and testing against the initial activity-based
experiments. Additionally, the consensus sequence for PKACa is RRXS; thus, by incorporating
more of the PKI scaffold, the probe now contains the consensus sequence.42,55,128 The 2-CTC
resin was first swelled with DCM for 5 minutes, then DMF for 5 minutes. Fmoc-Ile-OH was
added with triethylamine as the base and allowed to react for 1 hr. Once the first amino acid is
loaded onto the resin, iterative fmoc based chemistry can be used to add the additional amino
acids. All amino acids were purchased from ChemImpex as Fmoc-protected derivatives. The
Fmoc is removed with a 20% piperidine solution. There is a subsequent coupling with the next
amino acid in the sequence. This is followed by another deprotection in 20% piperidine. These
steps are repeated until the desired peptide is produced.
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Figure 31. Solid phase synthesis of the pentapeptide.

3.5.5: Assembly of the PentaPeptide Probe.
The glycine chloromethyl ketone was synthesized in the same manner as described above
(Scheme 5). The glycine was hypothesized to allow for the greatest maneuverability of the
electrophile to accomodate the trajectory of the thiol group on Cys199, while not interfering with
the positioning of the important PKI-Ile22 side chain.
The order in which the pieces of the probe are assembled is critical to the successful
synthesis. While the peptide is still on the resin it was treated with a solution of Rhodamine-NHS
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ester and triethylamine (TEA) in dimethylformamide (DMF). The reaction was stirred for 3 hr,
washed with DMF five times, then DCM five times.
The resin-bound product was taken directly to the next step. By attaching the rhodamine
while on solid phase the N-terminus is effectively capped, which is essentially for subsequent
reactions, and allows for easy work up. Rhodamine-PKI(18-22)-OH was then cleaved from the
resin with a 2% TFA in DCM (this preserves the side chain protecting groups). The solvent was
removed under vacuum (Scheme 8) and the product was characterized by MALDI mass
spectrometry and taken directly to the next step.
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Figure 32. Solid phase addition of rhodamine tag and soft cleavage.
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The next reaction is the coupling of the glycine chloromethyl ketone 32, the peptide is
preincubated

with

(benzotriazol-1-yloxy)tripyrrolidinophosphonium

hexafluorophosphate

(PyBOP), and diisopropylethylamine (DIEA) in DCM. Then, the glycine chloromethyl ketone
was added to the solution. The reaction was stirred for 16 h. Solvent was removed and the
purified on a silica gel flash column, 0-30% over 10 minutes MeOH/DCM. The probe is then
globally deprotected with 95:2.5:2.5 TFA:TIS:H2O (5 mL) for 1 hr, and triturated with ether to
afford crude product. This product was then purified on HPLC (95:5 to 75:25 H2O:ACN over 20
minutes). The two-stage purification has proven to be a necessary extra step for the successful
isolation of the final product (Scheme 9). Attempts to circumvent the silica column have resulted
in the inability to isolate final product with sufficient purity to conduct research.
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Figure 33. Coupling of the electrophile to 37 to generate 38.

3.6: First Protein Production Experiments
The initial experiments utilized PKACα protein prepared using the previously reported
procedure by Taylor et al.129 The PKACα plasmid is available from Addgene (Plasmid #14921),
The C199A mutant was prepared with a QIAquick exchange kit. PKACα is particularly suited
for expression in bacteria due to its ability to autophosphorylate. Upon transcription PKACα
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undergoes cis phosphorylation at Ser338.130 It does undergo autophosphorylation at Thr197;
however, this is a much slower reaction and does not result in complete conversion to the fully
phosphorylated protein.131
In mammalian cells, phosphorylation at Thr197 occurs rapidly and irreversibly by
PDK1.38,130 Competent E. coli cells were transformed with the wt or mutant PKACα plasmid and
grown for 16 hr at 37 °C with ampicillin selection and moderate shaking in a test tube. An
aliquot was taken into a 1 L Erlenmeyer flask with ampicillin selection and auto-induction media
and grown at 37 °C for 16 hr with moderate shaking. Following growth, cells were spun down at
6000 rpm for 10 min, and lysed into buffer (25 mM Tris, pH 8, 300 mM NaCl, and 10 mM
imidazole) at ambient temperature. Cellular debris was removed by centrifugation at 20,000 rpm
for 30 min and the soluble fraction was decanted onto a nickel column. Following sample
loading, the nickel column was washed with 5 column volumes of a non-eluting buffer that
prevents nonspecific binding to the nickel (25 mM Tris, pH 8, 300 mM NaCl, and 10 mM
imidazole). Isolated PKACα protein is then eluted with 100 mM imidazole and concentration
determined by absorption at 280 nm on a spectrophotometer. Purity was analyzed by Coomassie
stain (Figure 34 below).
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Figure 34. Coomassie stain of purified recombinant PKACα.

3.6.1 Validation of Rhodamine
Prior to completion of the fully assembled pentapeptide probe it was necessary to
determine whether or not the rhodamine analog synthesized could be detected on a GE Typhoon
gel imaging instrument. Recombinant PKACα was incubated with 25 equivalents of RhodamineNHS (35) for 1 hr at ambient temperature. To the solution was then added a denaturing sample
buffer and incubated at 100 °C for 5 minutes before being run on a 10% SDS page gel at 170 V
for 1 hr. The gel was imaged on a GE Typhoon gel imager set for detection of the similar
TAMARA fluorophore.
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As was anticipated, there was robust labeling of all contents of the protein solution. The
NHS ester (35) is a nonspecific electrophile and will robustly react with all available
nucleophiles in solution, if allowed to react for sufficient time in suitable conditions.

Figure 35. Evalutation of 35.

3.6.2: Discussion of Rhodamine-NHS Labeling Experiment.
There is significant labeling in the higher molecular weight regions mostly due to how
the sample was denatured. The initial experiments did not contain a disulfide reducing agent,
such as betameracaptoethanol (BME), which was omitted to ensure that there was no reversal of
any labeling reactions that may have occurred. This lack of disulfide reducing agent allowed
significant intermolecular disulfides to persist during the gel electrophoresis and imaging steps.
The described experiment provided the necessary proof for utilizing the rhodamine derivative
synthesized in the lab.
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3.7: Biological Characterization of the pentapeptide (38) as a probe for PKACα.
It was decided to examine the new probe for both its ability to inhibit wt PKACα in the
Z’Lyte kinase assay and its ability to label the protein as wt, mutant, and in complex biological
mixtures. All gels were cast in house and made to contain 10% acrylamide, following the exact
procedure detailed in the experimental. HCT-116 cell lysates are known to overexpress AKT
(Cys310 known to be nucleophilic see Chapter 1, section 1.3), these were procured in and
supplied by Dr. Richard G Moran’s lab in the pharmacology and toxicology Department of
VCU.
Multiple gel electrophoresis experiments were conducted to characterize the pentapeptide
probe and its interactions with various substances. The first gel electrophoresis experiment
shown below examined the labeling of the pentapeptide probe with wt recombinant protein,
C199A mutant, the HCT-116 cell lysates, and the HCT-116 cell lysates spiked with wt
recombinant protein. The ladder was purchased from Biorad and run at 1:100 dilution for
fluorescence experiments and at 1x for colorimetric experiments.

For lanes containing wt

protein recombinant PKACα was incubated in phosphate buffer (25 mM PO4 pH 7.2) with
different concentrations of probe for 1 hr at ambient temperature. The samples were quenched
with a denaturing sample buffer with bromophenol blue marker and incubated at 100 °C for 5
min. The resulting solution was loaded onto the gel and run at a constant 170 V for 1 hr. The
C199A mutant was incubated in the same manner and conditions as the wild type protein. The
HCT-116 cell lysates were incubated in identical conditions. The additional HCT-116 cell lysate
lanes were spiked with recombinant PKACα prior to incubation with probe. Then, all lanes were
imaged on a typhoon imager.
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Probe 38 Conc (µM)
Wt PKACa 5µg
C199A PKACa 5µg
HCT-116 Cell Lysates

-

+
-

30 - 30 + - - +
- + + - - -
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+
-

-

-

-

-

30 5 30 5
- - + +
- - + + + +

75kDa
PKACα

25kDa

Figure 36. Examination of Probe 38 with wt PKACα (lanes 2, 3, 6, and 8), C199A (lanes 4 and
5), and HCT-116 cell lysates (lanes 11-15).
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3.7.1: Discussion of Figure 36.
This gel (Figure 36) demonstrates a number of positive characteristics of the probe and
provides significant data with which to move forward. Due to the nature of how gels work, it can
be concluded that the probe does in fact covalently label the protein in an irreversible manner.
The labeling by the probe was robust and easily detected. The probe did not label non-selectively
in the HCT-116 cell lysates, meaning that there is not aberrant labeling throughout the lane.
What is particularly interesting is the location of the single band in lanes 13 and 15, which
contain 30 mM of probe 38 and 16 μg of lysates. This band strongly correlates with the
molecular weight of AKT1, and matches some of this labs previous results.34 It is also important
to note that the cysteine in AKT1 was found to be nucleophilic (see chapter 1, section 1.3). Probe
38 displays remarkable selectivity in a complex biological mixture. Additionally, high selectivity
for the upper band was retained in extreme excess of recombinant protein, it is possible that bio
reagents (such as ATP) in the lysate are inhibiting labeling of PKACα. The probe did however
label the C199A mutant of PKACα, which was unexpected in that the probe was designed to
only react with Cys199. It may be possible that the probe is alkylating another residue. There is
precedent with Lysine-72 being alkylated by a fluorosulphone analog, by Taylor et al.132
However, Lys72 is not located in the substrate-binding site. There is another cysteine residue.
However, it is not located near the substrate-binding site either.
3.7.2: Activity-based ATP effects on labeling.
To further examine the characteristics observed in the gel above and to test the hypothesis
that ATP may be inhibiting labeling, another gel (Figure 29) was run. Only recombinant PKACα
was run on this gel and various biologically relevant conditions were examined. Physiologically
relevant levels of magnesium chloride were examined: the Mg2+ cation is required for efficient
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catalytic activity and substrate turnover.80,82,93 ATP was examined at 1 equivalent to the enzyme
(~5.8 μM). These conditions were introduced prior to incubation with the probe. Additionally,
fluoresceine-maleimide and Rhodamine NHS-ester were utilized as well. The incubation
conditions for each of the probes were identical and are as follows. Recombinant PKACα was
incubated in phosphate buffer (25 mM PO4 pH 7.2) with different concentrations of probe and
physiologically relevant substances for 1 hr at ambient temperature. The samples were quenched
with a denaturing sample buffer with bromophenol blue marker and incubated at 100 °C for 5
minutes. The resulting solution was loaded onto the gel and run at a constant 170 V for 1 hr.

Probe
Probe Conc (µM)
Recombinant PKACa 5µg MgCl 2 (µM)
ATP (equivalents)

+
-

A A A
31 62 154
+ + +
- - -

A A A A
- - - B
62 62 62 154 - - - 10
+ +
+ +
- - + +
- 10k 6 6
- - + +
1 1
1 1
- - + +

C
5
+
+
+

-

75kDa
PKACα
25kDa

Figure 37. Examination of A = 38, B = fluoresceine-maleimide, and C = 35.

3.7.3: Results and Discussion of Figure 37.
As was demonstrated in the previous experiment, robust labeling occurs when
recombinant protein and probe are incubated together without any other additives. However,
when ATP is introduced (1 equivalent) to the incubation conditions, a slight reduction in labeling
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is noted (lane 6). Upon addition of 10 mM MgCl2, labeling is completely abolished (lane 7).
Addition of 1 equivalent of MgCl2 causes a reduction in labeling (lanes 8 and 9). FluoresceineMaleimide and Rhodamine-NHS both label robustly; however, fluoresceine-maleimide appears
to only label one band of PKACα (lane 13). The rhodamine-NHS labels nonspecifically (lane
14).
Both a divalent metal ion (such as Mg2+) and ATP are required for efficient phosphate
transfer to a substrate (it will occur in the absence of, but not efficiently).80 The addition of 1
equivalent of ATP incurred a minor reduction in labeling efficiency by the probe. This is an
unfortunate observation in that physiologically relevant concentrations of ATP are significantly
higher than those examined in the gel (3-10 mM).133 Also, addition of the MgCl2 salt at 10 mM
concentration completely abolished labeling (this is the salt concentration used in the inhibition
assays to be discussed below). While robust labeling is observed, the probe will not label in
active-like conditions, which excludes it from being classified as an activity-based probe for
PKACα; however, selective labeling of what appears to be AKT in the cell lysates is a positive
result.

3.7.4: Inhibition of PKACα with RAC-1-280.
To determine whether or not the probe was an effective inhibitor of wt PKACα, the
Z’Lyte kinase inhibition assay kit was utilized. The IC50 of probe 38 was determined to be 6.9
μM. While the IC50 was higher than would be expected for a covalent inhibitor, it is clear from
the gel experiments labeling is most likely inhibited in conditions that would allow for
phosphoryl transfer. It may be that the same protective features the previous Type IV irreversible
inhibitors (see Chapter 1, section 1.3) encountered with ATP in the inhibition assay are at work.
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As well as from MgCl2, the inhibition assay conditions are run at 10 mM MgCl2 (Invitrogen
Z’LYTE manufacturer protocol). This concentration of MgCl2 was shown to completely abolish
labeling. Therefore, the IC50 may only be indicative of the reversible peptide. The intention was
that this data, in conjunction with the mechanistic data gleaned from the in vitro gel experiments,
would validate the probe. The IC50 data plus the lack of selectivity for PKACa in a complex
biological mixture leads to a hypothesis that more of the inhibitor peptide sequence PKI was
needed to obtain selectivity for PKACα and to produce an activity-based probe.
3.7.5: DFG Sequence Alignment.
To determine the broad applicability of the method to the kinome, a sequence alignment
was performed on the eukaryote protein kinome. It was determined that 99 human protein
kinases share a similar cysteine in the activation loop. Among them is AKT1 (discussed in
Chapter 1, section 1.3), and the homologous PKG (from the same family of AGC kinases). The
results of the alignment are shown in the experimental (Chapter 4, Figure 69). The cysteine that
corresponds to the position in PKACα is highlighted in a red box. Other cysteines in the
activation loop are highlighted in orange text and present potential targets by a similar strategy;
that is a substrate based small molecule/peptide with an appropriately placed electrophile could
have the potential to react with these cysteines in an activity-dependent manner. The alignment
and analysis was performed with ClustalX 2.1 and the kinome fasta file was obtained from
kinase.com.
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3.7.6: Discussion of the Pentapeptide Experiments.
The pentapeptide analogue (Rh-PKI(18-22)-G-(CMK)) provided significant strides in the
production of active-site directed probes for the lab and established protocols for labeling and
imaging various samples. The rhodamine derivative synthesized was proven effective at labeling
and detection. The synthesis that was modified to obtain large quantities of the rhodamine-NHS
proved to be easily replicated and to have agreeable yields. The glycine chloromethyl ketone
moiety was shown to effectively label recombinant PKACα. The synthesis of the entire probe
was a significant step as well and the two-stage purification was shown to be necessary and this
synthesis is easily applied to other peptides and compatible electrophiles. This is the synthetic
method that was carried forward to the remaining probes. The probe also displayed remarkable
selectivity in HCT-116 cell lysates, albeit not for PKACα, but it is important to note that the
chloromethyl ketone moiety will readily react with free sulfurs and the level of selectivity
observed is a significant result. Additionally, the band that is labeled occurs at a molecular
weight consistent with the molecular weight of AKT, which has a nucleophilic cysteine (Cys310)
that has been demonstrated to react with various electrophiles (see chapter 1, section 1.3).
The characterization of (Rh-PKI(18-22)-G-(CMK)) also revealed a number of negative
attributes. Labeling can easily be abolished with physiologically relevant concentrations of
MgCl2. ATP appears to have a protective effect on (Rh-PKI(18-22)-G-(CMK)) labeling of wt
PKACα. (Rh-PKI(18-22)-G-(CMK)) does not label PKACα in HCT-116 cell lysates (to a
detectable level), even when the sample was spiked with excess PKACα. The IC50 determined by
the Z’Lyte kinase assay was indicative of reversible kinetics (high IC50 and a hill slope of 1). The
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data would suggest that, despite (Rh-PKI(18-22)-G-(CMK)) being an active-site directed probe,
it is not an activity-based probe in that it actually is prohibited from labeling in conditions
conducive to catalytic activity.
It was decided at this point to synthesize a larger portion of PKI in order to gain affinity
for the catalytic subunit and subsequently increase labeling. PKI(14-22)-Amide has been shown
to retain suitable affinity for PKACα (Ki 36 nM) while being synthetically accessible at 9 amino
acids in length. Therefore, the next analogue synthesized was Rh-PKI(14-22)-Gly-(CMK)
3.8: Preparation of PKI(14-22)Gly-CMK
The same order of operations was utilized to complete the synthesis of PKI(14-22)GlyCMK. The 2-CTC resin proved to be a valuable resin for this synthetic route and resin preloaded
with Ile was purchased from ChemImpex. The same batch of glycine chloromethyl ketone
produced utilizing the diazomethane intermediate was used. The synthetic route we chose to
make our rhodamine NHS ester provided us a route that enabled large scale production;
therefore, we did not have to synthesize more for the production of this probe as the previous
batch was sufficient. An additional step was added to the peptide synthesis, an acetyl capping
step to cap off any uncoupled N-termini after each coupling step.
Schemes 10 and 11 depict the production of the PKI(14-22)-GlyCMK probe. Briefly, 2chlorotrityl chloride (2-CTC) resin preloaded with Ile was purchased from ChemImpex (200-400
mesh, Catalog #03472). Peptide couplings were carried out manually via standard Fmoc amino
acid protection chemistry. Amino acids were activated and added to resin with (benzotriazol-1yloxy)tripyrrolidinophosphonium hexafluorophosphate (PyBOP) and diisopropylethylamin
(DIEA). The resin was swelled with DCM (5 min) then DMF (5 min). All amino acids were
added by the general procedure that follows (with the exception of Arg, which underwent double
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couplings): Fmoc deprotection (20% piperidine in DMF, 3 x 5 min), wash with DMF 3x, amino
acid coupling (PyBOP, DIEA 0.1 M in DMF, 1 hr, 2x for Arg), wash with DMF 3x, acetyl cap
(pyridine:acetic anhydride 20:20, 0.15 M in DMF, 30 min). After the final deprotection (Gly 14)
with 20% piperidine in DMF, the resin-bound product was taken directly to the next step.

2-Chlorotrityl
chloride resin
(Chem-Impex)

Cl
Cl

Iterative
Fmoc Solid Phase
Peptide Synthesis

H 2N Gly-Arg(Pbf)-Thr(t-Bu)-Gly-Arg(Pbf)-Arg(Pbf)-Asn(Trt)-Ala-Ile-O

39
Figure 38. Iterative solid phase synthesis of 39.

While the peptide is still on the resin it was treated with a solution of RhodamineNHS
ester and triethylamine (TEA) in dimethylformamide (DMF). The reaction was stirred for 3 h,
washed with DMF 5x, then DCM 5x. The resin-bound product was taken directly to the next
step. By attaching the rhodamine while on the solid phase the N-terminus is capped, which is
essential for subsequent reactions, and allows for easy work up. Rhodamine-PKI(18-22)-OH was
then cleaved from the resin with a weakly acidic solution of TFA in DCM (2% v/v). The solvent
was removed under vacuum and product taken directly to the next step. The next reaction is the
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coupling of the glycine chloromethyl ketone 32, where the peptide is preincubated with
(Benzotriazol-1-yloxy)tripyrrolidinophosphonium

hexafluorophosphate

(PyBOP)

and

diisopropylethylamine (DIEA) in DCM. Then the glycine chloromethyl ketone was added to the
solution. The reaction was stirred for 16 hr. Solvent was removed and the purified on a silica gel
flash column, 0-30% over 10 minutes MeOH/DCM. The probe is then globally deprotected
followed by trituration with ether to afford crude product. Product purified on HPLC.
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Figure 39. Mixed solid phase and solution phase chemical assembly of 41.
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3.9: Biological Characterization of Rh-PKI(14-22)-G-(CMK).
In a similar setup, the longer length probe was examined for its ability to label PKACα.
The limit of detection for protein amounts was examined. The saturability of labeling was
examined with non-covalent Myr-PKI(14-22)-Amide, which examines a number of
characteristics and will be discussed after in section 3.9.2. The labeling of the cysteine to alanine
mutant (C199A) examined the residue being labeled. Oxidation of the cysteine was attempted in
order to mimic the endogenous regulatory mechanism of glutathiolation. Labeling under
different pH conditions examined the differences in the two bands. The Coomassie stained gels
and fluorescent gels of applicable experiments underwent secondary analysis due to their overlap
and the predominant band species was determined and examined. Additionally, the protein
production was modified to better represent physiological conditions (see section 3.9.11). All
gels were cast in house and made to contain 10% acrylamide, the exact procedure is detailed in
Chapter 4, the biological experimental section.
3.9.1: Protein—Probe Limit of Detection.
Many gel electrophoresis experiments were conducted with the nonapeptide-based probe.
The first, of note, is detailed below where the limit of detection of protein in the presence of
excess probe was examined. Protein concentration was determined by absorbance at 280 nM and
diluted such that it was 1 mg/mL in phosphate buffer (25 mM PO4 pH 7.2). The probe was made
as a 10 mM stock in DMSO and diluted accordingly for appropriate final concentrations in the
gel experiments. The gel was cast as 1.5 mm thick and the wells were a total volume of 20 μL.
The samples were quenched with a denaturing sample buffer (made in-house and described in
the experimental) and incubated at 100 °C for 5 minutes. The denaturing sample buffer did not
contain a disulfide reducing agent (such as betamercaptoethanol, BME).
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Figure 40. Protein concentration detection analysis.

3.9.2: Results and Discussion of Figure 40.
The Rh-PKI(14-22)-G-(CMK) probe displays robust labeling of isolated recombinant
PKACα at varying amounts. The last prominent labeling signal is observed at 2 μg of
recombinant protein; 1 μg and less does not provide as potent signal. The lack of disulfide
reducing agent is apparent in the upper portions of the gel (indicating higher molecular weight);
these are most likely intermolecular disulfide bonds. The double banding of recombinant
PKACα is observed again. The extended length of the peptide recognition scaffold did not
provide the level of selectivity desired for single band images at all observable protein
concentrations. It is clear that optimization is necessary moving forward for a gel image that
consists of only one band.
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3.9.3: Mutant labeling experiments.
In order to fully characterize the mechanism of action of the Rh-PKI(14-22)-G-(CMK)
probe, additional gels were run to examine the effects of other changes. In Figure 41 below, the
labeling characteristics of the probe were examined against the cysteine mutant of PKACα
(C199A) and limit of detection experiments were included with a lower concentration of probe.
Both protein concentrations were determined by absorbance at 280 nm and diluted such that it
was 1 mg/mL in phosphate buffer (25 mM PO4 pH 7.2). The probe was made as a 10 mM stock
in DMSO and diluted accordingly for appropriate final concentrations in the gel experiments.
The gel was cast as 1.5 mm thick and the wells were a total volume of 20 μL. The samples were
quenched with a denaturing sample buffer (made in house and detailed in the biological
experimental section) and incubated at 100°C for 5 minutes. This time the denaturing sample
buffer did contain a disulfide reducing agent (betamercaptoethanol, BME). Coomassie staining
was performed with blue G250 in a H2O/MeOH/AcOH solution, and destained with a
H2O/MeOH/AcOH solution.
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Figure 41. Labeling analysis with wild-type and C199A PKACα.

3.9.4: Results and Discussion of Figure 41.
The Rh-PKI(14-22)-G-(CMK) probe displays robust labeling of isolated recombinant
PKACα at the reduced concentration (3 μM). However, robust labeling occurred with the C199A
mutant. It is possible that labeling is occurring at a different residue, e.g., Lysine-72 is in
proximity and has been shown to react with nucleophiles placed in close proximity; this is,
however, unlikely because lysine-72 resides more in the nucleotide-binding site than the
substrate-binding pocket. There is another lysine residue more appropriately placed, Lysine-83,
and may be a target of an appropriately placed electrophile. The distance from the alpha-carbon
at the P+2 position is 5.6 Å to Lys83 and it is 8.3 Å to Cys199. This observation is interesting
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and not necessarily an exclusion for qualification of an activity-based probe. The C199A mutant
does retain activity and such a probe would still label in an activity-dependent manner. What is
fortunate from this experiment, however, is the high molecular weight impurity in the C199A
samples. These two spots give points of reference for alignment, and as a result a secondary
analysis was performed by overlapping the Coomassie stained gel and the fluorescent image,
detailed below.

Figure 42. Coomassie and fluorescence image overlap from Figure 41.
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3.9.5: Saturability with Myr-PKI(14-22)-Amide.
To further characterize the mechanism of action of the Rh-PKI(14-22)-G-(CMK) probe
additional gels were run to examine the effects of competition with a known inhibitor with a
known mechanism of action. In Figure 44 below, the labeling characteristics of the probe were
examined against the wild-type recombinant PKACα and increasing concentrations of the
reversibile inhibitor Myr-PKI(14-22)-Amide (IC50 = 49.9 nM). Protein concentrations were
determined by absorbance at 280 nm and diluted such that it was 1 mg/mL in phosphate buffer
(25 mM PO4 pH 7.2). The probe was made as a 10 mM stock in DMSO and diluted accordingly
for appropriate final concentrations in the gel experiments. The gel was cast as 1.5 mm thick and
the wells were a total volume of 20 μL. The samples were prepared for gel electrophoresis as
above and Coomassie stain performed as above.
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Figure 43. Saturability of labeling.

3.9.6: Results and discussion of the saturability experiment.
The labeling lane (lane 3), which lacks any inhibitor, displays robust labeling. Increasing
the concentration of Myr-PKI(14-22)-Amide, an active-site directed reversible inhibitor, reduces
labeling in a dose dependent manner. DMSO did not inhibit labeling; therefore, the decrease in
labeling can be attributed to Myr-PKI(14-22)-Amide. The Coomassie stain gel image matches
the fluorescence image. The dose dependent decrease in signal appears to be linear for both
bands (upper and lower), indicating the labeling of each band is occurring in the active site.
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3.9.7 Cysteine oxidation with glutathione.
The mechanism of action of the Rh-PKI(14-22)-G-(CMK) probe must be further
characterized to understand what is happening on a molecular level; therefore, additional gels
were run to examine the effects of cysteine oxidation with glutathione. In Figure 44 below, the
labeling characteristics of the probe were examined against the wild-type recombinant PKACα
and with oxidative conditions to mimic the endogenous regulatory mechanism of
glutathiolaytion at Cys199. PKACα concentration was determined as described above. The
probe was made as a 10 mM stock solution in DMSO and diluted accordingly for appropriate
final concentrations in the gel experiments. The gel was cast as 1.5 mm thick and the wells were
a total volume of 20 μL. Prior to incubation with probe, the appropriate lanes were incubated for
1 hr with relevant reagents (diamide, glutathione (GSH), and diamide with GSH). Then the
samples were incubated with probe for an additional 1 hr. The samples were prepared for gel
electrophoresis as described above, imaging and staining was performed as described above.
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Figure 44. Examination of the effects of cysteine oxidation on labeling.

3.9.8: Results and discussion of the cysteine oxidation experiment (Figure 44).
The control labeling lane (lane 3) displays robust labeling. GSH alone has no observable
impact on labeling of wild-type recombinant PKACα. When diamide is introduced, the bottom
band was selectively knocked out. When diamide and GSH are both introduced, again the bottom
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band was selectively knocked out. The Coomassie image matches the fluorescent image and
indicates equal protein loading. The selective knockout of labeling for the bottom band is an
interesting result that has a number of possible explanations. The unphosphorylated form of the
protein at Thr197 has a disordered activation loop. Therefore, it is possible that Cys199 is more
easily accessible when the activation loop is disordered and, as a result, oxidizes much easier
than the ordered species. It is also possible that oxidation at Cys199 was incomplete. However,
the methods to perform this oxidation were previously reported by Taylor et al.37 Another
possibility is that oxidation is occurring but it is not inhibiting labeling: i.e., that is it is labeling
two different residues one for each band. This last hypothesis was further examined in the next
discussed gel.
3.9.9: Labeling analysis in different pH conditions.
The residue(s) that the Rh-PKI(14-22)-G-(CMK) probe is alkylating must be further
characterized to understand what is happening on a molecular level; therefore, additional gels
were run to examine the effects of pH changes to labeling. In Figure 45 below, the labeling
characteristics of the probe were examined against the wild-type recombinant PKACα and with
phosphate buffer solutions of increasing acidity. The PKACα concentration was determined and
adjusted appropriately as described above. The probe was made as a 10 mM stock solution in
DMSO and diluted accordingly for appropriate final concentrations in the gel experiments. The
gel was cast as 1.5 mm thick and the wells were a total volume of 20 μL. Then the samples were
incubated with probe for 1 hr. The individual samples were prepared for gel electrophoresis as
described above. Imaging and staining was conducted as described above.
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Figure 45. Analysis of pH effects on labeling.

3.9.10: Results and Discussion of Figure 45.
The Rh-PKI(14-22)-G-(CMK) probe displays robust labeling of isolated recombinant
PKACα at the standard buffer pH of 7.2. However, the labeling subsequently reduces with the
corresponding reduction in pH. The reduction in labeling is noted for both band species in a
similar fashion for each decrease in pH. At a concentration of 300 nM of probe, only the labeling
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at pH 7.2 is detectable. A similar reduction of labeling is observed with the off target bovine
serum albumin (BSA). Because the labeling is affected by pH changes for both bands in a similar
manner, the data suggest that the two bands are labeled at the same residue, as their isoelectric
points respond at the same rate to pH changes. This reduces the likelihood (the possibility
mentioned in the cysteine oxidation gel discussed above) that two different residues were being
labeled. Fortunately, with the BSA producing two spots, points of reference for alignment were
available and as a result a secondary analysis was performed by overlapping the Coomassie
stained gel and the fluorescent image, detailed below.

Figure 46. Overlap of fluorescence and Coomassie gel images from Figure 46.
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3.9.11: Analysis of PDK1 phosphorylation on PKACα and labeling.
To examine the effect of phosphorylation of Thr197 on labeling with Rh-PKI(14-22)-G(CMK) recombinant PKACα was phosphorylated in vitro. To promote phosphorylation at
Thr197, the enzyme that performs this catalytic action in vivo (3-phosphoinositide-dependent
protein kinase 1, PDK1) was purchased from Invitrogen. Recombinant PKACα was diluted and
mixed with appropriate amounts of PDK1. In Figure 47, the labeling characteristics of the probe
were examined against the wild-type recombinant PKACα and with recombinant PKACα that
was treated with PDK1. Both protein solution concentrations were determined as described
above. The probe was made as a 10 mM stock solution in DMSO and diluted accordingly for
appropriate final concentrations in the gel experiments. The gel was cast as 1.5 mm thick and the
wells were a total volume of 20 μL. Then the samples were incubated with probe for 1 hr. The
samples were prepared for gel electrophoresis as described above. Imaging and staining was
performed as described above.
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Treated with PDK1 - Figure 47. PKACα treated with PDK1 analyzed with 41.

3.9.12 Results and Discussion of Figure 47.
Probe 41 again displayed robust labeling of isolated recombinant PKACα at the standard
buffer pH of 7.2. Rh-PKI(14-22)-G-(CMK) revealed that by treatment of PKACα with PDK1, a
single band can be produced in the gel. This confirmed the hypothesis of the two bands differing
by a phosphate moiety. However, the method by which we produced the protein was inefficient
(only made 100 μg on the first run) and relies on outside sources of PDK1, which proved cost
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inefficient. Therefore, it was determined that a method to produce large enough quantities for
activity-based experiments of PKACα was necessary. Additionally, probe 41 did not display the
selective qualities necessary for the activity-based probe and it was determined that the
chloromethyl ketone moiety remained too reactive. As a result, a switch to an electrophile with a
reduced reactivity profile was selected.
3.9.13: Discussion of the Biological Characterization of 41.
The nonapeptide analogue 41 enabled extensive characterization of the interactions
between the specifically placed chloromethyl ketone moiety and different isoforms of PKACα.
The probe demonstrated selectivity for pThr197 PKACα over Thr197 PKACα. The labeling was
saturable as was demonstrated with Myr-PKI(14-22)-Amide. The probe did not respond to the
C199A mutant, as was expected. The probe did not respond to the glutathiolation experiments, as
was also expected. It is possible that it is labeling another amino acid. The phosphorylation of
Thr197 was successful and produced enough to confirm the hypothesis.
Based upon these observations, it was decided to synthesize a different derivative of PKI
in order to gain selectivity for the catalytic subunit and ideally increase specific labeling at
Cys199 in an activity-dependent manner. PKI(14-22) has already demonstrated itself to be a
good length and so it was decided not to change the recognition scaffold. It was, instead, decided
to change the reactivity of the electrophile. The hypothesis was that, by reducing the reactivity of
the electrophile, selective labeling would be achieved in both isolated and complex biological
mixtures.
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3.10: The fluoromethyl ketone electrophile
The fluoromethyl ketone moiety is less reactive than the chloromethyl ketone. Its
synthesis is a little more complicated in that the free base of glycine fluoromethyl ketone, for
example, is not stable and therefore a multistep synthesis is necessary.134,135 A multistep synthesis
for the production of glycine fluoromethyl ketone has been published and the results were
reproduced in this lab.135 The scheme is depicted below with the yields obtained in this lab, all
spectral data matched the previously reported values and are detailed in the experimental section.
The protected glycine fluoromethyl ketone was used in the same capacity as the glycine
chloromethyl ketone in terms of appending to the peptide scaffold.
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Figure 48. Synthesis of fluoromethyl ketone.

The chemistry scheme in Figures 49-50 depict the production of the PKI(14-22)-G(FMK) probe. Briefly, 2-Chlorotrityl Chloride (2-CTC) resin preloaded with Ile was purchased
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from ChemImpex (200-400 mesh, Catalog #03472). Peptide couplings were carried out manually
via standard fmoc amino acid protection chemistry. Amino acids were activated and added to
resin with (benzotriazol-1-yloxy)tripyrrolidinophosphonium hexafluorophosphate (PyBOP) and
diisopropylethylamin (DIEA). The resin was swelled with DCM (5 min) then DMF (5 min). All
amino acids were added by the general procedure that follows (with the exception of Arg, which
underwent double couplings): Fmoc deprotection (20% piperidine in DMF, 3 x 5 min), wash
with DMF 3x, amino acid coupling (PyBOP, DIEA 0.1 M in DMF, 1 hr, 2x for Arg), wash with
DMF 3x, acetyl cap (pyridine:acetic anhydride 20:20, 0.15 M in DMF, 30 min). After the final
deprotection (Gly 14) with 20% piperidine in DMF, the resin-bound product was taken directly
to the next step.

2-Chlorotrityl
chloride resin
(Chem-Impex)

Cl
Cl

Iterative
Fmoc Solid Phase
Peptide Synthesis

H 2N Gly-Arg(Pbf)-Thr(t-Bu)-Gly-Arg(Pbf)-Arg(Pbf)-Asn(Trt)-Ala-Ile-O

39
Figure 49. Production of peptide on resin.
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While the peptide is still on the resin it was treated with a solution of Rhodamine-NHS
ester and triethylamine (TEA) in dimethylformamide (DMF). The reaction was stirred for 3 h,
washed with DMF 5x, then DCM 5x. The resin-bound product was taken directly to the next
step. Rhodamine-PKI(14-22)-OH was then cleaved from the resin with a 2% TFA in DCM. The
solvent was then removed under vacuum. Product taken directly to the next step.
The subsequent reaction is the addition of the electrophile by coupling of the glycine
fluoromethyl ketone 47. Briefly, the peptide is preincubated with (Benzotriazol-1yloxy)tripyrrolidinophosphonium hexafluorophosphate (PyBOP), and diisopropylethylamine
(DIEA) in DCM. Then the glycine fluoromethyl ketone was added to the solution. The reaction
was stirred for 16 h. Solvent was removed and purified on a silica gel flash column, 0-30% over
10 minutes MeOH/DCM. The probe is then globally deprotected with 95:2.5:2.5 TFA:TIS:H2O
(5 mL) for 1 hr, then triturated with ether to afford crude product. The crude product was
purified on HPLC (95:5 to 75:25 H2O:ACN over 20 minutes).
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Figure 50. Assembly of Rh-PKI(14-22)-G-(FMK).
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3.11: Expression of Phosphorylated PKACα
To adequately examine a probe for activity-based protein profiling (ABPP), relatively
large quantities of isolated protein are required for activity-based experiments. Previously, it was
determined that in order to examine the physiologically relevant form of PKACα
(phosphorylated at Thr197) we needed to devise a method that would produce pThr197 PKACα
as the only species (at least by probe detection limits). The PDK1 plasmid was a generous gift
from Justin Rettenmaier at the University of California, San Francisco. However, useful
quantities could not be isolated from E. coli due to poor solubility and low expression levels.
Therefore, the initial method of mixing the isolated proteins would not work when attempting to
produce in-house PDK1.
3.11.1: Crude lysate mixture method.
The next experiment to produce pThr197 PKACα involved the generation of PDK1
lysates, without purifying, as the source of PDK1. Briefly, competent E. coli cells were
transformed with the PDK1 plasmid and grown for 16 hr at 37 °C with ampicillin and moderate
shaking in a test tube. An aliquot was taken into a 1 L Erlenmeyer flask with ampicillin selection
and auto-induction media and grown at 37 °C for 16 hr with moderate shaking. Following
growth, cells were spun down at 6000 rpm for 10 min, and lysed into MOPS buffer (50 mM
MOPS, pH 7.4, 100 mM NaCl, 10 mM BME, 10 mM MgCl2, and 1 mM ATP) at ambient
temperature. Cellular debris was removed by centrifugation at 20,000 rpm for 30 min. The
supernatant was taken onto the next step without further purification.
Simultaneously, competent E. coli cells were transformed with the wt-PKACα plasmid
and grown for 16 hr at 37 °C with ampicillin and moderate shaking in a test tube. An aliquot was
taken into a 1 L Erlenmeyer flask with ampicillin selection and auto-induction media and grown
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at 37°C for 16 hr with moderate shaking. Following growth, cells were spun down at 6000 rpm
for 10 min, and lysed into buffer (25 mM tris, pH 8, 300 mM NaCl, and 10 mM imidazole) at
ambient temperature. Cellular debris was removed by centrifugation at 20,000 rpm for 30 min
and the soluble fraction was decanted onto a nickel column. Following sample loading, the
nickel column was washed with 5 column volumes of a non-eluting buffer (25 mM tris, pH 8,
300 mM NaCl, and 10 mM imidazole). Isolated PKACα protein is then eluted with 100 mM
imidazole and concentration determined by absorption at 280 nm on a spectrophotometer.
The purified PKACα was then added directly to the lysates which were made from the
PDK1 transformed E. coli cells and lysed into MOPS buffer. The solution was allowed to react
for 90 minutes at ambient temperature. Then the solution was buffer exchanged into buffer for
the nickel column (25 mM tris, pH 8, 300 mM NaCl, and 10 mM imidazole), and decanted onto
a nickel column. The same procedure was followed for purifying PKACα as stated above.
3.11.2: Gel of Pure PKACα treated with PDK1 lysates.
In Figure 51, below, the labeling characteristics of the probe were examined against the
wild-type recombinant PKACα that was treated with PDK1 lysates. The final PKACα solution
concentration was determined by absorbance at 280 nm and diluted to 1 mg/mL in phosphate
buffer (25 mM PO4 pH 7.2). Appropriate amounts of protein were added to reaction vessels
(epindorf tubes). The probe was made as a 10 mM stock solution in DMSO and diluted
accordingly for appropriate final concentrations in the gel experiments. The gel was cast as 1.5
mm thick and the wells were a total volume of 20 μL. The samples were incubated with probe
for 1 hr. The samples were prepared for gel electrophoresis as described above. Fluorescence
imaging and Coomassie staining were performed as described above.
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48 (5 µM) - PKACα (2 µg) - +
Treated PKACα (2 µg) - Treated Lysates of PKACα (2 µL) - -

+
+
-

- + - - +
- - - + + - - - - - + +

Figure 51. Examination of labeling on treated PKACα.

3.11.3: Results and Discussion of Figure 51.
The Rh-PKI(14-22)-G-(CMK) probe again displayed robust labeling of isolated
recombinant PKACα at the standard buffer pH of 7.2. Additionally, Rh-PKI(14-22)-G-(CMK)
labeled the treated with lysates PKACα in a similar way to the treated with commercial PDK1.
This confirmed the hypothesis of treating with PDK1 to obtain the phosphorylated species as the
predominant form. Unfortunately, it is a rather crude method for producing the protein and the
results were not immediately reproducible. Therefore, it was necessary to explore an alternative
route of producing PKACα pThr197.
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3.11.4 Co-expression of PKACα and PDK1.
To co-express the two proteins they must each be selected for in the bacterial growth
media. Therefore, the original plasmid PDK1 had to be switched to a compatible vector. The
PDK1 plasmid was isolated with a QIAprep Spin Mini Prep Kit (procedure in the experimental
section). A pRSF Duet Plasmid (Kan resistant) was isolated from an overnight culture with the
same kit. The PDK1 plasmid was digested with BglII and NdeI restriction enzymes and the
pRSF Duet plasmid with Bam HI and NdeI. The resulting solutions were run on agarose gel (cast
in house, see experimental) and the appropriate bands were imaged with ethidium bromide and
excised with a scalpel (Figure 40 below). They were ligated together with a DNA ligase enzyme.
The resulting solution was used to transform competent E. coli cells (detailed in experimental).
After subsequent incubation, the new plasmid was isolated with a QIA Spin Mini Prep Kit and
then transfected into cells already expressing PKACα. The same process was done with cells
expressing the mutant C199A PKACα.
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PDK1 pRSF Duet

pRSF Duet

PDK1

!

Figure 52. Agarose gel electrophoresis of PDK1 plasmid and pRSF duet.
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3.11.5: Labeling of coexpressed PKACα and PDK1.
In Figure 53, below, the labeling characteristics of the probe were examined against the
wild-type, and C199A, recombinant PKACα that was coexpressed with PDK1. The final
PKACα solution concentration was determined by absorbance at 280 nm and diluted to 1 mg/mL
in phosphate buffer (25 mM PO4 pH 7.2). The probe was made as a 10 mM stock solution in
DMSO and diluted accordingly for appropriate final concentrations in the gel experiments. The
gel was cast as 1.5 mm thick and the wells were a total volume of 20 μL. Then the samples were
incubated with probe for 1 hr. The samples were quenched with a denaturing sample buffer
(made in house and detailed in the biological experimental section) and incubated at 100°C for 5
minutes.

The

denaturing

sample

buffer

contained

a

disulfide

reducing

agent

(betamercaptoethanol, BME). Fluorescent images were taken on an Amersham 600 Imager.
Coomassie staining was performed with blue G250 in a H2O/MeOH/AcOH solution, and
destained with a H2O/MeOH/AcOH solution. Images of the Coomassie stained gel were taken on
an Amersham 600 Imager.
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-

48 (2.3 µM)
Fluorosceine-Maleimide (50 µM)
Coexpressed PKACα (2 µg)
Coexpressed C199A PKACα (2 µg)
Coexpressed R194A PKACα (8 µg)

- +
- + +
- - -

+
-

+
+
-

- - +
+ - - - + - - + +

+
+

-

Figure 53. Examination of coexpressed PKACα and PDK1 labeling with 48.

3.11.6: Results and Discussion of Figure 53.
The Rh-PKI(14-22)-G-(CMK) probe again displayed robust labeling of isolated
recombinant PKACα at the standard buffer pH of 7.2. This time only one band is observed. This
confirmed the utility of the coexpression platform. However, it is now abundantly clear that the
conditions

for

expression

can

be

tuned

with

the

isolated

PKACα

to

promote

phosphorylation.42,83,129-131 In effect, a method was developed to easily produce large quantities of
PKACα phosphorylated at Thr197 without the close monitoring of conditions.
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3.12: Biological Characterization of 48.
In a similar setup to the chloromethyl ketone derivative, the fluoromethyl ketone probe
was examined for its ability to label PKACα. Saturability of labeling was examined with noncovalent Myr-PKI(14-22)-Amide. The labeling of the cysteine to alanine mutant (C199A) was
examined to examine the residue being labeled. Oxidation of the cysteine was attemped to mimic
the endogenous regulatory mechanism of glutathiolation. Labeling with increasing
concentrations of ATP and MgCl2 was examined as was labeling in many complex biological
mixtures such as: MCF7 cells, MDA-MB-231 cells, bovine heart tissue lysates, mouse heart
tissue lysates, and E. coli lysates. All gels were cast in house and made to contain 10%
acrylamide, the exact procedure is detailed in the biological experimental section.
3.12.1: Activity-Based Experiment: Probe labeling saturation.
To analyze the labeling characteristics of the Rh-PKI(14-22)-G-(FMK) (48) probe
saturation gels were run to examine the effects of competition with a known inhibitor with a
known mechanism of action. In Figure 54 below, labeling of PKACα with probe 48 was
competed off with incrementally increasing concentrations of commercially available MyrPKI(14-22)-Amide (IC50 = 49.9 nM) . Protein concentration and probe concentrations were
prepared and determined as described above. The samples were prepared for gel electrophoresis
as described above. Fluorescence imaging and Coomassie staining were performed as described
above.
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PKACα (µg)
2 2
2 2 2 2 48 (µM)
0 2.3 2.3 2.3 2.3 2.3 PKI (14-22) (µM) 0 0 0.2 1 10 58 75 kDa
PKACα
75 kDa

Figure 54. Saturability of labeling of probe 48.

Compound 48 displayed robust labeling of isolated enzyme. The labeling was reduced in
a dose dependent manner by competition with Myr-PKI(14-24)-Amide. As increasing amount of
reversible inhibitor are added, non specific labeling is not observed. The Coomassie stain gel
image matches the fluorescence image.
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3.12.2: Activity-Based Experiment: Cysteine Oxidation.
In Figure 55 below, the labeling characteristics of the probe were examined against the
wild-type recombinant PKACα and with oxidative conditions to mimic the endogenous
regulatory mechanism of glutathiolaytion at Cys199. Prior to incubation with probe, the
appropriate lanes were incubated for 1 and 4 hr with Ellman’s reagent (a generic cysteine
oxidizer). Then the samples were incubated with probe for an additional 1 hr. The gel cast,
detection, staining, and imaging were the same as above.

PKACα (µg)
48 (µM)
Ellman's Reagent (mM)
Time (hours)

2
0
0
0

2
2.3
0
0

2
2.3
2
1

2
2.3
2
4

Figure 55. Cysteine oxidation effect on labeling by Ellman’s reagent.
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Probe 48 displayed robust labeling in the control lane (lane 2). Ellman’s reagent (2 mM)
inhibited labeling over the course of 4 hr. The activation loop cysteine is held in conformation
when Thr197 is phosphorylated and as a result the oxidation at Cys199 takes longer to occur.

3.12.3: Selectivity Experiment: C199A Mutant.
To analyze the effects of probe 48 on labeling the C199A mutant of PKACα and further
confirm the mechanism of labeling, the gel below was run (Figure 56) where conditions were the
same as above. Imaging, detection, and staining were repeated same as above.

PKACα (µg)
C199A (µg)
48 (µM)

2
0
0

2
0
2.3

0
2
0

0
2
2.3

Figure 56. Selectivity labeling experiment with wild-type and mutant PKACα.

Probe 48 displayed selectivity for the wild-type PKACα over the C199A mutant. Robust
labeling was detected in the control lane (lane 2), and no detectable labeling occurred in lane 4
which contains the C199A mutant.
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3.12.4: Activity-Based: Effects of ATP and MgCl2 on Labeling Efficiency.
Previous results from this lab indicated that these probes have decreased labeling
efficiency in physiological conditions. To examine this hypothesis, probe 48 was incubated with
wild-type PKACα with increasing concentrations of ATP and in the buffer used for the Z’LYTE
kinase assay (high MgCl2 concentration 10 mM, buffer B).133

PKACα (2 µg)
Buffer
48 (300 nM)
ATP (mM)

-

+
A
-

+ +
A A
+ +
- 0.25

+
A
+
1

+
A
+
2

+
B
+
2

Figure 57. Labeling in the presence of ATP and MgCl2.

Probe 48 displays positive labeling characteristics with low levels of ATP (0.25 – 1 mM)
in lanes 4 and 5. However, when the concentration is increased to 2 mM, labeling is decreased,
but not abolished, which is a significant first for these types of probes. The effect of the kinase
buffer B did not affect labeling in a significant manner.
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3.12.5: Additional investigation into Cys199 labeling mechanism of action.
Trypsin digest mass spectrometry was utilized to confirm the location of binding of probe
48 to PKACα. Briefly, unmodified or treated PKACα was buffer exchanged into a lysis buffer
((25 mM Tris pH 7.6, 1 mM EDTA, 150 mM NaCl, 1% Triton X-100, 0.1% SDS, and 10 mM
DTT). The protein solution was mixed with trypsin at a ratio of 20:1 protein to protease. The
resulting solution was incubated at 37 oC for 24 hr (in a sealed eppendorf tube). The sample was
analyzed by MALDI mass spectrometry with CHCA matrix (Sigma) on a Voyager DE-ProTM
MALDI TOF Mass Spectrometer.

Table 12: Trypsin Digest Mass Spec Results
PKACα/Tryspin/Fragment:/TWpTLCGTPEYLAPEIILSK
Mass$Calculated

Mass$Found

Untreated

2215.0893

2215.6430

Treated$with$RAC727116

2609.2960

2609.5996

Table 12: Mass found was the PKACα sequence + Probe Fragment (NAIG) + Na+. Exact mass
of probe fragment (NAIG) was calculated to be 371.2169.
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3.12.6: Examination in Complex Biological Mixture: MCF7 Lysates.
Once the labeling mechanism of action had been extensively characterized and shown to
display characteristics consistent with an activity-based probe, selectivity in complex biological
mixtures was the necessary next step. MCF7 cells (a breast cancer cell line) were grown in T75
flasks with RPMI buffer and 10% FBS (no antibiotic). Once confluent, the cells were collected
by centrifugation and the RPMI media exchanged with phosphate buffer. Cells were lysed with a
Dounce homogenizer and debris removed by centrifugation. Concentrations were determined by
Bradford assay (detailed procedure and results in experimental).

PKACα (µg)
MCF7 (µg)
48 (µM)
cAMP (1 mM)

-

2
-

2 - 100 100
0.3 - 0.3
- -

100 100
- 0.3
+

75 kDa
PKACα
25 kDa

Figure 58. Labeling in MCF7 cell lysates.
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Probe 48 displayed robust labeling of the control PKACα lane (lane 3). The cell lysates
were treated with/without probe and with/without cAMP to ensure release of the catalytic
subunit from the holoenzyme. A single band was observed in both MCF7 cell lanes (lanes 5 and
7); however, the molecular weight does not match that of PKACα and more closely matches the
homologous PKG (~76 kDa).
3.12.7: Examination in Complex Biological Mixture: MDA-MB-231 Lysates.
The MCF7 cells were revealed to have very little total amounts of PKA.136 MDA-MB231 cancer cells do have large quantities of PKA (contained in the holoenzyme).136 Therefore,
MDA-MB-231 cells were examined with probe 48. MDA-MB-231 cells (another breast cancer
cell line) were grown in T75 flasks with RPMI buffer, 1% ampicillin, and 10% FBS. Once
confluent, the cells were collected by centrifugation and the RPMI media exchanged with
phosphate buffer with 1x Rouche Protease inhibitor cocktail. Cells were lysed with a Dounce
homogenizer and debris removed by centrifugation. Concentration determined by Bradford assay
(detailed procedure and results in experimental).
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PKACα (µg)
MDA-MB-231 (µg)
48 (0.3 µM)
PKI (µM)
cAMP (1 mM)

-

2
-

2
+
-

- 100 100 100 100 100
+ + + +
- 0.3 3 30
+
+ + + +

Figure 59. Examination of MDA-MB-231 Lysates with compound 48.

Probe 48 effectively labels recombinant PKACα in the control lane (lane 3). There is
selective labeling in the lysates. The band does not correspond with the molecular weight of
PKACα. Myr-PKI(14-22)-Amide does not competitively knock out labeling at equivalents up to
50x.
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3.12.7: Examination in Complex Biological Mixture: Bovine heart lysates.
Early work with PKACα was performed with tissue samples.44,114 Specifically, bovine
heart was used extensively. Testing the hypothesis that PKA is not abundant enough in the
samples for adequate labeling, bovine heart tissue was examined. Briefly, bovine heart tissue was
cut into equal parts of 10 g pieces. One piece was incubated with protease inhibitor and the
lysates were produced with a tissue homogenizer. The debris was removed by sequential
centrifugation. Lysate concentrations were determined by Bradford assay and probe incubation
performed as previously described. A PKACα pThr197 specific antibody was used for Western
blot (detailed procedure available in experimental).

PKACα (µg)
Bovine Heart Lysates (µg)
48 (µM)

2 0
0 0 0 0 0 0 0 0
0 800 700 600 500 400 300 200 100 40
0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2

Mirror
Image
Western Blot with pT197 Specific Antibody

Lysates
PKACα

PKACα
Lysates

Figure 60. Examination of bovine heart lysates with compound 48.
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The dense nature of these tissues allowed for the facile production of concentrated
lysates. A significant load of lysates was analyzed and probe 48 did display selective labeling.
However, the band is similar to that observed in the MDA-MB-231 lysates and does not
correspond with PKACα. Moreover, the antibody detection indicates the band being observed by
fluorescence is not that being labeled by antibody.
3.12.9: Examination in Complex Biological Mixture: Mouse heart lysates.
To examine the possibility of species variance in PKACα production and labeling, mouse
heart lysates were prepared in the same manner as above. Protein concentration determined by
Bradford, and antibody detection with a PKACα pThr197 antibody, all as described above.

PKACα (2 µg)
Lysates (400 µg)
48 (µM)
cAMP (µM)

-

+
-

+
0.3
-

+
-

+
+
0.3 0.3
- 100

Western Blot with pThr197 PKA Antibody

75 kDa
Recombinant
PKACα
PKACα

PKACα

25 kDa

Figure 61. Examination of mouse heart lysates with compound 48.

A similar labeling profile was noted in the mouse heart lysates as with the bovine heart
lysates. That is, heavy lysate loads were found in each lane with selective labeling of one band
that does not correspond with the expected molecular weight. The antibody reveals a similar
result as that of bovine: the band labeled is not the band that corresponds with PKACα.
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3.12.10: Discussion of Biological Characterization of Probe 48.
The fluoromethyl ketone probe was examined extensively by multiple mechanisms and
variables. The saturability of labeling by competition with Myr-PKI(14-22)-Amide was
examined. The labeling was reduced with increasing concentrations of the reversible inhibitor in
a dose dependent manner. Cysteine oxidation’s effect on labeling with the use of Ellman’s
reagent to oxidize Cys199 was examined.137 Upon treatment with Ellman’s reagent for 4 hrs
labeling was effectively abolished. Rh-PKI(14-22)-G(FMK) (48) did not detectably label the
C199A mutant of PKACα. The trypsin digest mass spec indicated that a residue in the activation
loop is being modified. The IC50 of the probe was determined to be 11 nM (as determined by
Invitrogen). Thse results were very favorable for a selective probe that labels the catalytic
subunit in an activity-dependent manner. As a result, the probe was examined in a number of
biological systems.
The first system examined was MCF7 cell lysates. The procedure for growing up these
cells and producing lysates is detailed in the experimental. The MCF7 cell line is a breast cancer
cell line. When we examined the labeling in these lysates, the probe displayed remarkable
selectivity. However, this singular band did not correspond with PKACα and as a result we set
out to examine a different biological system with potentially greater amounts of PKA.
Cell lysates were reexamined to test the hypothesis that there was not enough PKA for
labeling. The MDA-MB-231 cell line was selected due to it having demonstrated robust
production of PKA. The growing conditions were similar to the MCF7 cell line but with protease
inhibitor in the lysate solution, which may have influenced the labeling. However, the band does
not match PKACα in molecular weight, nor is it labeled by antibody.

	
  

128	
  

Bovine heart was readily available from the local butcher, and early PKA work in the
literature dealt with PKA isolated from bovine hearts (Chapter 2). The tissue was marinated in
protease inhibitor and homogenized. The debris was removed by sequential centrifugation and
concentration determined by Bradford assay. A detailed work up is described in the experimental
section. While selective labeling occurred again, the molecular weight again did not match that
would be expected from PKA, it was slightly higher. The Western blot with anti-PKACα
confirmed that the labeled band does not correspond with the PKA identified with antibody, and
does seem to be the same band labeled in the MDA-MB-231 lysates.
We reexamined the labeling of the probe in mouse heart lysates. The mouse hearts were a
generous gift from Dr. Jolene Windle. The tissue was marinated in protease inhibitor and
homogenized. The debris was removed by sequential centrifugation and concentration
determined by Bradford assay. A detailed work up is described in the experimental section.
Again, selective labeling was observed on a band not consistent with the molecular weight of
PKACα but similar to that observed in bovine heart and MDA-MB-231 cell lysates (3 species
covered). In an effort to determine the identity of the labeled peptide, biotinylated analogues
were synthesized for pull-down experiments.
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3.13: Development of a Biotinylated Peptide Probe.
To determine the identity of the fluorescently labeled protein, biotinylated analogues
were designed for pull-down experiments. The full length probe was assembled in the same
fashion as Rh-PKI(14-22)-G-FMK and the scheme is depicted below (a detailed procedure is
available in the experimental section). Biotin-NHS was synthesized according to a previously
described route and the spectral data matched previously reported values.138 The synthetic
scheme is depicted below.
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Figure 62. Synthesis of Biotin-NHS.
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Figure 63. Synthesis of Biotin-PKI(14-22)-G-(FMK).
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3.13.1: Biological Characterization of 51, Biotin-PKI(14-22)-G-(FMK).
The biotinylated probe did not detectably label recombinant PKACα in conditions that
paralleled that of the fluorescently labeled probe (300 nM). Later experiments show minimal
labeling and will be discussed in a later section. The hypothesis at the time was that there was a
difference between PKACα produced recombinately and endogenously expressed PKACα. As a
result, the pull-down experiment was performed and the results are detailed below.
Briefly, mouse heart lysates were passed through a streptavidin column to remove
endogenously biotinylated proteins from the untreated lysates. Then the eluent was diluted 10
fold into phosphate buffer and incubated with 300 nM of biotin-PKI(14-22)-G-(FMK) for 1 hr.
The solution was then incubated with the column for 1 hr and subsequently eluted with a biotin
solution. A detailed procedure is available in the experimental.

PKA Thr197 Antibody
recombinant PKACα (.2µg)
Pull Down sample

+

+
-

Figure 64. Western blot of the pull-down sample with pThr197 antibody.
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Avidin-HRP
+

Recombinant PKACα (0.2 µg)
Pull-Down Sample

+
-

Figure 65. Western blot of the pull-down sample with streptavidin-HRP.

Recombinant PKACα (0.2 µg)
Pull-Down Sample

+

+
-

Figure 66. Coomassie stain of pull-down sample, major bands highlighted.
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3.13.2: Results and Discussion of the Biological Characterization of 51.
The IC50 of biotin-PKI(14-22)-G-(FMK) was determined to be 149 nM (by Invitrogen).
The results of the pull-down experiment reveal that PKACα was pulled down. But, in addition
another prominent protein with a much higher molecular weight was observed. The streptavidinhrp blot indicates a relative larger quantity of the higher molecular weight protein. Similarly, the
Coomassie stain image appears to indicate that the higher molecular weight protein is present in
larger quantities (reminiscent of the results obtained when examining the MCF7 cell line). When
the IC50 is considered along with the pull-down results, it is reasonable to assume the probe does
not covalently interact with PKACα on a level of selectivity necessary for ABPP of PKA. It was
hypothesized that the linker was not long enough and so another analogue was designed to
extend the linker between biotin and the recognition scaffold.
3.13.3: Addition of a linker.
The 8-(Fmoc-amino)octanoic acid (AOC) linker is solid-phase chemistry compatible and
has been utilized in similar probes as a linker. The synthesis was carried out on a peptide
synthesizer and assembly of the probe was similar to that of the previous probes. A detailed
procedure is available in the experimental section. The probe was analyzed under similar
conditions; however, labeling was demonstrated at relatively high concentrations.
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Figure 67. Synthesis of Biotin-Aoc-PKI(14-22)-G-(FMK).
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3.13.4: Biological Characterization of Compound 54.
To examine the labeling efficiency of the new probe and test the limits of detection. The
probe was incubated with recombinant PKACα and detected by streptavidin-HRP ECL substrate
on an Amersham 600 imager (detailed experimental available in Chapter 4).

PKACα (2 µg) 51 (µM)
54 (µM)

+ + +
- 0.5 1
- - -

+ + +
2
- 0.5 1

+
2

Figure 68. Detection of recombinant PKACα labeled with 51 (lanes 3-5)and 54 (lanes 6-8).

3.13.5: Results and Discussion of the Biotinylated Derivatives.
The IC50 of the biotin-AOC-PKI(14-22)-(FMK) probe against PKACα was determined to
be 14.1 nM (by Invitrogen). This confirmed the hypothesis that the linker length was not long
enough. Without the linker, the IC50 was 149 nM. The IC50 is also indicative of increased binding
over the reversible inhibitor (IC50 = 49 nM, determined by Invitrogen). However, labeling of
recombinant protein remained an issue: even at high concentrations, only trace labeling was
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detectable. No labeling was detected in MDA-MB-231 lysates (only endogenous biotinylated
peptides were shown by Western blot), and no labeling of commercial bovine PKACα was
obersved. The biotinylated peptide-based probes did not label in a manner consistent with the
fluorescently labeled probes. This suggests that the rhodamine is influencing the position of the
electrophile such that labeling is occurring more robustly than non-interfering tags.
3.14: Results, Discussion, and Future Directions.
The active site of protein kinases has been shown to be influenced by certain posttranslational modifications, as was suggested by others.40,128,137,139-141 While this work did not
produce an activity-based probe suitable for activity-based protein profiling of PKACα in
complex biological mixtures, it did produce probes capable of investigating the active-site of
PKACα, as demonstrated by the selectivity for pThr197 and sensitivity to cysteine oxidation.
Additionally, the probes are capable of assessing those post-translational modifications in a
concerted, in vitro, manner without the use of multiple proteomic techniques. The reactivity of
Cys199 has not been systematically studied, although, these probes are capable of such
characterization. In addition, ABPs may have been developed for proteins of interest by probe 38
and probes 48 and 51 (as evidenced by their proteome wide selectivity and interactions with a
PKI fragment) and further investigations into these ABPs is warranted. This represents a large
step forward in the characterization of active site substrate-binding dynamics in the kinome.
A sequence alignment of the human kinome revealed that a total of ninety-nine kinases
carry a cysteine in the position similar to PKACα–C199 (see Figure 69). These kinases are
mainly clustered in the AGC family and the CaMK family. Access to the cysteine in these
kinases is restricted by selectivity filters in the P+1 binding site and the substrate-binding groove,
allowing selective targeting of each cysteine and kinase with a high affinity peptide scaffold.
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High affinity inhibitory peptides are known for several of the kinases in Figure 69, including
AKT, PKG, AMPK, CaMKI, CHK2, and multiple isoforms of PKC. The activation loop
cysteines in several of these kinases, including AKT1-C310, RSK1-C220, S6K1-C254, and
MSK1-C214, have been shown to react with electrophiles. The flexible, efficient, and modular
synthetic method presented here will allow the incorporation of a variety of electrophiles and
detection tags into these peptides to prepare additional substrate competitive inhibitor probes for
the kinases in Figure 69.
While an ABP probe was not developed for PKACα specifically, a general strategy for
developing substrate competitive inhibitor probes for kinases that targets the activation loop was
developed and implemented. Work to further enhance peptide-based probe labeling and
selectivity for PKACα (modification of the electrophile reactivity and position) in complex
biological mixtures, and the use of it to study PKACα activity in diverse biological systems is
currently underway in our lab.
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Chapter 4. Experimentals
4.1 ClustalX Sequence Alignment
Kinome activation loop (DFG-APE) sequence alignment:

CLUSTAL 2.1 MULTIPLE SEQUENCE ALIGNMENT
File: /Users/RCoover3159/Desktop/Kinome_DFG_alignment1
Date: Sat May 9 18:40:50 2015
Page 1 of 12
Other_IRE__IRE1
Other_IRE__IRE2
AGC_AKT__AKT1
AGC_AKT__AKT2
AGC_AKT__AKT3
AGC_SGK__SGK
AGC_SGK__SGK3
AGC_SGK__SGK2
AGC_PKC_Alpha_PKCa
AGC_PKC_Alpha_PKCb
AGC_PKC_Alpha_PKCg
AGC_PKC_Eta_PKCh
AGC_PKC_Eta_PKCe
AGC_PKC_Delta_PKCd
AGC_PKC_Delta_PKCt
AGC_PKC_Iota_PKCi
AGC_PKC_Iota_PKCz
AGC_PKN__PKN1
AGC_PKN__PKN2
AGC_PKN__PKN3
AGC_RSK_MSK_MSK1
AGC_RSK_MSK_MSK2
AGC_RSK_p70_p70S6K
AGC_RSK_p70_p70S6Kb
AGC_RSK_RSK_RSK1
AGC_RSK_RSK_RSK2
AGC_RSK_RSK_RSK3
AGC_RSK_RSK_RSK4
AGC_PKA__PRKX
AGC_PKA__PRKY
AGC_PKA__PKACa
AGC_PKA__PKACb
AGC_PKA__PKACg
AGC_PKG__PKG1
AGC_PKG__PKG2
AGC_MAST__MAST1
AGC_MAST__MAST4
AGC_MAST__MAST2
AGC_MAST__MAST3
AGC_DMPK_GEK_MRCKb
AGC_DMPK_GEK_MRCKa
AGC_DMPK_GEK_DMPK2
AGC_DMPK_GEK_DMPK1

	
  

DFGLCKK-------LAVG-------------------------------------------------------RHSFSRRSGVPGTEGWIA-PE
DFGLCKK-------LPAG-------------------------------------------------------RCSFSLHSGIPGTEGWMA-PE
DFGLCKE-------GIKDG-A---------------------------------------------------------TMKTFCGTPEYLA-PE
DFGLCKE-------GISDG-A---------------------------------------------------------TMKTFCGTPEYLA-PE
DFGLCKE-------GITDA-A---------------------------------------------------------TMKTFCGTPEYLA-PE
DFGLCKE-------NIEHN-S---------------------------------------------------------TTSTFCGTPEYLA-PE
DFGLCKE-------GIAIS-D---------------------------------------------------------TTTTFCGTPEYLA-PE
DFGLCKE-------GVEPE-D---------------------------------------------------------TTSTFCGTPEYLA-PE
DFGMCKE-------HMMDG-V---------------------------------------------------------TTRTFCGTPDYIA-PE
DFGMCKE-------NIWDG-V---------------------------------------------------------TTKTFCGTPDYIA-PE
DFGMCKE-------NVFPG-T---------------------------------------------------------TTRTFCGTPDYIA-PE
DFGMCKE-------GICNG-V---------------------------------------------------------TTATFCGTPDYIA-PE
DFGMCKE-------GILNG-V---------------------------------------------------------TTTTFCGTPDYIA-PE
DFGMCKE-------NIFGE-S---------------------------------------------------------RASTFCGTPDYIA-PE
DFGMCKE-------NMLGD-A---------------------------------------------------------KTNTFCGTPDYIA-PE
DYGMCKE-------GLRPG-D---------------------------------------------------------TTSTFCGTPNYIA-PE
DYGMCKE-------GLGPG-D---------------------------------------------------------TTSTFCGTPNYIA-PE
DFGLCKE-------GMGYG-D---------------------------------------------------------RTSTFCGTPEFLA-PE
DFGLCKE-------GMGYG-D---------------------------------------------------------RTSTFCGTPEFLA-PE
DFGLCKE-------GIGFG-D---------------------------------------------------------RTSTFCGTPEFLA-PE
DFGLSKE-------FVADETE---------------------------------------------------------RAYSFCGTIEYMA-PD
DFGLSKE-------FLTEEKE---------------------------------------------------------RTFSFCGTIEYMA-PE
DFGLCKE-------SIHDG-T---------------------------------------------------------VTHTFCGTIEYMA-PE
DFGLCKE-------SIHEG-A---------------------------------------------------------VTHTFCGTIEYMA-PE
DFGLSKE-------AIDHD-K---------------------------------------------------------RAYSFCGTIEYMA-PE
DFGLSKE-------SIDHE-K---------------------------------------------------------KAYSFCGTVEYMA-PE
DFGLSKE-------AIDHE-K---------------------------------------------------------KAYSFCGTVEYMA-PE
DFGLSKE-------SVDQE-K---------------------------------------------------------KAYSFCGTVEYMA-PE
DFGFAKK-------LVD-------------------------------------------------------------RTWTLCGTPEYLA-PE
DFGFAKK-------LVD-------------------------------------------------------------RTWTLCGTPEYLA-PE
DFGFAKR-------VKG-------------------------------------------------------------RTWTLCGTPEYLA-PE
DFGFAKR-------VKG-------------------------------------------------------------RTWTLCGTPEYLA-PE
DFGFAKR-------VKG-------------------------------------------------------------RTWTLCGTPEYLA-PE
DFGFAKK-------IGFGK-----------------------------------------------------------KTWTFCGTPEYVA-PE
DFGFAKK-------IGSGQ-----------------------------------------------------------KTWTFCGTPEYVA-PE
DFGLSKM-------GLMSLTTNLYEGHIE-----------------------------------------KDAREF--LDKQVCGTPEYIA-PE
DFGLSKV-------GLMSMTTNLYEGHIE-----------------------------------------KDAREF--LDKQVCGTPEYIA-PE
DFGLSKI-------GLMSLTTNLYEGHIE-----------------------------------------KDAREF--LDKQVCGTPEYIA-PE
DFGLSKI-------GLMSMATNLYEGHIE-----------------------------------------KDAREF--IDKQVCGTPEYIA-PE
DFGSCLK-------MN-------------------------------------------------------DDGTV--QSSVAVGTPDYIS-PE
DFGSCLK-------LM-------------------------------------------------------EDGTV--QSSVAVGTPDYIS-PE
DFGSCLR-------LN-------------------------------------------------------TNGMV--DSSVAVGTPDYIS-PE
DFGSCLK-------LR-------------------------------------------------------ADGTV--RSLVAVGTPDYLS-PE
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CAMK_MAPKAPK_MNK_MNK2
CAMK_RSKb_MSKb_Domain2_MSK1
CAMK_RSKb_MSKb_Domain2_MSK2
CAMK_RSKb_RSKb_Domain2_RSK2
CAMK_RSKb_RSKb_Domain2_RSK3
CAMK_RSKb_RSKb_Domain2_RSK1
CAMK_RSKb_RSKb_Domain2_RSK4
CAMK_PKD__PKD1
CAMK_PKD__PKD3
CAMK_PKD__PKD2
CAMK_RAD53__CHK2
CAMK_CAMK-Unique__STK33
CAMK_CAMKL_AMPK_AMPKa1
CAMK_CAMKL_AMPK_AMPKa2
CAMK_CAMKL_BRSK_BRSK2
CAMK_CAMKL_BRSK_BRSK1
CAMK_CAMKL_MARK_MARK2
CAMK_CAMKL_MARK_MARK1
CAMK_CAMKL_MARK_MARK3
CAMK_CAMKL_MARK_MARK4
CAMK_CAMKL_QIK_QIK
CAMK_CAMKL_QIK_SIK
CAMK_CAMKL_QIK_QSK
CAMK_CAMKL_NuaK_NuaK1
CAMK_CAMKL_NuaK_NuaK2
CAMK_CAMKL_MELK_MELK
CAMK_CAMKL_NIM1_NIM1
CAMK_CAMKL_SNRK_SNRK
CAMK_CAMKL_HUNK_HUNK
CAMK_TSSK__SSTK
CAMK_TSSK__TSSK3
CAMK_TSSK__TSSK2
CAMK_TSSK__TSSK1
CAMK_TSSK__TSSK4
CAMK_PIM__PIM3
CAMK_PIM__PIM1
CAMK_PIM__PIM2
CAMK_CAMKL_PASK_PASK
Other_CAMKK_Meta_CaMKK2
Other_CAMKK_Meta_CaMKK1
CAMK_CAMKL_LKB_LKB1
CAMK_CAMKL_CHK1_CHK1
Other_AUR__AurC

	
  

DFDLGSG-------IKLNGDCSPIS-----------------------------------------------TP----ELLTPCGSAEYMA-PE
DFGFARL-------KPPD------------------------------------------------------NQ----PLKTPCFTLHYAA-PE
DFGFARL-------RPQSP-----------------------------------------------------GV----PMQTPCFTLQYAA-PE
DFGFAKQ-------LRAE------------------------------------------------------NG----LLMTPCYTANFVA-PE
DFGFAKQ-------LRAE------------------------------------------------------NG----LLMTPCYTANFVA-PE
DFGFAKQ-------LRAG------------------------------------------------------NG----LLMTPCYTANFVA-PE
DFGFAKQ-------LRGE------------------------------------------------------NG----LLLTPCYTANFVA-PE
DFGFARI-------IGE-------------------------------------------------------KS----FRRSVVGTPAYLA-PE
DFGFARI-------IGE-------------------------------------------------------KS----FRRSVVGTPAYLA-PE
DFGFARI-------IGE-------------------------------------------------------KS----FRRSVVGTPAYLA-PE
DFGHSKI-------LGE-------------------------------------------------------TS----LMRTLCGTPTYLA-PE
DFGLAVK-------KQSRS-----------------------------------------------------EA----MLQATCGTPIYMA-PE
DFGLSNM-------M-------------------------------------------------------SDGE----FLRTSCGSPNYAA-PE
DFGLSNM-------M-------------------------------------------------------SDGE----FLRTSCGSPNYTA-PE
DFGMASL-------Q-------------------------------------------------------VGDS----LLETSCGSPHYAC-PE
DFGMASL-------Q-------------------------------------------------------VGDS----LLETSCGSPHYAC-PE
DFGFSNE-------F-------------------------------------------------------TFGN----KLDTFCGSPPYAA-PE
DFGFSNE-------F-------------------------------------------------------TVGN----KLDTFCGSPPYAA-PE
DFGFSNE-------F-------------------------------------------------------TVGG----KLDTFCGSPPYAA-PE
DFGFSNE-------F-------------------------------------------------------TLGS----KLDTFCGSPPYAA-PE
DFGFGNF-------F-------------------------------------------------------KSGE----LLATWCGSPPYAA-PE
DFGFGNF-------Y-------------------------------------------------------KSGE----PLSTWCGSPPYAA-PE
DFGFSNL-------F-------------------------------------------------------TPGQ----LLKTWCGSPPYAA-PE
DFGLSNL-------Y-------------------------------------------------------QKDK----FLQTFCGSPLYAS-PE
DFGLSNL-------Y-------------------------------------------------------HQGK----FLQTFCGSPLYAS-PE
DFGLCAK-------P-------------------------------------------------------KGNKDY--HLQTCCGSLAYAA-PE
DFGFSTV-------S-------------------------------------------------------KKGE----MLNTFCGSPPYAA-PE
DFGFSNK-------F-------------------------------------------------------QPGK----KLTTSCGSLAYSA-PE
DFGLSNC-------AG------------------------------------------------------ILGYSD--PFSTQCGSPAYAA-PE
DFGFGR---------------------------------------------------------------QAHGYPD--LSTTYCGSAAYAS-PE
DFGFAKV--------------------------------------------------------------LPKSHRE--LSQTFCGSTAYAA-PE
DFGFSKR-------C----------------------------------------------------LRDSNGRII--LSKTFCGSAAYAA-PE
DFSFSKR-------C----------------------------------------------------LRDDSGRMA--LSKTFCGSPAYAA-PE
DFGFAKM-------VPSNQPVGCSPS-----------------------------------------YRQVNCFSH--LSQTYCGSFAYAC-PE
DFGSGAL-------LK--------------------------------------------------------DT----VYTDFDGTRVYSP-PE
DFGSGAL-------LK--------------------------------------------------------DT----VYTDFDGTRVYSP-PE
DFGSGAL-------LH--------------------------------------------------------DE----PYTDFDGTRVYSP-PE
DFGSAAY-------LER-------------------------------------------------------GK----LFYTFCGTIEYCA-PE
DFGVSNE-------FK--------------------------------------------------------GSDA--LLSNYVGTPAFMA-PE
DFGVSNQ-------FE--------------------------------------------------------GNDA--QLSSTAGTPAFMA-PE
DLGVAEA-------LHP------------------------------------------------------FAADD--TCRTSQGSPAFQP-PE
DFGLATV-------FRY------------------------------------------------------NNRER--LLNKMCGTLPYVA-PE
DFGWSVH-------TPLP------------------------------------------------------------ERKTMCGTLDYLP-PE
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Other_AUR__AurB
Other_AUR__AurA
Other_PLK__PLK3
Other_PLK__PLK2
Other_PLK__PLK1
Other_PLK__PLK4
CAMK_DAPK__DAPK1
CAMK_DAPK__DAPK3
CAMK_DAPK__DAPK2
CAMK_DAPK__DRAK1
CAMK_DAPK__DRAK2
CAMK_MLCK__caMLCK
CAMK_MLCK__SgK085
CAMK_MLCK__skMLCK
CAMK_MLCK__smMLCK
CAMK_MLCK__TTN
CAMK_Trio__Trio
CAMK_Trio__Trad
CAMK_Trio__SPEG
CAMK_Trio__Obscn
CAMK_Trio__Domain2_SPEG
CAMK_Trio__Domain2_Obscn
CMGC_CDK_CDC2_CDK2
CMGC_CDK_CDC2_CDK3
CMGC_CDK_CDC2_CDC2
CMGC_CDK_CDK5_CDK5
CMGC_CDK_TAIRE_PCTAIRE1
CMGC_CDK_TAIRE_PCTAIRE2
CMGC_CDK_TAIRE_PCTAIRE3
CMGC_CDK_TAIRE_PFTAIRE1
CMGC_CDK_TAIRE_PFTAIRE2
CMGC_CDK_CDK4_CDK4
CMGC_CDK_CDK4_CDK6
CMGC_CDK_CDK10_CDK10
CMGC_CDK_PITSLRE_PITSLRE
CMGC_CDK_CDK7_CDK7
CMGC_CDK__CCRK
CMGC_CDK_CRK7_CHED
CMGC_CDK_CRK7_CRK7
CMGC_CDK_CDK9_CDK9
CMGC_CDK_CDK8_CDK8
CMGC_CDK_CDK8_CDK11
CMGC_MAPK_ERK_Erk1

	
  

DFGWSVH-------APSL------------------------------------------------------------RRKTMCGTLDYLP-PE
DFGWSVH-------APSS------------------------------------------------------------RRTTLCGTLDYLP-PE
DFGLAAR-------LEPPE------------------------------------------------------Q----RKKTICGTPNYVA-PE
DFGLAAR-------LEPLE------------------------------------------------------H----RRRTICGTPNYLS-PE
DFGLATK-------VEYDG------------------------------------------------------E----RKKTLCGTPNYIA-PE
DFGLATQ-------LKMPH------------------------------------------------------E----KHYTLCGTPNYIS-PE
DFGLAHK-------IDFGNEF-----------------------------------------------------------KNIFGTPEFVA-PE
DFGIAHK-------IEAGNEF-----------------------------------------------------------KNIFGTPEFVA-PE
DFGLAHE-------IEDGVEF-----------------------------------------------------------KNIFGTPEFVA-PE
DFGLSRI-------LKNSEEL-----------------------------------------------------------REIMGTPEYVA-PE
DFGMSRK-------IGHACEL-----------------------------------------------------------REIMGTPEYLA-PE
DFGLARR-------YKPREKL-----------------------------------------------------------KVNFGTPEFLA-PE
DFGLARR-------YKPREKL-----------------------------------------------------------KVNFGTPEFLA-PE
DFGLARR-------YNPNEKL-----------------------------------------------------------KVNFGTPEFLS-PE
DFGLARR-------LENAGSL-----------------------------------------------------------KVLFGTPEFVA-PE
EFGQARQ-------LKPGDNF-----------------------------------------------------------RLLFTAPEYYA-PE
DFGDAVQ-------LNTTYYI-----------------------------------------------------------HQLLGNPEFAA-PE
DLEDAVQ-------ISGHFHI-----------------------------------------------------------HHLLGNPEFAA-PE
DFGNAQE-------LTPGEPQ-----------------------------------------------------------YCQYGTPEFVA-PE
DFGFAQN-------ITPAELQ-----------------------------------------------------------FSQYGSPEFVS-PE
DFGSAQP-------YNPQALRP---------------------------------------------------------LGHRTGTLEFMA-PE
DLGNAQS-------LSQEKVLP---------------------------------------------------------SDKFKDYLETMA-PE
DFGLARA-------FG-----------------------------------------------------VP-VRT----YTHEVVTLWYRA-PE
DFGLARA-------FG-----------------------------------------------------VP-LRT----YTHEVVTLWYRA-PE
DFGLARA-------FG-----------------------------------------------------IP-IRV----YTHEVVTLWYRS-PE
DFGLARA-------FG-----------------------------------------------------IP-VRC----YSAEVVTLWYRP-PD
DFGLARA-------KS-----------------------------------------------------IP-TKT----YSNEVVTLWYRP-PD
DFGLARA-------KS-----------------------------------------------------VP-TKT----YSNEVVTLWYRP-PD
DFGLARA-------KS-----------------------------------------------------VP-TKT----YSNEVVTLWYRP-PD
DFGLARA-------KS-----------------------------------------------------VP-SHT----YSNEVVTLWYRP-PD
DFGLARA-------KS-----------------------------------------------------IP-SQT----YSSEVVTLWYRP-PD
DFGLARI-------YS-----------------------------------------------------Y--QMA----LTPVVVTLWYRA-PE
DFGLARI-------YS-----------------------------------------------------F--QMA----LTSVVVTLWYRA-PE
DFGLARA-------YG-----------------------------------------------------VP-VKP----MTPKVVTLWYRA-PE
DFGLARE-------YG-----------------------------------------------------SP-LKA----YTPVVVTLWYRA-PE
DFGLAKS-------FG-----------------------------------------------------SP-NRA----YTHQVVTRWYRA-PE
DFGLARV-------FS-----------------------------------------------------PDGSRL----YTHQVATRWYRA-PE
DFGLARL-------YS-----------------------------------------------------SEESRP----YTNKVITLWYRP-PE
DFGLARL-------YN-----------------------------------------------------SEESRP----YTNKVITLWYRP-PE
DFGLARA-------FSL----------------------------------------------------AKNSQPN--RYTNRVVTLWYRP-PE
DMGFARL-------FN-----------------------------------------------------SPLKPLA--DLDPVVVTFWYRA-PE
DMGFARL-------FN-----------------------------------------------------SPLKPLA--DLDPVVVTFWYRA-PE
DFGLAR--------I-AD--------------------------------------------------PEHDHTG---FLTEYVATRWYRA-PE
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CMGC_MAPK_ERK_Erk2
CMGC_MAPK_ERK_Erk5
CMGC_MAPK_nmo_NLK
CMGC_MAPK_JNK_JNK1
CMGC_MAPK_JNK_JNK3
CMGC_MAPK_JNK_JNK2
CMGC_MAPK_p38_p38a
CMGC_MAPK_p38_p38b
CMGC_MAPK_p38_p38g
CMGC_MAPK_p38_p38d
CMGC_MAPK_Erk7_Erk7
CMGC_MAPK_ERK_Erk3
CMGC_MAPK_ERK_Erk4
CMGC_RCK__MAK
CMGC_RCK__ICK
CMGC_RCK__MOK
CMGC_CDKL__CDKL2
CMGC_CDKL__CDKL3
CMGC_CDKL__CDKL1
CMGC_CDKL__CDKL4
CMGC_CDKL__CDKL5
CMGC_GSK__GSK3A
CMGC_GSK__GSK3B
CMGC_CLK__CLK1
CMGC_CLK__CLK4
CMGC_CLK__CLK2
CMGC_CLK__CLK3
CMGC_SRPK__SRPK2
CMGC_SRPK__MSSK1
CMGC_SRPK__SRPK1
CMGC_DYRK_Dyrk1_DYRK1B
CMGC_DYRK_Dyrk1_DYRK1A
CMGC_DYRK_Dyrk2_DYRK2
CMGC_DYRK_Dyrk2_DYRK3
CMGC_DYRK_Dyrk2_DYRK4
CMGC_DYRK_HIPK_HIPK1
CMGC_DYRK_HIPK_HIPK2
CMGC_DYRK_HIPK_HIPK3
CMGC_DYRK_HIPK_HIPK4
CMGC_DYRK_PRP4_PRP4
Other_CK2__CK2a1
Other_CK2__CK2a2
Other_NKF1__SgK069

	
  

DFGLAR--------V-AD--------------------------------------------------PDHDHTG---FLTEYVATRWYRA-PE
DFGMARG-------L-CT--------------------------------------------------SPAEHQY---FMTEYVATRWYRA-PE
DFGLAR-----------V--------------------------------------------------EELDESR---HMTQEVVTQYYRA-PE
DFGLAR---------------------------------------------------------------TAGTSF---MMTPYVVTRYYRA-PE
DFGLAR---------------------------------------------------------------TAGTSF---MMTPYVVTRYYRA-PE
DFGLAR---------------------------------------------------------------TACTNF---MMTPYVVTRYYRA-PE
DFGLAR---------------------------------------------------------------HTDD-----EMTGYVATRWYRA-PE
DFGLAR---------------------------------------------------------------QADE-----EMTGYVATRWYRA-PE
DFGLAR---------------------------------------------------------------QADS-----EMTGYVVTRWYRA-PE
DFGLAR---------------------------------------------------------------HADA-----EMTGYVVTRWYRA-PE
DFGLARS-------LGDL--------------------------------------------------PEGPEDQ---AVTEYVATRWYRA-PE
DFGLAR---------IMD--------------------------------------------------PHYSHKG---HLSEGLVTKWYRS-PR
DFGLAR---------IVD--------------------------------------------------QHYSHKG---YLSEGLVTKWYRS-PR
DFGLAR---------------------------------------------------------------ELRSQP---PYTDYVSTRWYRA-PE
DFGLAR---------------------------------------------------------------EIRSKP---PYTDYVSTRWYRA-PE
DFGSCR---------------------------------------------------------------SVYSKQ---PYTEYISTRWYRA-PE
DFGFART-------LAA-----------------------------------------------------P-GEV----YTDYVATRWYRA-PE
DFGFART-------LAA-----------------------------------------------------P-GDI----YTDYVATRWYRA-PE
DFGFARL-------LTG-----------------------------------------------------P-SDY----YTDYVATRWYRS-PE
DFGFAQI-------LI------------------------------------------------------P-GDA----YTDYVATRWYRA-PE
DFGFARN-------LSEG----------------------------------------------------N-NAN----YTEYVATRWYRS-PE
DFGSAKQ-------LVR-------------------------------------------------------GEP----NVSYICSRYYRA-PE
DFGSAKQ-------LVR-------------------------------------------------------GEP----NVSYICSRYYRA-PE
DFGSATY-------DDEH-------------------------------------------------------------HSTLVSTRHYRA-PE
DFGSATY-------DDEH-------------------------------------------------------------HSTLVSTRHYRA-PE
DFGSATF-------DHEH-------------------------------------------------------------HSTIVSTRHYRA-PE
DFGSATF-------DHEH-------------------------------------------------------------HTTIVATRHYRP-PE
DLGNACW-------VHKH-------------------------------------------------------------FTEDIQTRQYRS-IE
DLGNACW-------VHKH-------------------------------------------------------------FTEDIQTRQYRA-VE
DLGNACW-------VHKH-------------------------------------------------------------FTEDIQTRQYRS-LE
DFGSSCQ-------LGQR-------------------------------------------------------------IYQYIQSRFYRS-PE
DFGSSCQ-------LGQR-------------------------------------------------------------IYQYIQSRFYRS-PE
DFGSSCY-------EHQR-------------------------------------------------------------VYTYIQSRFYRA-PE
DFGSSCF-------EYQK-------------------------------------------------------------LYTYIQSRFYRA-PE
DFGSSCY-------EHQK-------------------------------------------------------------VYTYIQSRFYRS-PE
DFGSASH-------VSKA-------------------------------------------------------V-----CSTYLQSRYYRA-PE
DFGSASH-------VSKA-------------------------------------------------------V-----CSTYLQSRYYRA-PE
DFGSASH-------VSKT-------------------------------------------------------V-----CSTYLQSRYYRA-PE
DFGSASI-------FSEVR-----------------------------------------------------YV-----KEPYIQSRFYRA-PE
DFGSASH-------VADN-------------------------------------------------------D-----ITPYLVSRFYRA-PE
DWGLAEF-------YH------------------------------------------------------PGQEYN-----VRVASRYFKG-PE
DWGLAEF-------YH------------------------------------------------------PAQEYN-----VRVASRYFKG-PE
DFGHTRP-------RG------------------------------------------------------TLLRLA--GPPIPYTAPELCA-PP
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Other_NKF1__SgK110
Other_NKF1__SBK
Other_IKK__IKKa
Other_IKK__IKKb
Other_IKK__IKKe
Other_IKK__TBK1
STE_STE11__MAP3K2
STE_STE11__MAP3K3
STE_STE11__MAP3K8
STE_STE11__MAP3K5
STE_STE11__MAP3K7
STE_STE11__MAP3K6
STE_STE11__MAP3K4
STE_STE11__MAP3K1
STE_STE20_FRAY_OSR1
STE_STE20_FRAY_STLK3
STE_STE20_STLK_STLK5
STE_STE20_STLK_STLK6
STE_STE20_KHS_KHS1
STE_STE20_KHS_KHS2
STE_STE20_KHS_GCK
STE_STE20_KHS_HPK1
STE_STE20_MSN_ZC1/HGK
STE_STE20_MSN_ZC3/MINK
STE_STE20_MSN_ZC2/TNIK
STE_STE20_MSN_ZC4/NRK
STE_STE20_NinaC_MYO3B
STE_STE20_NinaC_MYO3A
STE_STE20_MST_MST1
STE_STE20_MST_MST2
STE_STE20_YSK_MST3
STE_STE20_YSK_YSK1
STE_STE20_YSK_MST4
STE_STE20_SLK_SLK
STE_STE20_SLK_LOK
STE_STE20_TAO_TAO2
STE_STE20_TAO_TAO1
STE_STE20_TAO_TAO3
STE_STE20_PAKA_PAK1
STE_STE20_PAKA_PAK3
STE_STE20_PAKA_PAK2
STE_STE20_PAKB_PAK4
STE_STE20_PAKB_PAK5

	
  

DLGLTRP-------EG------------------------------------------------------SPTPAP--PVPLPTAPPELCL-LL
DFGMTRR-------VG------------------------------------------------------CRVKRV--SGTIPYTAPEVCQ-AG
DLGYAKD-------VDQGS-----------------------------------------------------------LCTSFVGTLQYLA-PE
DLGYAKE-------LDQGS-----------------------------------------------------------LCTSFVGTLQYLA-PE
DFGAARE-------LDDDE-----------------------------------------------------------KFVSVYGTEEYLH-PD
DFGAARE-------LEDDE-----------------------------------------------------------QFVSLYGTEEYLH-PD
DFGASKR-------LQTIC---------------------------------------------------LSGTG----MKSVTGTPYWMS-PE
DFGASKR-------LQTIC---------------------------------------------------MSGTG----MRSVTGTPYWMS-PE
DFGCARR-------LAWAG---------------------------------------------------LNGTHS-DMLKSMHGTPYWMA-PE
DFGTSKR-------LAGIN---------------------------------------------------PC-------TETFTGTLQYMA-PE
DFGTSKR-------LAGVN---------------------------------------------------PC-------TETFTGTLQYMA-PE
DFGTSKR-------LAGIT---------------------------------------------------PC-------TETFTGTLQYMA-PE
DFGCSVK-------LKNNA---------------------------------------------------QTMPG---EVNSTLGTAAYMA-PE
DFGAAAR-------LASKG---------------------------------------------------TGAG---EFQGQLLGTIAFMA-PE
DFGVSAF-------LATGG---------------------------------------------------DITR--NKVRKTFVGTPCWMA-PE
DFGVSAF-------LATGG---------------------------------------------------DVTR--NKVRKTFVGTPCWMA-PE
GLRSNLS-------MISHG---------------------------------------------------QRQRVVHDFPKYSVKVLPWLS-PE
GLSHLHS-------LVKHG---------------------------------------------------QRHRAVYDFPQFSTSVQPWLS-PE
DFGVAAK-------ITAT-----------------------------------------------------IAK-----RKSFIGTPYWMA-PE
DFGVSAQ-------ITAT-----------------------------------------------------IAK-----RKSFIGTPYWMA-PE
DFGVSGE-------LTAS-----------------------------------------------------VAK-----RRSFIGTPYWMA-PE
DFGISAQ-------IGAT-----------------------------------------------------LAR-----RLSFIGTPYWMA-PE
DFGVSAQ-------LDRT-----------------------------------------------------VGR-----RNTFIGTPYWMA-PE
DFGVSAQ-------LDRT-----------------------------------------------------VGR-----RNTFIGTPYWMA-PE
DFGVSAQ-------LDRT-----------------------------------------------------VGR-----RNTFIGTPYWMA-PE
DFGVSAQ-------VSRT-----------------------------------------------------NGR-----RNSFIGTPYWMA-PE
DFGVSAQ-------LTST-----------------------------------------------------RLR-----RNTSVGTPFWMA-PE
DFGVSAQ-------LTST-----------------------------------------------------RHR-----RNTSVGTPFWMA-PE
DFGVAGQ-------LTDT-----------------------------------------------------MAK-----RNTVIGTPFWMA-PE
DFGVAGQ-------LTDT-----------------------------------------------------MAK-----RNTVIGTPFWMA-PE
DFGVAGQ-------LTDT-----------------------------------------------------QIK-----RNTFVGTPFWMA-PE
DFGVAGQ-------LTDT-----------------------------------------------------QIK-----RNTFVGTPFWMA-PE
DFGVAGQ-------LTDT-----------------------------------------------------QIK-----RNTFVGTPFWMA-PE
DFGVSAK-------NTRT-----------------------------------------------------IQR-----RDSFIGTPYWMA-PE
DFGVSAK-------NLKT-----------------------------------------------------LQK-----RDSFIGTPYWMA-PE
DFGSASI-------MAP--------------------------------------------------------------ANSFVGTPYWMA-PE
DFGSASM-------ASP--------------------------------------------------------------ANSFVGTPYWMA-PE
DFGSASM-------ASP--------------------------------------------------------------ANSFVGTPYWMA-PE
DFGFCAQ-------ITPE-----------------------------------------------------QSK-----RSTMVGTPYWMA-PE
DFGFCAQ-------ITPE-----------------------------------------------------QSK-----RSTMVGTPYWMA-PE
DFGFCAQ-------ITPE-----------------------------------------------------QSK-----RSTMVGTPYWMA-PE
DFGFCAQ-------VSKE-----------------------------------------------------VPR-----RKSLVGTPYWMA-PE
DFGFCAQ-------VSKE-----------------------------------------------------VPK-----RKSLVGTPYWMA-PE
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STE_STE20_PAKB_PAK6
STE_STE7__MAP2K1
STE_STE7__MAP2K2
STE_STE7__MAP2K5
STE_STE7__MAP2K6
STE_STE7__MAP2K3
STE_STE7__MAP2K4
STE_STE7__MAP2K7
Other_NKF4__CLIK1
Other_NKF4__CLIK1L
Other_ULK__ULK1
Other_ULK__ULK2
Other_ULK__ULK3
Other_ULK__ULK4
Other_ULK__Fused
Other_NEK__NEK1
Other_NEK__NEK5
Other_NEK__NEK3
Other_NEK__NEK4
Other_NEK__NEK2
Other_NEK__NEK9
Other_NEK__NEK8
Other_NEK__NEK6
Other_NEK__NEK7
Other_NEK__NEK11
Other_NEK__NEK10
Other_TLK__TLK1
Other_TLK__TLK2
CAMK_Trbl__Trb1
CAMK_Trbl__Trb2
CAMK_Trbl__Trb3
CAMK_CAMK-Unique__SgK495
Other_NKF3__SgK223
Other_NKF3__SgK269
Other_NAK__AAK1
Other_NAK__BIKE
Other_NAK__GAK
Other_PEK_PEK_PEK
Other_PEK__PKR
Other_PEK_GCN2_GCN2
Other_WEE__Wee1
Other_WEE__Wee1B
Other_WEE__MYT1

	
  

DFGFCAQ-------ISKD-----------------------------------------------------VPK-----RKSLVGTPYWMA-PE
DFGVSGQ-------LIDSM---------------------------------------------------ANS---------FVGTRSYMS-PE
DFGVSGQ-------LIDSM---------------------------------------------------ANS---------FVGTRSYMA-PE
DFGVSTQ-------LVNSI---------------------------------------------------AKT---------YVGTNAYMA-PE
DFGISGY-------LVDSV---------------------------------------------------AKTI--------DAGCKPYMA-PE
DFGISGY-------LVDSV---------------------------------------------------AKTM--------DAGCKPYMA-PE
DFGISGQ-------LVDSI---------------------------------------------------AKTR--------DAGCRPYMA-PE
DFGISGR-------LVDSK---------------------------------------------------AKTR--------SAGCAAYMA-PE
DFGLSKV-------CAGLAPR-----G---------------------------------KEGNQDNKNVNVNK---YWLSSACGSDFYMA-PE
DFGLSKV-------CS--------------------------------------------ASGQNPEEPVSVNK---CFLSTACGTDFYMA-PE
DFGFARY-------LQSN-----------------------------------------------------------MMAATLCGSPMYMA-PE
DFGFARY-------LHSN-----------------------------------------------------------MMAATLCGSPMYMA-PE
DFGFAQH-------MSPW-----------------------------------------------------------DEKHVLRGSPLYMA-PE
NFCLAKV-------EGENLEEFFALVAA--------------------------------EEGGGDNGENVLKK---SMKSRVKGSPVYTA-PE
DFGFARA-------MSTN-------------------------------------------------------T---MVLTSIKGTPLYMS-PE
DFGIARV-------LNSTVE----------------------------------------------------------LARTCIGTPYYLS-PE
DFGIARV-------LNNSME----------------------------------------------------------LARTCIGTPYYLS-PE
DFGSARL-------LSNPMA----------------------------------------------------------FACTYVGTPYYVP-PE
DLGIARV-------LENHCD----------------------------------------------------------MASTLIGTPYYMS-PE
DFGLARI-------LNHDTS----------------------------------------------------------FAKTFVGTPYYMS-PE
DYGLAKK-------LNSEYS----------------------------------------------------------MAETLVGTPYYMS-PE
DFGISKI-------LSSK---------------------------------------------------------------S---TPCYIS-PE
DLGLGRF-------FSSETT----------------------------------------------------------AAHSLVGTPYYMS-PE
DLGLGRF-------FSSKTT----------------------------------------------------------AAHSLVGTPYYMS-PE
DFGVSRL-------LMGSCD----------------------------------------------------------LATTLTGTPHYMS-PE
DFGLAKQ-------KQENSK----------------------------------------------------------LT-SVVGTILYSC-PE
DFGLSKI-------MDDDSYG----------------------------------------------------VDGMDLTSQGAGTYWYLP-PE
DFGLSKI-------MDDDSYNS---------------------------------------------------VDGMELTSQGAGTYWYLP-PE
SLEDTHI-------MKGED----------------------------------------------------------DALSDKHGCPAYVS-PE
SLEDAYI-------LRGDD----------------------------------------------------------DSLSDKHGCPAYVS-PE
NLEDSCV-------LTGPD----------------------------------------------------------DSLWDKHACPAYVG-PE
NFCLGKH-------LVSEG----------------------------------------------------------DLLKDQRGSPAYIS-PD
NFLKAKQ-------KPG-G----------------------------------------------------------TPNLQQKKSQARLA-PE
NFSQAKQ-------KS--H----------------------------------------------------------LVDPEILRDQSRLA-PE
DFGSATN-------KFQNP--------------------------------------------------QTEGVNAVEDEIKKYTTLSYRA-PE
DFGSATN-------KFLNP--------------------------------------------------QKDGVNVVEEEIKKYTTLSYRA-PE
DFGSATT-------ISHYPDYS-------W---------------------------------------SAQRRALVEEEITRNTTPMYRT-PE
DFGLVT-------AMDQDEEEQT----------------------------------------------VLTPMPAYARHTGQVGTKLYMS-PE
DFGLVT-------SLKND-----------------------------------------------------------GKRTRSKGTLRYMS-PE
DFGLATDHLAFSADSKQDDQTGD----------------------------------------------LIKSDPS-GHLTGMVGTALYVS-PE
D-EDDW--ASNKVMFKIGDLGH-------------------------------------------------V--TRISSPQVEEGDSRFLA-NE
ENEADWF-LSANVMYKIGDLGH-------------------------------------------------A--TSINKPKVEEGDSRFLA-NE
D---FG------LLVELGTAG---------------------------------------------------------AGEVQEGDPRYMA-PE
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TKL_STKR_Type1_ALK1
TKL_STKR_Type1_ALK2
TKL_STKR_Type1_ALK4
TKL_STKR_Type1_TGFbR1
TKL_STKR_Type1_ALK7
TKL_STKR_Type1_BMPR1A
TKL_STKR_Type1_BMPR1B
TKL_STKR_Type2_ACTR2
TKL_STKR_Type2_ACTR2B
TKL_STKR_Type2_TGFbR2
TKL_STKR_Type2_MISR2
TKL_STKR_Type2_BMPR2
RGC_RGC__ANPa
RGC_RGC__ANPb
RGC_RGC__HSER
RGC_RGC__CYGD
RGC_RGC__CYGF
TK_Abl__ABL
TK_Abl__ARG
TK_Tec__BTK
TK_Tec__BMX
TK_Tec__TEC
TK_Tec__TXK
TK_Tec__ITK
TK_Src__HCK
TK_Src__LYN
TK_Src__LCK
TK_Src__BLK
TK_Src__SRC
TK_Src__YES
TK_Src__FYN
TK_Src__FGR
TK_Src__FRK
TK_Src__BRK
TK_Src__SRM
TK_Csk__CSK
TK_Csk__CTK
TK_Fer__FER
TK_Fer__FES
TK_FGFR__FGFR2
TK_FGFR__FGFR3
TK_FGFR__FGFR1
TK_FGFR__FGFR4

	
  

DLGLAVM-------HSQ---GSD---------------------------------------------------YLDIGNNPRVGTKRYMA-PE
DLGLAVM-------HSQ---STN---------------------------------------------------QLDVGNNPRVGTKRYMA-PE
DLGLAVR-------HDA---VTD---------------------------------------------------TIDIAPNQRVGTKRYMA-PE
DLGLAVR-------HDS---ATD---------------------------------------------------TIDIAPNHRVGTKRYMA-PE
DLGLAVK-------HDS---ILN---------------------------------------------------TIDIPQNPKVGTKRYMA-PE
DLGLAVK-------FNS---DTN---------------------------------------------------EVDVPLNTRVGTKRYMA-PE
DLGLAVK-------FIS---DTN---------------------------------------------------EVDIPPNTRVGTKRYMP-PE
DFGLALK-------FEA---GKS---------------------------------------------------AGD--THGQVGTRRYMA-PE
DFGLAVR-------FEP---GKP---------------------------------------------------PGD--THGQVGTRRYMA-PE
DFGLSLR-------LDP---TLS---------------------------------------------------VDDLANSGQVGTARYMA-PE
DLGLALV-------LPG--LTQPPAW--------------------------------------------TPTQPQGPAAIMEAGTQRYMA-PE
DFGLSMR-------LTGNRLVRP-----------------------------------------------G---EEDNAAISEVGTIRYMA-PE
DYGLESF-------R-----DLD-----------------------------------------------------PEQGHTVYAKKLWTA-PE
DYGLASF-------RS----TAE-----------------------------------------------------PDDSHALYAKKLWTA-PE
DFGCNSI-------LP----PK---------------------------------------------------------------KDLWTA-PE
DHGHGRL-------LE----AQK-----------------------------------------------------VLPEPPRAEDQLWTA-PE
DYGFNDI-------LE----MLR-----------------------------------------------------LSEEESSMEELLWTA-PE
DFGLSRL-------MT----GDT---------------------------------------------------YT-AHAGA-KFPIKWTA-PE
DFGLSRL-------MT----GDT---------------------------------------------------YT-AHAGA-KFPIKWTA-PE
DFGLSRY-------VL----DDE---------------------------------------------------YT-SSVGS-KFPVRWSP-PE
DFGMTRY-------VL----DDQ---------------------------------------------------YV-SSVGT-KFPVKWSA-PE
DFGMARY-------FL----DDQ---------------------------------------------------YT-SSSGA-KFPVKWCP-PE
DFGMTRY-------VL----DDE---------------------------------------------------YV-SSFGA-KFPIKWSP-PE
DFGMTRF-------VL----DDQ---------------------------------------------------YT-SSTGT-KFPVKWAS-PE
DFGLARV-------IE----DNE---------------------------------------------------YT-AREGA-KFPIKWTA-PE
DFGLARV-------IE----DNE---------------------------------------------------YT-AREGA-KFPIKWTA-PE
DFGLARL-------IE----DNE---------------------------------------------------YT-AREGA-KFPIKWTA-PE
DFGLARI-------ID----S-E---------------------------------------------------YT-AQEGA-KFPIKWTA-PE
DFGLARL-------IE----DNE---------------------------------------------------YT-ARQGA-KFPIKWTA-PE
DFGLARL-------IE----DNE---------------------------------------------------YT-ARQGA-KFPIKWTA-PE
DFGLARL-------IE----DNE---------------------------------------------------YT-ARQGA-KFPIKWTA-PE
DFGLARL-------IK----DDE---------------------------------------------------YN-PCQGS-KFPIKWTA-PE
DFGLARV-------FKV---DNEDI-------------------------------------------------YE-SRHEI-KLPVKWTA-PE
DFGLARL-------IK----EDV---------------------------------------------------Y--LSHDH-NIPYKWTA-PE
DFGLARL-------LK----DDI---------------------------------------------------YS-PSSSS-KIPVKWTA-PE
DFGLTKE-------AS----STQ---------------------------------------------------DT-G-----KLPVKWTA-PE
DFGLAKA-------ER----KGL---------------------------------------------------DS-S-----RLPVKWTA-PE
DFGMSRQ-------ED----GGV---------------------------------------------------YS-SSG-LKQIPIKWTA-PE
DFGMSRE-------EA----DGV---------------------------------------------------YA-ASGGSRQVPVKWTA-PE
DFGLARD-------INN---IDY---------------------------------------------------YK-KTTNG-RLPVKWMA-PE
DFGLARD-------VHN---LDY---------------------------------------------------YK-KTTNG-RLPVKWMA-PE
DFGLARD-------IHH---IDY---------------------------------------------------YK-KTTNG-RLPVKWMA-PE
DFGLARG-------VHH---IDY---------------------------------------------------YK-KTSNG-RLPVKWMA-PE
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TK_Ret__RET
TK_VEGFR__KDR
TK_VEGFR__FLT1
TK_VEGFR__FLT4
TK_PDGFR__FMS
TK_PDGFR__KIT
TK_PDGFR__PDGFRa
TK_PDGFR__PDGFRb
TK_PDGFR__FLT3
TK_Tie__TIE2
TK_Tie__TIE1
TK_Alk__ALK
TK_Alk__LTK
TK_Sev__ROS
TK_InsR__INSR
TK_InsR__IGF1R
TK_InsR__IRR
TK_DDR__DDR1
TK_DDR__DDR2
TK_Trk__TRKB
TK_Trk__TRKC
TK_Trk__TRKA
TK_Musk__MUSK
TK_Ror__ROR1
TK_Ror__ROR2
TK_CCK4__CCK4
TK_Axl__AXL
TK_Axl__MER
TK_Axl__TYRO3
TK_Met__MET
TK_Met__RON
TK_Ryk__RYK
TK_Ack__ACK
TK_Ack__TNK1
TK_EGFR__EGFR
TK_EGFR__HER2/ErbB2
TK_EGFR__HER4/ErbB4
TK_EGFR__HER3/ErbB3
TK_Syk__SYK
TK_Syk__ZAP70
TK_Eph__EphA3
TK_Eph__EphA5
TK_Eph__EphA4

	
  

DFGLSRD-------VYE---EDS---------------------------------------------------YV-KRSQG-RIPVKWMA-IE
DFGLARD-------IYK---DPD---------------------------------------------------YV-RKGDA-RLPLKWMA-PE
DFGLARD-------IYK---NPD---------------------------------------------------YV-RKGDT-RLPLKWMA-PE
DFGLARD-------IYK---DPD---------------------------------------------------YV-RKGSA-RLPLKWMA-PE
DFGLARD-------IMN---DSN---------------------------------------------------YI-VKGNA-RLPVKWMA-PE
DFGLARD-------IKN---DSN---------------------------------------------------YV-VKGNA-RLPVKWMA-PE
DFGLARD-------IMH---DSN---------------------------------------------------YV-SKGST-FLPVKWMA-PE
DFGLARD-------IMR---DSN---------------------------------------------------YI-SKGST-FLPLKWMA-PE
DFGLARD-------IMS---DSN---------------------------------------------------YV-VRGNA-RLPVKWMA-PE
DFGLSR----------G---QEV---------------------------------------------------YV-KKTMG-RLPVRWMA-IE
DFGLSR----------G---EEV---------------------------------------------------YV-KKTMG-RLPVRWMA-IE
DFGMARD-------IYR---ASY---------------------------------------------------Y--RKGGCAMLPVKWMP-PE
DFGMARD-------IYR---ASY---------------------------------------------------Y--RRGDRALLPVKWMP-PE
DFGLARD-------IYK---NDY---------------------------------------------------Y--RKRGEGLLPVRWMA-PE
DFGMTRD-------IYE---TDY---------------------------------------------------Y--RKGGKGLLPVRWMA-PE
DFGMTRD-------IYE---TDY---------------------------------------------------Y--RKGGKGLLPVRWMS-PE
DFGMTRD-------VYE---TDY---------------------------------------------------Y--RKGGKGLLPVRWMA-PE
DFGMSRN-------LYA---GDY---------------------------------------------------Y--RVQGRAVLPIRWMA-WE
DFGMSRN-------LYS---GDY---------------------------------------------------Y--RIQGRAVLPIRWMS-WE
DFGMSRD-------VYS---TDY---------------------------------------------------Y--RVGGHTMLPIRWMP-PE
DFGMSRD-------VYS---TDY---------------------------------------------------Y--RVGGHTMLPIRWMP-PE
DFGMSRD-------IYS---TDY---------------------------------------------------Y--RVGGRTMLPIRWMP-PE
DFGLSRN-------IYS---ADY---------------------------------------------------Y--KANENDAIPIRWMP-PE
DLGLSRE-------IYS---ADY---------------------------------------------------Y--RVQSKSLLPIRWMP-PE
DLGLFRE-------VYA---ADY---------------------------------------------------Y--KLLGNSLLPIRWMA-PE
ALGLSKD-------VYN---SEY---------------------------------------------------Y--HFR-QAWVPLRWMS-PE
DFGLSKK-------IYN---GDY---------------------------------------------------Y--RQGRIAKMPVKWIA-IE
DFGLSKK-------IYS---GDY---------------------------------------------------Y--RQGRIAKMPVKWIA-IE
DFGLSRK-------IYS---GDY---------------------------------------------------Y--RQGCASKLPVKWLA-LE
DFGLARD-------MYD---KEY---------------------------------------------------YSVHNKTGAKLPVKWMA-LE
DFGLARD-------ILD---REY---------------------------------------------------YSVQQHRHARLPVKWMA-LE
DNALSRD-------LFP---MDY---------------------------------------------------H--CLGDNENRPVRWMA-LE
DFGLMRA-------LPQN--DDH---------------------------------------------------Y--VMQEHRKVPFAWCA-PE
DFGLVRP-------LGGA--RGR---------------------------------------------------Y--VMGGPRPIPYTWCA-PE
DFGLAKL-------LGAE--EKE---------------------------------------------------Y--HAE-GGKVPIKWMA-LE
DFGLARL-------LDID--ETE---------------------------------------------------Y--HAD-GGKVPIKWMA-LE
DFGLARL-------LEGD--EKE---------------------------------------------------Y--NAD-GGKMPIKWMA-LE
DFGVADL-------LPPD--DKQ---------------------------------------------------L--LYS-EAKTPIKWMA-LE
DFGLSKA-------LRAD--ENY---------------------------------------------------Y--KAQTHGKWPVKWYA-PE
DFGLSKA-------LGAD--DSY---------------------------------------------------Y--TARSAGKWPLKWYA-PE
DFGLSRV-------LEDDP-EAA---------------------------------------------------Y--TTR-GGKIPIRWTS-PE
DFGLSRV-------LEDDP-EAA---------------------------------------------------Y--TTR-GGKIPIRWTA-PE
DFGMSRV-------LEDDP-EAA---------------------------------------------------Y--TTR-GGKIPIRWTA-PE
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TK_Eph__EphA6
TK_Eph__EphA7
TK_Eph__EphB1
TK_Eph__EphB2
TK_Eph__EphB3
TK_Eph__EphB4
TK_Eph__EphA8
TK_Eph__EphA2
TK_Eph__EphA1
TK_Eph__EphB6
TK_Eph__EphA10
TK_Fak__FAK
TK_Fak__PYK2
TK_JakA__JAK1
TK_JakA__TYK2
TK_JakA__JAK2
TK_JakA__JAK3
TK_Lmr__LMR1
TK_Lmr__LMR3
TK_Lmr__LMR2
TK_JakB__Domain2_JAK1
TK_JakB__Domain2_TYK2
TK_JakB__Domain2_JAK2
TK_JakB__Domain2_JAK3
TKL_LISK_LIMK_LIMK2
TKL_LISK_LIMK_LIMK1
TKL_LISK_TESK_TESK1
TKL_LISK_TESK_TESK2
TKL_MLK_HH498_HH498
TKL_MLK_TAK1_TAK1
TKL_MLK_LZK_DLK
TKL_MLK_LZK_LZK
TKL_MLK_MLK_MLK1
TKL_MLK_MLK_MLK3
TKL_MLK_MLK_MLK4
TKL_MLK_MLK_MLK2
TKL_MLK_MLK_ZAK
TKL_RAF__BRAF
TKL_RAF__RAF1
TKL_RAF__ARAF
TKL_RAF__KSR1
TKL_RAF__KSR2
TKL_RIPK__ANKRD3

	
  

DFGLSRV-------LEDDP-EAA---------------------------------------------------Y--TTT-GGKIPIRWTA-PE
DFGLSRV-------IEDDP-EAV---------------------------------------------------Y--TTT-GGKIPVRWTA-PE
DFGLSRY-------LQDDTSDPT---------------------------------------------------Y--TSSLGGKIPVRWTA-PE
DFGLSRF-------LEDDTSDPT---------------------------------------------------Y--TSALGGKIPIRWTA-PE
DFGLSRF-------LEDDPSDPT---------------------------------------------------Y--TSSLGGKIPIRWTA-PE
DFGLSRF-------LEENSSDPT---------------------------------------------------Y--TSSLGGKIPIRWTA-PE
DFGLSRV-------LEDDP-DAA---------------------------------------------------Y--TTT-GGKIPIRWTA-PE
DFGLSRV-------LEDDP-EAT---------------------------------------------------Y--TTS-GGKIPIRWTA-PE
DFGLTRL-------LDD--FDGT---------------------------------------------------Y--ETQ-GGKIPIRWTA-PE
RLGHS-------------------------------------------------------------------------PQ-GPSCLLRWAA-PE
GFGRGP---------RDRS-EAV---------------------------------------------------Y--TTM-SGRSPALWAA-PE
DFGLSRY-------MED---STY---------------------------------------------------Y--KAS-KGKLPIKWMA-PE
DFGLSRY-------IED---EDY---------------------------------------------------Y--KAS-VTRLPIKWMS-PE
DFGLTKA-------IET---DKE---------------------------------------------------YYTVKDDR-DSPVFWYA-PE
DFGLAKA-------VPE---GHE---------------------------------------------------YYRVREDG-DSPVFWYA-PE
DFGLTKV-------LPQ---DKE---------------------------------------------------YYKVKEPG-ESPIFWYA-PE
DFGLAKL-------LPL---DKD---------------------------------------------------YYVVREPG-QSPIFWYA-PE
DYGLAHC-------KYR---EDY-----------------------------------------------------FVTADQLWVPLRWIA-PE
DYGLAHS-------NYK---EDY-----------------------------------------------------YLTPERLWIPLRWAA-PE
DYGIGFS-------RYK---EDY-----------------------------------------------------IETDDKKVFPLRWTA-PE
DPGIPIT-------VLS------------------------------------------------------------RQEC--IERIPWIA-PE
DPGVGLG-------ALS------------------------------------------------------------REER--VERIPWLA-PE
DPGISIT-------VLP------------------------------------------------------------KDIL--QERIPWVP-PE
DPGVSPA-------VLS------------------------------------------------------------LEML--TDRIPWVA-PE
DFGLSRL-------IVEERKRAPMEKATTKK--------------------------------------RTLRKNDRKKRYTVVGNPYWMA-PE
DFGLARL-------MVDEKTQP------EGL--------------------------------------RSLKKPDRKKRYTVVGNPYWMA-PE
DFGLAEK-------IPVYREGA------------------------------------------------------RKEPLAVVGSPYWMA-PE
DFGLAEK-------IPDVSMGS------------------------------------------------------EK--LAVVGSPFWMA-PE
DFGESRF-------LQSLD-ED--------------------------------------------------------NMTKQPGNLRWMA-PE
DFGTACD-------IQT-------------------------------------------------------------HMTNNKGSAAWMA-PE
DFGTSKE-------LSD---KS--------------------------------------------------------TKMSFAGTVAWMA-PE
DFGTSKE-------LSD---KS--------------------------------------------------------TKMSFAGTVAWMA-PE
DFGLARE-------WH----RT--------------------------------------------------------TKMSAAGTYAWMA-PE
DFGLARE-------WH----KT--------------------------------------------------------TQMSAAGTYAWMA-PE
DFGLARE-------WH----RT--------------------------------------------------------TKMSTAGTYAWMA-PE
DFGLARE-------WH----KT--------------------------------------------------------TKMSAAGTYAWMA-PE
DFGASRF-------HN----HT--------------------------------------------------------THMSLVGTFPWMA-PE
DFGLATV-------KSRWSGSH--------------------------------------------------------QFEQLSGSILWMA-PE
DFGLATV-------KSRWSGSQ--------------------------------------------------------QVEQPTGSVLWMA-PE
DFGLATV-------KTRWSGAQ--------------------------------------------------------PLEQPSGSVLWMA-AE
LFGISGV-------VREGRREN--------------------------------------------------------QLKLSHDWLCYLA-PE
LFSISGV-------LQAGRRED--------------------------------------------------------KLRIQNGWLCHLA-PE
DFGLAKC-------NGLS-H-----------------------------------------------------SHDLSMDGLFG-TIAYLP-PE
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TKL_RIPK__SgK288
TKL_RIPK__RIPK2
TKL_RIPK__RIPK3
TKL_RIPK__RIPK1
TKL_IRAK__IRAK1
TKL_IRAK__IRAK3
TKL_IRAK__IRAK2
TKL_IRAK__IRAK4
Other_NRBP__NRBP1
Other_NRBP__NRBP2
Other_Wnk__Wnk1
Other_Wnk__Wnk3
Other_Wnk__Wnk2
Other_Wnk__Wnk4
CK1_CK1__CK1a
CK1_CK1__CK1a2
CK1_CK1__CK1d
CK1_CK1__CK1e
CK1_CK1__CK1g3
CK1_CK1__CK1g1
CK1_CK1__CK1g2
CK1_TTBK__TTBK2
CK1_TTBK__TTBK1
CK1_VRK__VRK1
CK1_VRK__VRK2
CK1_VRK__VRK3
Other_NKF5__SgK307
Other_NKF5__SgK424
Other_NAK__MPSK1
Other_PEK__HRI
Other_TTK__TTK
STE_STE-Unique__COT
STE_STE-Unique__NIK
Other_CDC7__CDC7
TK_TK-Unique__SuRTK106
TKL_LRRK__LRRK2
Other_Other-Unique__SgK496
Other_MOS__MOS
Other_TBCK__TBCK
TKL_LRRK__LRRK1
Other_Other-Unique__KIS
TKL_TKL-Unique__MLKL
Other_Bud32__PRPK

	
  

DFGLSKW-------MEQSTR-----------------------------------------------------MQYIERSALRG-MLSYIP-PE
DFGLSKW-------RMMSLS-----------------------------------------------------QSRSSKSAPEGGTIIYMP-PE
DFGLSTF-------QGGS--------------------------------------------------------QSGTGSGEPGGTLGYLA-PE
DLGLASF-------KMWSKLNN------EE---------------------------------------HNELREVDGTAKKNGGTLYYMA-PE
DFGLARF-------SRFAG-SSP------------------------------------------------SQSSMVARTQTVRGTLAYLP-EE
DFAMAHF-------R--S--HLE------------------------------------------------HQSCTINMTSSSSKHLWYMP-EE
HP-MAHL-------CP----VNK------------------------------------------------RSKYTMMKTHLLRTSAAYLP-ED
DFGLARA-------S--------------------------------------------------------EKFAQTVMTSRIVGTTAYMA-PE
VAPDTIN-------NH------------------------------------------------------------VKTCREEQKNLHFFA-PE
ALPDDLR-------SP------------------------------------------------------------IRAEREELRNLHFFP-PE
DLGLATL-------KR------------------------------------------------------------ASFAKSVIGTPEFMA-PE
DLGLATL-------MR------------------------------------------------------------TSFAKSVIGTPEFMA-PE
DLGLATL-------KR------------------------------------------------------------ASFAKSVIGTPEFMA-PE
DLGLATL-------KR------------------------------------------------------------ASFAKSVIGTPEFMA-PE
DFGLAKK-------YRDN---------------------------------------------------RTRQHIPYREDKNLTGTARYAS-IN
DFGLAKK-------YRDN---------------------------------------------------RTRQHIPYREDKHLIGTVRYAS-IN
DFGLAKK-------YRDA---------------------------------------------------RTHQHIPYRENKNLTGTARYAS-IN
DFGLAKK-------YRDA---------------------------------------------------RTHQHIPYRENKNLTGTARYAS-IN
DFGLAKE-------YIDP---------------------------------------------------ETKKHIPYREHKSLTGTARYMS-IN
DFGLAKE-------YIDP---------------------------------------------------ETKKHIPYREHKSLTGTARYMS-IN
DFGLAKE-------YIDP---------------------------------------------------ETKKHIPYREHKSLTGTARYMS-IN
DFGLARQ-------FTN----------------------------------------------------SCGDVRPPRAVAGFRGTVRYAS-IN
DFGLARQ-------YTN----------------------------------------------------TTGDVRPPRNVAGFRGTVRYAS-VN
DYGLAYR-------YCPE---------------------------------------------------GVHKEYKEDPKRCHDGTIEFTS-ID
DYGLSYR-------YCPN---------------------------------------------------GNHKQYQENPRKGHNGTIEFTS-LD
GYGFAFR-------YCPS---------------------------------------------------GKHVAYVEGSRSPHEGDLEFIS-MD
NLEYMLE-------SEDR---------------------------------------------------GVQRDLTRVPLP--TQLYNWAA-PE
---------------------------------------------------------------------------------------------SMNQACIH------VEGSR-----------------------------------------------------QALTLQDWAAQRCTISYRA-PE
DFGLACT-----DILQKNTDWTN------------------------------------------------RNGKRTPTHTSRVGTCLYAS-PE
DFGIANQ-------MQPDTTS--------------------------------------------------------VVKDSQVGTVNYMP-PE
DFGLSVQ-------MTED----------------------------------------------------------VYFPKDLRGTEIYMS-PE
DFGHAVC-------LQPDGLG-----------------------------------------------------KSLLTGDYIPGTETHMA-PE
NFNIHSSISHESPAVKLMKQSKTVDVLSRKLATKKKAISTKVMNSAVMRKTASSCPASLTCDCYATDKVCSICLSRRQQVAPRAGTPGFRA-PE
-LGLAYE-------VYTRG----------------------------------------------------------AISSTQTIPLKWLA-PE
DYGIAQY------CCRMG-------------------------------------------------------------IKTSEGTPGFRA-PE
DLGFCKP--------------------------------------------------------------------EAMMSGSIVGTPIHMA-PE
DFGCSEK-------LEDLLCFQTP-------------------------------------------------------SYPLGGTYTHRA-PE
KFGLYH--------MTAHG----------------------------------------------------------DDVDFPIGYPSYLA-PE
DYGISRQ------SFHEG-------------------------------------------------------------ALGVEGTPGYQA-PE
DFGLSFK--------EGN------------------------------------------------------------QDVKYIQTDGYRA-PE
ELRKTQTS------MSLG---------------------------------------------------------TTREKTDRVKSTAYLS-PQ
DFGLS---------FIS-------------------------------------------------------------ALPEDKGVDLYVL-EK
.....990......1000......1010......1020......1030......1040......1050......1060......1070......
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32
33
30
41
37
34
33
30
26
26
26
26
26
26
35
35
35
35
35
35
35
34
34
35
35
35
33
34
40
30
28
33
93
27
26
25
31
27
26
25
30
23

CLUSTAL 2.1 MULTIPLE SEQUENCE ALIGNMENT
File: /Users/RCoover3159/Desktop/Kinome_DFG_alignment1
Date: Sat May 9 18:40:50 2015
Page 12 of 12
Other_NKF2__PINK1
Other_TOPK__PBK
AGC_MAST__MASTL
Other_Other-Unique__RNAseL
TKL_MLK_ILK_ILK
Other_Other-Unique__SgK071
STE_STE-Unique__Domain2_GCN2
Other_SCY1__SCYL2
Other_SCY1__SCYL1
Other_SCY1__SCYL3
Other_Other-Unique__SgK196
Other_VPS15__PIK3R4
Other_BUB__BUB1
Other_BUB__BUBR1
Other_Other-Unique__SgK493
Other_Other-Unique__SgK396
Other_Slob__Slob
Other_Haspin__Haspin

DFGCCLADESIGLQLPFSS-----------------------------------------------------------WYVDRGGNGCLMA-PE
DVGVSLP-------LDEN-------------------------------------------------------MTVTDPEACYIGTEPWKP-KE
DFGLSK---------VT-------------------------------------------------------------LNRDINMMDILTT-PS
DFDKS---------------------------------------------------------------------------------IKWAGDPQ
DVKFSFQ------------------------------------------------------------------------CPGRMYAPAWVA-PE
DLSSNVL-------MTDKAKWN-------------------------------------------------------IRAEEDPFRKSWMA-PE
DYSISKR-------LAD-------------------------------------------------------------ICKEDVFEQTRVRFSD
DFCVSST-------NPSEQE-----------------------------------------------------PKFPCKEWDPNLPSLCLPNPE
DYMYSAQ--------GNGGG---------------------------------------------------------PPRKGIPELEQYDP-PE
--GMET------------------------------------------------------------------------VCKVSQATPEFLRSIQ
QYLLTSN-------FS-------------------------------------------------------------ILANDLDALPLVNHSSG
DFASFKPTYLPEDNPADFNYFFDTSRRR----------------------------------------TCYIAPERFVDGGMFATELEYMRDPS
DLGQSID-------MKLFPKG--------------------------------------------------------TIFTAKCETSGFQC-VE
DFSYSVD--------LRVQLD--------------------------------------------------------VFTLSGFRTVQILEGQK
DLDDAR--------VEETP-----------------------------------------------------------CAGSTDCILEFPARNF
DFDFTKS-------VSQR-----------------------------------------------------------ASVNMMVGDLSLMS-PE
DLENS-------------------------------------------------------------------------LLGLPSFYRSYFSQFR
-YTLNGK-------SSTIP-----------------------------------------------------------SCGLQVSIIDYTLSRL
.....990......1000......1010......1020......1030......1040......1050......1060......1070......

Figure 69. Human kinome DFG-APE sequence alignment.
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34
31
23
13
21
31
26
34
28
20
26
54
30
30
27
27
21
27

4.2 General Chemical Methods:
Chemical reagents and solvents were purchased from Sigma-Aldrich (MO, USA), Alfa-Aesar
(MA, USA), Fisher Scientific (PA, USA). Amino acids and coupling reagents were purchased
from Chem-Impex. Analytical Thin Layer Chromatography (TLC) was performed using silica
gel GHLF plates (Analtech Inc., DE, USA). Flash Chromatography was performed on
TELEDYN ISCO CombiFlash® Rf instrument using RediSep Rf Normal-phase Flash Columns
(4g, 12g, 24g, or 40g). 1H NMR and 13C NMR were recorded on a Bruker Topspin 400MHz
using Chloroform-d and deuterated DMSO. All chemical shifts are reported as δ in units of parts
per million (ppm) relative to chloroform and DMSO residual peaks at 7.26 and 2.50 respectively
(1H) and 77.16 and 39.52 respectively (13C). The multiplicity (s = singlet, d = doublet, dd =
doublet of doublets, t = triplet, q = quartet, m = muliplet), coupling constants(s) (Hz).
Electrospray ionization (ESI) mass spectra were obtained from Perkin Elmer Flexar
UPLC/AxION2 TOF Mass Spectrometer. Matrix-Assisted Laser Desorption/Ionization
(MALDI) spectra were obtained from Voyager DE-ProTM MALDI TOF Mass Spectrometer.
4.2.1

H
N

O

O
OH

O

12

((prop-2-yn-1-yloxy)carbonyl)-L-phenylalanine (12). To a vial add 8 mL H2O, 467.52 mg
NaOH, and 660.8 mg phenylalanine (freebase form). To the solution add 0.39 mL
propargylcarbamate. Allot to react for 16 hr at ambient tempterature. Wash with 2 N
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HCl/EtOAc, collect organic layer. (438 mg, 43.8%). Rf (90:10 DCM:MeOH)= 0.47. Crude
product taken forward to Weinreb Amide formation.

4.2.2
H
N

O

O
OH

O

16

((prop-2-yn-1-yloxy)carbonyl)-L-isoleucine (16). To a vial add 8 mL H2O, 467.52 mg NaOH,
and 616 mg isoleucine (freebase form). To the solution add 0.39 mL propargylcarbamate. Allot
to react for 16 hr at ambient tempterature. Wash with 2 N HCl/EtOAc, collect organic layer. (463
mg, 46.3%). Rf (90:10 EtOAc:Hexanes)= 0.44. Crude product taken forward to Weinreb Amide
formation.

4.3 General Procedure for the Formation of Weinreb Amide Intermediates.
To a vial was added 1 equivalent of amino acid (Boc or Poc protected). To the vial was added
DCM (.25 M final concentration of amino acid). To the solution was added N-(3Dimethylaminopropyl)-N′-ethylcarbodiimide (EDCI, 1.2 equivalents), 1-Hydroxybenzotriazole
(HOBt) hydrate (1 equivalent), and 4-methylmorpholine (4 equivalents). This solution was
allowed to react for 15 minutes at ambient T. To the solution was then added N,ODimethylhydroxylamine hydrochloride (1.1 equivalents) and allowed to react for 16 hr. The
reaction solution was washed with 1N HCl once, then with saturated NaCO3, then the organic
solvent was collected and solvent removed in vacuo. The crude product was purified by flash
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chromatography on silica by CombiFlash instrument (0-100% EtOAc:Hexanes over 20 column
volumes).

4.3.1

H
N

O

O
O
N

O

2

tert-butyl (S)-(1-(methoxy(methyl)amino)-1-oxo-3-phenylpropan-2-yl)carbamate (2). (2g, 87%)
1

H NMR (400 MHz, CDCl3) δ 7.28 (m, 2H) 7.22 (d, J=7.2, 1H), 7.17 (d, J=7.6, 2H), 5.14 (br,

1H), 4.95 (br, 1H), 3.65 (s, 3H), 3.16 (s, 3H), 3.05 (dd, J1=6.2, J2=13.5, 1H), 2.89 (m, 1H), 1.39
(s, 9H).

4.3.2

H
N

O

O
N

O

O

5

tert-butyl ((2S,3S)-1-(methoxy(methyl)amino)-3-methyl-1-oxopentan-2-yl)carbamate (5). (574
mg 67%) 1H NMR (400 MHz, CDCl3) δ 5.2 (s, 1H), 4.6 (s, 1H), 3.7 (s, 3H), 3.2 (s, 3H), 2.1 (s,
1H), 1.7 (m, 1H), 1.5 (m 1H), 1.4 (s, 9H), 1.0 (m, 1H), 1.9 (m, 6H).
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4.3.3

O

H
N

O

N

O

O

8

tert-butyl (2-(methoxy(methyl)amino)-2-oxoethyl)carbamate (8). (302 mg, 77%) 1H NMR (400
MHz, CDCl3) δ 5.2 (s, 1H), 4.0 (s, 2H), 3.6 (s, 3H), 3.1 (s, 3H), 1.4 (s, 9H).

4.3.4

H
N

O

O
N

O

O

13

prop-2-yn-1-yl(S)-(1-(methoxy(methyl)amino)-1-oxo-3-phenylpropan-2-yl)carbamate

(13).

(0.312 g, 61% yield). 1H NMR (400MHz, CD3OD) δ 7.23-7.29 (m, 5H), 4.89 (m, 1H), 4.60 (s,
2H), 3.73 (s, 3H), 3.17 (s, 3H), 3.04 (dd, J1=5.9, J2=13.3, 1H), 2.86 (m, 2H).
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4.3.5
H
N

O

O
N

O

O

17

((prop-2-yn-1-yloxy)carbonyl)-L-isoleucine (17). (480 mg, 94%) 1H NMR (400 MHz, CDCl3) δ
5.3 (d, 1H, J=9), 4.6 (m, 3H), 3.7 (s, 3H), 3.1 (s, 3H), 2.4 (s, 1H), 2.0 (s, 1H), 1.7 (m, 1H), 1.5
(m, 1H), 1.0 (m, 1H), 0.9 (m, 6H).

4.4 General Procedure for Grignard Reactions with Weinreb Amides.
The appropriate Weinreb amide (above) (1 equivalent) was dissolved in anhydrous THF (.3 M).
The solution was then cooled to -40 °C in a dry ice/ACN bath and purged with argon before 1M
vinyl magnesium bromide in Ether (5 equivalents) was added dropwise (over 5 minutes). After
3h stirring at -40 °C, the reaction mixture was poured into cold 3N HCl, and extracted three
times with ethyl acetate. The combined organic layers were dried over anhydrous sodium
sulphate and concentrated in vacuo. The crude product was purified over silica gel
chromatography to obtain the desired product.
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4.4.1

H
N

O

O

O

3

tert-butyl (S)-(3-oxo-1-phenylpent-4-en-2-yl)carbamate (3). (156 mg, 67%) 1H NMR (400MHz,
CDCl3) δ 7.25 (m, 3H) 7.10 (d, J=7.4, 2H), 6.41 (m, 2H), 5.83 (d, J=10.4, 1H), 5.22 (m, 1H),
4.86 (q, J=9, 1H), 3.14 (dd, J1=6.4, J2=13.8, 1H), 2.98 (dd, J1=8.0, J2=15.4, 1H), 1.42 (s, 9H).
13

C NMR (100MHz, CDCl3) δ 197.9, 155.2, 136.0, 133.5, 130.2, 129.6, 128.6, 127.1, 79.9, 58.3,

38.2, 28.4. HRMS (ESI) C16H21NO3 m/z [M+Na+] found 298.1415, expected 298.1419.

4.4.2

H
N

O

O

O

6

tert-butyl ((4S,5S)-5-methyl-3-oxohept-1-en-4-yl)carbamate (6). (34 mg, 45%)

1

H NMR

(400MHz, CDCl3) δ 6.4 (m, 2H), 5.8 (d, 1H, J=10.32), 5.1 (s, 1H), 4.5 (m, 1H), 1.8 (m, 1H), 1.5
(s, 1H), 1.3 (m, 2H), 1.4 (s, 9H), 1 (m, 3H), 0.8 (m, 3H). 13C NMR (100MHz, CDCl3) δ 199.2,
155.9, 134.2, 129.7, 79.7, 61.9, 37.8, 28.4, 24.3, 16.3, 11.7.
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4.4.3
O

H
N

O
O

10

tert-butyl ((3S,4S)-3-methyl-5-oxoheptan-4-yl)carbamate (10). To a solution of 6 was added
Pd/C (0.1 mol%) with H2(g) at ATM and ambient temperature for 16 hr. The solution was
filtered through celite and solvent removed in vacuo. (22 mg, Quantitative) 1H NMR (400MHz,
CDCl3) δ 5.0 (s, 1H), 4.2 (s, 1H), 2.4 (m, 1H), 1.8 (s, 1H), 1.4 (s, 3H), 1.3 (s, 9H), 1.0 (m, 3H),
0.9 (d, 3H, J=6.8), 0.8 (m, 3H). 13C NMR (100MHz, CDCl3) δ 210.5, 155.9, 79.6, 63.6, 37.2,
34.3, 28.3, 24.2, 16.1, 11.6, 7.5.

4.4.4
O

H
N

O
O

9

tert-butyl (2-oxobut-3-en-1-yl)carbamate (9). (34 mg, 45%) 1H NMR (400MHz, CDCl3) δ 6.3
(m, 2H), 5.9 (d, 1H J=8.2), 5.2 (s, 1H), 4,2 (s, 2H), 1.4 (s, 9H). 13C NMR (100MHz, CDCl3) δ
205.3, 155.4, 79.6, 62.9, 36.4, 34.1, 28.3.
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4.4.5
H
N

O

O

O

14

prop-2-yn-1-yl (S)-(3-oxo-1-phenylpent-4-en-2-yl)carbamate (14). (135.7 mg, 38%) 1H NMR
(400MHz, CD3OD) δ 7.22-7.28 (m, 5H), 6.61 (dd, J1=10.1, J2=12.4, 1H), 6.36 (d, J=17.4, 1H),
5.87 (d, J=11.4, 1H), 4.72 (m, 1H), 4.60 (s, 2H), 3.24 (dd, J1=5.5, J2=13.9, 1H), 2.87 (m, 2H).

4.4.6

H
N

O

O

O

18

prop-2-yn-1-yl ((4S,5S)-5-methyl-3-oxohept-1-en-4-yl)carbamate (18). (50.86 mg, 33%) Rf
(50:50 Hexanes:EtOAc) = 0.68. 1H NMR (400MHz, CDCl3) δ 6.4 (m, 1H), 6.3 (m, 1H), 5.8 (d,
1H, J=10.28), 5.4 (s, 1H), 4.6 (m, 3H), 2.4 (s, 1H), 2.0 (m, 1H), 1.3 (m, 2H), 1.2 (m, 1H), 0.9 (d,
3H, J=6.8), 0.8 (m, 3H). 13C NMR (100MHz, CDCl3) δ 198.3, 155.5, 133.9, 130.0, 78.1, 74.7,
62.4, 52.8, 37.6, 24.2, 16.1, 11.6.
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4.5 Synthesis of Remaining Single Amino Acid Analogues
4.5.1

O

H
N

O

OH

N
H

O

19

tert-butyl ((2S,3S)-1-((2-hydroxyethyl)amino)-3-methyl-1-oxopentan-2-yl)carbamate (19). (936
mg, 93.6%). To a dry reaction vessel add 841.9 mg of Boc-Ile-OH and 18.2 mL of anhydrous
DCM. To the solution at .85 mL NMM, 906.7 mg EDCI, 590.5 mg HOBt, and was allowed to
equilibrate for 15 minutes. To the reaction solution was added ethanolamine (0.26 mL) dropwise
over 1 minute. Solution allowed to react for 16 hr at ambient temperature. The crude product was
purified over silica gel chromatography to obtain the desired product. 1H NMR (400MHz,
CDCl3) δ 6.8 (s, 1H), 5.2 (s, 1H), 3.9 (t 1H, J1=7.08, J2=8.28), 3.7 (s, 2H), 3.4 (m, 2H) 3.3 (s,
1H), 1.8 (s, 1H), 1.5 (s, 1H), 1.4 (s, 9H), 1.1 (m, 1H), 0.9 (m, 6H).

4.5.2

H
N

O
O

O

O
N
H

N
O

tert-butyl((2S,3S)-1-((2-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)ethyl)amino)-3-methyl-1oxopentan-2-yl)carbamate (20). (93.33 mg, 31%). To a dry reaction vessel, add anhydrous THF,
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flush with argon, and cool to -78°C under argon. To the THF slowly add triphenyl phosphine
Ph3P and allow to equilibrate for 5 minutes. To the solution, slowly add diethyl azodicarboxylate
(DEAD) and allow to equilibrate for 5 minutes. To the solution, add 19 and allow to equilibrate
for 5 minutes. To the solution, add maleimide, stir, allow to reach ambient temperature, and let
react for 16 hrs. Solvent removed in vacuo. The crude product was purified over silica gel
chromatography to obtain the desired product.

1

H NMR (400MHz, CDCl3) δ 6.6 (s, 2H), 6.2 (s,

1H), 4.8 (m, 1H), 4.2 (s, 1H), 3.8 (m, 2H), 3.6 (m, 2H), 3.4 (s, 2H), 1.8 (s, 1H), 1.5 (s, 2H), 1.4
(s, 9H), 08 (m, 6H). 13C NMR (100MHz, CDCl3) δ 174.3, 171.0, 168.9, 134.4, 72.3, 67.1, 58.2,
38.1, 36.5, 24.7, 14.7, 11.5.

4.5.3

H
N

O

O
N
H

O

tert-butyl

SH

((2S,3S)-1-((2-mercaptoethyl)amino)-3-methyl-1-oxopentan-2-yl)carbamate

(21).

(102.93 mg, 51%). To a dry reaction vessel add 159.6 mg of Boc-Ile-OH and 3.45 mL of
anhydrous DCM. To the solution add 17 mL NMM, 172.5 mg EDCI, 112.1 mg HOBt, and was
allowed to equilibrate for 15 minutes. To the reaction solution was added cysteinamine (058.6
mg) slowly. Solution allowed to react for 16 hr at ambient temperature. The reaction mixture was
poured into cold 1N HCl, and extracted three times with ethyl acetate. The combined organic
layers were dried over anhydrous sodium sulphate and concentrated in vacuo. The crude product
was purified over silica gel chromatography to obtain the desired product. 1H NMR (400MHz,
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CDCl3) δ 6.3 (s, 1H), 4.9 (s, 1H), 3.8 (t, 1H J1=6.48, J2=8.52), 3.4 (m, 2H), 2.6 (m, 2H), 1.8 (s,
1H), 1.4 (s, 9H), 0.8 (m, 6H). 13C NMR (100MHz, CDCl3) δ 201.3, 171.8, 155.7, 65.2, 42.3,
39.3, 37.2, 28.3, 24.5, 15.8, 11.4.

4.5.4

H
N

O

O
N
H

O

tert-butyl

I

((2S,3S)-1-((2-iodoethyl)amino)-3-methyl-1-oxopentan-2-yl)carbamate

(22).

Procedure adapted from Helmboldt, H. et al.142 (37 mg, 27%) To a dry reaction vessel add
anhydrous DCM (1 mL), flush with argon, and cool to 0°C under argon. To the DCM slowly add
triphenyl phosphine (Ph3P, 99.6 mg) and allow to equilibrate for 5 minutes. To the solution
slowly add imidazole (25.9 mg) and allow to equilibrate for 5 minutes. To the solution slowly
add I2 allow to equilibrate for 15 minutes. To the solution add 19, stir, allow to reach ambient
temperature, and let react for 4 hrs. Solvent removed in vacuo. Taken back up in non polar
solvent and passed through celite. The crude product was purified over silica gel chromatography
to obtain the desired product. 1H NMR (400MHz, CDCl3) δ 6.4 (s, 1H), 5.0 (s, 1H), 3.9 (t, 1H
J1=2.4, J2=6.4), 3.6 (m, 1H), 3.5 (m, 1H), 3.2 (m, 2H), 1.8 (s, 1H), 1.4 (s, 9H), 0.8 (m, 6H). 13C
NMR (100MHz, CDCl3) δ 171.7, 155.8, 80.1, 59.5, 41.8, 37.0, 28.3, 24.8, 15.7, 11.4, 4.6.
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4.5.5
H
N

O

O
N
H

O

tert-butyl

Br

((2S,3S)-1-((2-bromoethyl)amino)-3-methyl-1-oxopentan-2-yl)carbamate

(23).

Procedure adapted from Bora, I. et al.143 (47.65 mg, 51%). To a dry reaction vessel add 0.5 mL of
DCM. To the DCM add 77.18 mg of 19. To the solution add 102.8 mg of CBr4. Cool to 0°C. To
the solution slowly add 81.3 mg of Ph3P over 20 minutes. Allow to react for 4hr. Pour solution
into excess hexanes and filter out the salt precipitate. Remove solvent in vacuo. The crude
product was purified over silica gel chromatography to obtain the desired product. 1H NMR
(400MHz, CDCl3) δ 6.7 (s, 1H), 5.1 (s, 1H), 4.0 (t, 1H J1=2.4, J2=6.4), 3.7 (m, 1H), 3.6 (m, 1H),
3.4 (m, 2H), 1.9 (s, 1H), 1.5 (s, 9H), 0.9 (m, 6H). 13C NMR (100MHz, CDCl3) δ 171.7, 155.8,
80.1, 59.5, 41.1, 37.1, 31.9, 28.3, 24.8, 15.7, 11.4.
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4.5.6

H
N

O

O
N
H

O

tert-butyl

Cl

((2S,3S)-1-((2-chloroethyl)amino)-3-methyl-1-oxopentan-2-yl)carbamate

(24).

Procedure adapted from Bora, I. et al.143 (55.72 mg, 68%). To a dry reaction vessel add 0.5 mL of
DCM. To the DCM add 77.18 mg of 19. To the solution add 47.7 mg of CCl4. Cool to 0°C. To
the solution slowly add 81.3 mg of Ph3P over 20 minutes. Allow to react for 4hr. Pour solution
into excess hexanes and filter out the salt precipitate. Remove solvent in vacuo. The crude
product was purified over silica gel chromatography to obtain the desired product. 1H NMR
(400MHz, CDCl3) δ 6.6 (s, 1H), 5.0 (s, 1H), 4.0 (t, 1H J1=2.4, J2=6.4), 3.7 (m, 1H), 3.6 (m, 1H),
3.4 (m, 2H), 1.9 (s, 1H), 1.5 (s, 9H), 0.9 (m, 6H). 13C NMR (100MHz, CDCl3) δ 171.7, 155.8,
80.1, 59.4, 43.6, 41.1, 37.1, 28.3, 24.8, 15.7, 11.4.
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4.6 Alternative Route to Chloromethyl Ketone.
4.6.1

N
H

Cl
OH

1-(benzylamino)-3-chloropropan-2-ol (25). Procedure adapted from patent US6362188.144
(1.75g, 88%) To a solution of benzylamine (1.08927g) in cyclohexane (1M, 10.17 mL) was
added epichlorohydrin (1 equivalent, 0.82 mL). The solution was allowed to react and precipitate
collected by vacuum filtration and wash with cold cyclohexane. Product taken directly to next
step.

4.6.2

N
O

Cl
O

OH

tert-butyl benzyl(3-chloro-2-hydroxypropyl)carbamate (26). Procedure adapted from Org. Lett
2010, 12, 2746-2749.145 (358.2 mg, 45%). To a solution of 25 in DCM (0.25M) was added 1
equivalent of Boc anhydride. The solution was allowed to react for 30 minutes and then the
solvent was removed in vacuo. The crude product was purified over silica gel chromatography to
obtain the desired product as a white crystalline solid. Spectral data matched previously
reported.146
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4.6.3

N
O

Cl
O

O

tert-butyl benzyl(3-chloro-2-oxopropyl)carbamate (27). Procedure adapted from JOC 2001, 66,
8661.146 (98 mg, quantitative). Swern oxidation: to a dry vial add anhydrous DCM (3.3 mL) at
-78°C. To the DCM add oxalyl chloride (0.03 mL). Seperately prepare a solution of DMSO in
DCM (1 mL). Add the DMSO solution to the oxalyl chloride solution slowly over 10 minutes.
Prepare a third solution of 26 in DCM (1 mL). Add the alchol containing solution to the mother
liqour dropwise over 10 minutes, stir for 20 minutes. Prepare a solution of excess TEA (4.5
equivalents) in DCM, and add dropwise. Stir for 30 minutes. Wash with H2O and extract with
DCM 3X. Collect organic layers and remove solvent in vacuo to produe product of sufficient
purity to move forward (one spot by TLC, RF = .77 in 70:30 EtOAc:Hexanes). 1H NMR
(400MHz, CDCl3) δ 7.2 (m, 5H), 4.5 (s, 1H), 4.5 (s, 1H), 4.1 (s, 1H), 4.08 (s, 1H), 4.0 (s, 1H),
3.9 (s, 1H), 1.4 (s, 9H). 146
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4.6.4

HN
O

Cl
O

O

tert-butyl (3-chloro-2-oxopropyl)carbamate (28). First attempt with Pd/C at atmospheric pressure
(H2) and ambient temperature did not produce any effect. The addition of PdOH/C (25% w/w)
did produce multiple spots. Only a small fraction was able to be recovered as pure product after
celite and silica column workup (~10%).

4.7 Diazomethane route to Chloromethyl ketones

4.7.1

H
N

O

O

O
O

O

O

(2S,3S)-2-((tert-butoxycarbonyl)amino)-3-methylpentanoic (isobutyl carbonic) anhydride (29).
Procedure adapted from J. Med. Chem 1995, 38, 1015-1021.127 To a dry round bottom flask was
added 12.5 mL of anhydrous THF. To the THF was added Boc-Ile-OH (1.15645g) and 1

	
  

165	
  

equivalent of NMM (0.55 mL). To the solution was added isobutylchloroformate (0.78 mL).
Crude used in next step.

4.7.2

O
Cl H 3N

Cl

(3S,4S)-1-chloro-4-methyl-2-oxohexan-3-aminium chloride (30). To the solution of 29 prepared
in the previous step was added a solution of diazomethane in ether (formed in situ with a
minidiazald kit according to manufacturers instructions). The solution was allowed to react for 5
hr and allowed to reach ambient temperature. Then the remaining diazomethane was quenched
with glacial acetic acid (~1 mL until no more bubbling occurred). The diazo intermediate was
isolated by silicia chromatography and then treated with 4 equivalents of HCl (4N in dioxane)
and allowed to react for 5 hrs. ~75% solvent removed under vacuum and the remaining was
tritutated with ether to crash out the product. 1H NMR (400MHz, CD3OD) δ 4.6 (s, 2H), 4.4 (s,
1H), 3.3 (s, 3H), 2.2 (m, 1H), 1.4 (m, 1H), 1.3 (m, 1H), 1.2 (d, 3H, J=6.88), 1.0 (m, 3H).
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4.7.3

H
N

O

O

O
O

O

O

2-((tert-butoxycarbonyl)amino)acetic (isobutyl carbonic) anhydride (31). Procedure adapted
from J. Med. Chem 1995, 38, 1015-1021.127 To a dry round bottom flask was added 12.5 mL of
anhydrous THF. To the THF was added Boc-Gly-OH (0.87590g) and 1 equivalent of NMM
(0.55 mL). To the solution was added isobutylchloroformate (0.78 mL). Crude used in next step.

4.7.4
O
Cl H 3N

Cl

3-chloro-2-oxopropan-1-aminium chloride (32). To the solution of 31 prepared in the previous
step was added a solution of diazomethane in ether (formed in situ with a minidiazald kit
according to manufacturers instructions). The solution was allowed to react for 5 hr and allowed
to reach ambient temperature. Then the remaining diazomethane was quenched with glacial
acetic acid (~1 mL until no more bubbling occurred). The diazo intermediate was isolated by
silicia chromatography and then treated with 4 equivalents of HCl (4N in dioxane) and allowed
to react for 5 hrs. ~75% solvent removed under vacuum and the remaining was tritutated with
ether to crash out the product. 1H NMR (400MHz, CD3OD) δ 4.6 (s, 2H), 4.2 (s, 2H), 3.3 (s, 3H).
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4.8 Synthesis of Rhodamine derivatives
4.8.1
O

N
O

O

O
N

O
33

N

3,6-bis(diethylamino)-9-(2-(((2,5-dioxopyrrolidin-1-yl)oxy)carbonyl)phenyl)xanthylium
(33): To a solution of rhodamine B (5.0 g, 10.44 mmol) and EDC (3.0 g, 15.66 mmol) in DCM
(250 mL) was added N-hydroxysuccinimide (1.3 g, 11.48 mmol). The reaction was stirred at
ambient temperature for 12 hr. Solvent was removed and the product was purified via flash
chromatography (silica DMC:MeOH 9:1). Yield 75.4% (4.3 g, 7.9 mmol). Analytical data (1H
NMR, 13C NMR, mass spec) matched the previously reported data.125

4.8.2

O
N

OH

O
N

N

O
34

9-(2-((3-carboxypropyl)(methyl)carbamoyl)phenyl)-3,6-bis(diethylamino)xanthylium (34):
To a solution of 33 (2.9 g, 5.29 mmol) and DIEA (2.7 g, 21.16 mmol) in I (52.9 mL) was added
4-methylaminebutyric acid hydrochloride (1.2 g, 7.94 mmol). The reaction was stirred at ambient
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temperature for 16 hr. Solvent was removed under vacuum and product was isolated by
extraction (H2O/CHCl3). The organic layers were combined, dried, and taken directly to next
step. Yield 87.5%. MS (MALDI) C32H40N3O4 calculated 542.3013 found 542.5626. Analytical
data (1H NMR, mass spec) matched the previously reported data.126

4.8.3

O
N

O

O
N

O

O
N
O

N

35

3,6-bis(diethylamino)-9-(2-((4-((2,5-dioxopyrrolidin-1-yl)oxy)-4-oxobutyl)(methyl)
carbamoyl)phenyl)xanthylium (35): To a solution of 34 (2.2 g, 4.00 mmol) and DCC (1.1 g,
5.2 mmol) in DMF (35 mL) was added N-Hydroxysuccinimide (0.5 g, 4.00 mmol). The reaction
was stirred at ambient temperature for 16 hr. The filtrate was collected then triturated with
diethyl ether, centrifuged, and solvent decant. The product, collected in the bottom of the
centrifuge tube as an oil, was taken to next step. Yield 85.6%. MS (MALDI) C37H43N4O6
calculated 639.3177 found 639.8263. 1H-NMR (400 MHz, CD3Cl): δ 7.98 (s, 1H), 7.65 (m, 2H),
7.52 (m, 1H), 7.34 (m, 1H), 7.22 (d, 1H J = 9.5 Hz), 6.94 (d, 2H J = 9.6 Hz), 6.76 (s, 2H), 3.61
(m, 8H), 3.27 (t, 2H J = 7.0 Hz), 2.92 (s, 3H) 2.85 (m, 6H), 2.17 (t, 2H J = 7.0 Hz), 1.29 (t, 12H J
= 7.0 Hz);
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C NMR (125 MHz, CDCl3): δ 172.27, 169.21, 168.51, 167.77, 162.51, 157.61,
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155.66, 136.16, 131.93, 130.03, 127.37, 114.04, 96.47, 53.85, 46.12, 42.22, 37.76, 36.45, 31.36,
27.90, 25.60, 21.39, 18.61, 17.31, 12.60.

4.9 General Protocol for Probe Assembly.
First Phase.

1.

Prepare the peptide on the synthesizer or manually (ensure removal of the the last Fmoc).

2. Prepare an appropriately sized solid-phase extraction (SPE) column with a stopcock (the
white end piece that fits on those plastic SPE columns nicely). If you are only using a portion
of your peptide (which I recommend but it is not necessary you can use all that you’ve made)
use one of the smaller SPE columns, however I prefer the ones that can hold >15 mL.
3. Add a stir bar.
4. Transfer the amount of peptide (still on resin) you wish to carry forward through the
synthesis (example: if you have 1 mol of peptide on resin and it’s in 1 mL of a mixture (mix
thoroughly), if you transfer 0.5 mL you will have transferred 0.5 moles).
5. Wash with DMF 5 times for 3 minutes each (use volumes appropriate to your SPE column, I
use ~ 5mL usually, with the stir bar on) to ensure no residual deprotection agent.
6. To the SPE column add 5 mL of DMF.
7. To the mixture add 10 equivalents of triethylamine.
8. To the mixture add 5 equivalents of your tag (in this case biotin-NHS).
9. Allow to react for 5 hours (you can let it go overnight but at your own peril as it is generally
completed after 5 hours and the resin is sensitive).
10. Wash with DMF 5 times for 3 minutes each.
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11. Wash with DCM 5 times for 3 minutes each (this removes all the DMF).

This completes the first phase of your probe synthesis. Next will be the soft cleavage from the
resin.

Second Phase.

1. Still in your SPE column. Treat your resin with 2% TFA in DCM for 2 minutes (2.5 mL,
there should be a visible reaction). Collect the flow through. Repeat one additional time
to ensure cleavage.
2. The resin should have turned black (or very dark in any case). If it is not, repeat step 1
from phase 2.
3. Remove deprotection cocktail under vaccum.
4. Weigh your sample (determine how many moles you have as well).

You have now produced a tagged portion of your peptide with a free C-terminal acid. Next you
will couple your electrophile.

Third Phase.

1. Take your peptide starting material up in DCM (5 mL).
2. To the solution add 20 equivalents of diispropylethylamine.
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3. To the solution add 3 equivalents of EDCI.
4. To the solution add 2 equivalents of HOBt.
5. Allow to solution to react for 15 minutes at RT.
6. To the solution add 4 equivalents of your electrophile (in this case it’s the HCl salt of Ilechloromethyl ketone).
7. Allow to react for at least 4 hours.
8. Monitor reaction by TLC in DCM:MeOH 90:10 until no change is observed.
9. Remove solvent under vacuum.
10. Run on combiflash. The default time for the column you select should be fine, the
columns have approximate weight ranges for your reference. Use DCM:MeOH gradient
0-30% MeOH over the course of the gradient. Do not exceed 30% MeOH if you can
avoid it.
11. You will have to check your fractions by MALDI to find your peptide (the MALDI
matrix solution is slightly acidic and may deprotect some of your peptide, watch for
deprotection peaks as well).
12. Collect appropriate fractions and remove solvent under vacuum.

You now have produced TAG-Peptide(protected)-Electrophile. Next is global deprotection and
purification.

Fourth Phase.

1. Weigh your sample.
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2. Prepare the deprotection cocktail: 95:2.5:2.5 TFA:TIS:H2O (10 mL is plenty for any size
application 0.2 mmol or less)
3. To your sample add the deprotection cocktail.
4. Stir for 4 hours.
5. Triturate with ether (abundant precipitate should form).
6. Spin down for 10 minutes on the Genevac (no vacuum!).
7. Decant off solution (save it until you confirm you have your product).
8. Dry the solid precipitate under vacuum.
9. Confirm by MALDI that you have successfully synthesized the probe before attempting
to purify it.
10. Take up your sample in as little DMSO as possible. Use the best DMSO you can find as
water and other contaminates will react with your electrophile. I keep a bottle in the
biolab, with the gel reagents, for such purposes you can use this but do not contaminate it
lest you plan to order more and wait.
11. The methods I have prepared on the HPLC will work for your biotinylated peptide (look
for “Prep Scale” Methods, “after deprotection” “isohold” in the methods section of the
HPLC software).
12. When considering how much to inject, it helps if you work out the math at how much you
could possibly recover per injection volume and the resolution you are obtaining (if your
product is more pure upfront this is easy). In short though, more is generally better and
you will just have to feel it out as it is a new compound.
13. Determine/confirm where the compound elutes by MALDI.
14. Collect the appropriate fraction(s).
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15. Remove sample under vacuum (Genevac allows for the most hands free approach, set to
HPLC and confirm that it is still running every so often).
16. Weigh your sample (and calculate the moles, it is a salt).
17. If you have enough; produce a 10 mM stock solution of your peptide and freeze it as soon
as possible.

4.9.1

2-Chlorotrityl
chloride resin
(Chem-Impex)

Cl
Cl

Iterative
Fmoc Solid Phase
Peptide Synthesis

H 2N Arg(Pbf)-Arg(Pbf)-Asn(Trt)-Ala

H
N

36

O
O
Me

Me

PKI(14-22)-2-Cl-trityl Resin Synthesis. 2-Chlorotrityl Chloride (2-CTC) resin preloaded with
Ile was purchased from ChemImpex (200-400 mesh, Catalog #03472). Peptide couplings were
carried out manually via standard Fmoc amino acid protection chemistry. Amino acids were

	
  

174	
  

activated

and

added

to

resin

with

(Benzotriazol-1-yloxy)tripyrrolidinophosphonium

hexafluorophosphate (PyBOP) and diisopropylethylamin (DIEA). The resin was swelled with
DCM (5 min) then DMF (5 min). All amino acids were added by the general procedure that
follows (with the exception of Arg, which underwent double couplings): Fmoc deprotection
(20% piperidine in DMF, 3 x 5 min), wash with DMF 3x, amino acid coupling (PyBOP,DIEA
0.1 M in DMF, 1 hr, X2 for Arg), wash with DMF 3x. After the final deprotection (Arg 22) with
20% piperidine in DMF, the resin-bound product was taken directly to the next step.

4.9.2

Et 2N

O

NEt 2

O
N
Me

H
N Arg(Pbf)-Arg(Pbf)-Asn(Trt)-Ala

H
N

O

O
OH
Me

Me

37

Rhodamine-PKI(18-22)-2-Cl-trityl Resin Synthesis. To the peptide on resin was added 35 (6
eq) and TEA (10 eq) in DMF (0.05 M of 35). The reaction was stirred for 3 h, washed with DMF
5x, then DCM 5x. The resin-bound product was taken directly to the next step. The Rhodaminepeptide bound to resin was cleaved under soft conditions with 2% TFA in DCM. Solvent
removed in vacuo. MS (MALDI) C103H132N15O16S2 calculated 1898.9418, found 1898.6289.
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4.9.3

Et 2N

O

NEt 2

O
N
Me

H
H
N Arg-Arg-Asn-Ala-Ile N

O
Cl

O

38

38. Rhodamine-PKI(18-22)-OH (0.05 mmol, 37) was taken up in DCM (5 mL). PyBOP (0.065
mmol), DIEA (0.2 mmol), and chloromethyl ketone 32 (0.065 mmol) were added to the solution.
The reaction was stirred for 16 h. Solvent was removed and the purified on a silica gel gravity
column, washed with DCM, and eluted with 20% MeOH/DCM. The solid was then globally
debrotected with 95:2.5:2.5 TFA:TIS:H2O (5 mL) for 1 hr. Then triturated with ether to afford
the crude product. Product purified on HPLC (95:5 to 75:25 H2O:ACN over 20 minutes). MS
(MALDI) C61H92ClN16O10 calculated 1243.6871, found 1244.1763.
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4.9.4

H 2N Gly-Arg(Pbf)-Thr(t-Bu)-Gly-Arg(Pbf)-Arg(Pbf)-Asn(Trt)-Ala-Ile-O

39
PKI(14-22)-2-Cl-trityl Resin Synthesis (39). 2-Chlorotrityl Chloride (2-CTC) resin preloaded
with Ile was purchased from ChemImpex (200-400 mesh, Catalog #03472). Peptide couplings
were carried out manually via standard Fmoc amino acid protection chemistry. Amino acids
were activated and added to resin with (Benzotriazol-1-yloxy)tripyrrolidinophosphonium
hexafluorophosphate (PyBOP) and diisopropylethylamin (DIEA). The resin was swelled with
DCM (5 min) then DMF (5 min). All amino acids were added by the general procedure that
follows (with the exception of Arg, which underwent double couplings): Fmoc deprotection
(20% piperidine in DMF, 3 x 5 min), wash with DMF 3x, amino acid coupling (PyBOP,DIEA
0.1 M in DMF, 1 hr, X2 for Arg), wash with DMF 3x, acetyl cap (pyridine:acetic anhydride
20:20, 0.15 M in DMF, 30 min). After the final deprotection (Gly 14) with 20% piperidine in
DMF, the resin-bound product was taken directly to the next step.
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4.9.5

Et 2N

O

NEt 2

O
N
Me

H
N Gly-Arg(Pbf)-Thr(t-Bu)-Gly-Arg(Pbf)-Arg(Pbf)-Asn(Trt)-Ala-Ile-OH
O

40

40. To the peptide on resin (39) was added 35 (6 eq) and TEA (10 eq) in DMF (0.05 M of 35).
The reaction was stirred for 3 h, washed with DMF 5x, then DCM 5x. The resin-bound product
was taken directly to the next step. The Rhodamine-peptide bound to resin was cleaved under
soft conditions with 2% TFA in DCM. Solvent removed in vacuo. MS (MALDI)
C134H181N22O24S3 calculcated 2578.2781, found 2578.9558.
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4.9.6

Et 2N

O

NEt 2

O
N
Me

H
H
N Gly-Arg-Thr-Gly-Arg-Arg-Asn-Ala-Ile- N
O

O
Cl

41

41. Rhodamine-PKI(14-22)-OH (0.05 mmol, 40) was taken up in DCM (5 mL). PyBOP (0.065
mmol), DIEA (0.2 mmol), and chloromethyl ketone 32 (0.065 mmol) were added to the solution.
The reaction was stirred for 16 h. Solvent was removed and the purified on a silica gel gravity
column, washed with DCM, and eluted with 20% MeOH/DCM. The solid was then globally
deprotected with 95:2.5:2.5 TFA:TIS:H2O (5 mL) for 1 hr. Then triturated with ether to afford
the crude product. Product purified on HPLC (95:5 to 75:25 H2O:ACN over 20 minutes). MS
(MALDI) C75H118ClN23O15 calculated 1615.8850 , [C75H118ClN23O15 + Na] calculated 1638.8748
found 1638.7704.
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4.10 Synthesis of Fluoromethyl Ketone
4.10.1

O

OH

N

F

O

2-(3-fluoro-2-hydroxypropyl)isoindoline-1,3-dione (42). Procedure adapted from ChemBioChem
2012, 13, 80-84.135 (1.34465g, 60%). To a round bottom flask add 10 mL DMF and 1.7596g of
potassium phthalamide. To the mixture add 1-chloro-3-fluoro-2-propanol (0.87 mL). Reflux for
16 hr. Triturate with ether, collect precipitate. The crude product was purified over silica gel
chromatography to obtain the desired product. 1H NMR (400MHz, CDCl3) δ 7.8 (m, 2H), 7.7 (m,
2H), 4.5 (m, 1H), 4.4 (m, 1H) 4.1 (m, 1H), 3.8 (m, 1.5H), 3.1 (s, 0.5H), 2.9 (s, 1H), 2.8 (s, 1H),
2.0 (s, 0.5H), 1.2 (m, 1H). HRMS (ESI) [C11H10FNO3 +H] calculated 224.0645, found 224.0716.

4.10.2

OH
H 2N

F

1-amino-3-fluoropropan-2-ol (43). Procedure adapted from ChemBioChem 2012, 13, 80-84.135
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To a solution of 42 (1.12g, 5 mmol) in MeOH (100 mL) was added hydrazine hydrate (0.23mL,
0.95 equiv to 42) and the reaction mixture was stirred at ambient temperature for 20h, during
which time a precipitate formed. Conc. aq. HCl (1mL of a 37% soln, 2 equiv to 42) was added
and the mass was stirred 3 hours. The precipitate was then filtered out. The MeOH was removed
in vacuo. Then 30 mL of water was added and then cooled to 0°C. Crude solution taken forward
to next step.

4.10.3

H
N

O

OH
F

O

(9H-fluoren-9-yl)methyl (3-fluoro-2-hydroxypropyl)carbamate (44). Procedure adapted from
ChemBioChem 2012, 13, 80-84.135 To the solution of 43 generated previously was added 10%
Na2CO3 (30 mL). To the solution was added 1.102g fmoc-chloride dissolved in 50 mL dioxane.
Solution allowed to reach 16 hr. Dioxane was removed under vacuum and crude product was
extracted with EtOAc. The organic layer was washed with saturated NaCl solution and solvent
removed in vacuo. The crude product was purified over silica gel chromatography to obtain the
desired product. 1H NMR (400MHz, CDCl3) δ 7.8 (d, 2H J=7.52), 7.6 (m, 2H), 7.4 (m, 2H), 7.3
(m, 2H), 4.4 (m, 2H), 4.1 (m, 1H), 2.9 (s, 4H), 1.3 (s, 2H). HRMS (ESI) [C18H18FNO3 +Na]
calculated 315.1271, 338.1161 (Na adduct) found 338.1172.
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4.10.4

H
N

O

O
F

O

(9H-fluoren-9-yl)methyl (3-fluoro-2-oxopropyl)carbamate (45). Procedure adapted from
ChemBioChem 2012, 13, 80-84.135 44 (81.33 mg, 0.26 mmol) was taken up in DCM (5 mL). To
the solution was added DMP (275.69 mg, 0.65 mmol). Reaction monitored by TLC to
completion. Solvent removed in vacuo. The crude product was purified over silica gel
chromatography to obtain the desired product. 1H NMR (400MHz, CDCl3) δ 7.8 (d, 2H J=7.52),
7.6 (m, 2H), 7.4 (m, 2H), 7.3 (m, 2H), 5.4 (s, 1H), 5.0 (s, 1H), 4.9 (s, 1H), 4.4 (m, 2H), 4.3 (s,
2H), 4.2 (m, 1H), 1.2 (s, 1H). 13C NMR (125 MHz, CDCl3): δ 202.2, 156.3, 143.9, 141.4, 127.9,
127.2, 125.0, 120.1, 84.1, 67.2, 48.2, 47.3. HRMS (ESI) [C18H16FNO3 +Na] calculated 313.1114,
336.1012 (Na adduct) found 336.1017.

4.10.5

Me 3Si

O

O

SiMe 3

2,2,5,5,8,8-hexamethyl-3,7-dioxa-2,8-disilanonane. To a round bottom flask was added 32 mL
diethylether. To the diethylether was added 2,2-dimethylpropane-1,3-diol (1g, 9.6 mmol). To the
solution was added 3.35 mL TEA (24 mmol). To the solution was added TMSCl over 5 minutes
and allowed to react for 16 hr at ambient temperature. White precipitate filtered off. Ether layer
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washed with water. Solvent removed in vacuo to afford pure product as a clear liquid. 1H NMR
(400MHz, CDCl3) δ 3.2 (s, 4H), 0.7 (s, 6H), 0.0 (s, 18H). 13C NMR (125 MHz, CDCl3): δ 68.5,
37.7, 22.0, 0.2.

4.10.6

H O
N

O

O

F

O

(9H-fluoren-9-yl)methyl

((2-(fluoromethyl)-5,5-dimethyl-1,3-dioxan-2-yl)methyl)carbamate

(46). Procedure adapted from ChemBioChem 2012, 13, 80-84.135 45 (61.24 mg, 0.20 mmol) was
taken up in DCM (7 mL). To the solution was added THS protected diol from previous step
(69.58 mg, 0.28 mmol). Solution cooled to 0°C. To the reaction was added TMSOTf (catalytic,
0.02 mmol). Reaction allowed to reach ambient temperature and equilibrate for 16 hr. Solvent
removed in vacuo. The crude product was purified over silica gel chromatography to obtain the
desired product. 1H NMR (400MHz, CDCl3) matched previously reported data.135 δ 7.8 (d, 2H
J=7.52), 7.6 (m, 2H), 7.4 (m, 2H), 7.3 (m, 2H), 5.4 (s, 1H), 5.0 (s, 1H), 4.9 (s, 1H), 4.4 (m, 2H),
4.3 (s, 2H), 4.2 (m, 1H), 1.2 (s, 1H). 13C NMR (125 MHz, CDCl3): δ 202.2, 156.3, 143.9, 141.4,
127.9, 127.2, 125.0, 120.1, 84.1, 67.2, 48.2, 47.3. HRMS (ESI) [C23H26FNO3 +Na] calculated
399.1846, 422.1744 (Na adduct) found 422.1751.
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4.10.7

H 2N

O

O

F

(2-(fluoromethyl)-5,5-dimethyl-1,3-dioxan-2-yl)methanamine (47). 46 (52 mg) was taken up in 3
mL ACN. To the solution was added 0.23 mL diethyl amine and reaction monitored by TLC.
Solvent removed under vacuum. Crude reaction mixture used as is in the following steps.
4.11 Synthesis of Remaining Peptide Probes.
4.11.1

Et 2N

O

NEt 2

O
N
Me

H
H
N Gly-Arg-Thr-Gly-Arg-Arg-Asn-Ala-Ile- N

O
F

O

48

Rhodamine-PKI(14-22)-OH (0.05 mmol, 40) was taken up in DCM (5 mL). PyBOP (0.065
mmol), DIEA (0.2 mmol), and fluoromethyl ketone 47 (0.065 mmol) were added to the solution.
The reaction was stirred for 16 h. Solvent was removed and the purified on a silica gel gravity
column, washed with DCM, and eluted with 20% MeOH/DCM. The solid was then globally
deprotected with 95:2.5:2.5 TFA:TIS:H2O (5 mL) for 1 hr. Then triturated with ether to afford
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the crude product. Product purified on HPLC (95:5 to 75:25 H2O:ACN over 20 minutes). MS
(MALDI) C142H195FN23O25S3 calculated 2737.3841, found 2737.3524.

4.11.2
O
HN

NH

O
O N

S

O
49

2,5-dioxopyrrolidin-1-yl

O

5-(2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl)pentanoate

(49).

Procedure adapted from JACS 2007, 129, 13987.138 To a round bottom flask add 17.2 mL DMF,
590 mg D-biotin (2.41 mmol), and 277 mg N-hydroxysuccinimide (2.41 mmol). To the mixture
add N,N′-Dicyclohexylcarbodiimide (DCC, 645 mg, 3.13 mmol). Heat until dissolved, stir then
allow to reach ambient T. Allow to react for 16 hr. Triturate with ether and collect precipitate.
Spectral data matched previously reported.138
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4.11.3
O
HN

NH
H
N Gly-Arg(Pbf)-Thr(t-Bu)-Gly-Arg(Pbf)-Arg(Pbf)-Asn(Trt)-Ala-Ile-OH

S
O

50

50. To the peptide on resin was added 49 (6 eq) and TEA (10 eq) in DMF (0.05 M of 35). The
reaction was stirred for 3 h, washed with DMF 5x, then DCM 5x. The resin-bound product was
taken directly to the next step. The Biotin-peptide bound to resin was cleaved under soft
conditions with 2% TFA in DCM. Solvent removed in vacuo. MS (MALDI) C111H157N21O23S4
calculated 2280.0644 [C111H157N21O23S4 + Na] calculated 2303.0542 found 2301.0534.

4.11.4

O
HN

NH
H
H
N Gly-Arg-Thr-Gly-Arg-Arg-Asn-Ala-Ile-N

S

O
F

O

51
Biotin-PKI(14-22)-OH (0.05 mmol, 50) was taken up in DCM (5 mL). PyBOP (0.065 mmol),
DIEA (0.2 mmol), and fluoromethyl ketone 47 (0.065 mmol) were added to the solution. The
reaction was stirred for 16 h. Solvent was removed and the purified on a silica gel gravity
column, washed with DCM, and eluted with 20% MeOH/DCM. The solid was then globally
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deprotected with 95:2.5:2.5 TFA:TIS:H2O (5 mL) for 1 hr. Then triturated with ether to afford
the crude product. Product purified on HPLC (95:5 to 75:25 H2O:ACN over 20 minutes). MS
(MALDI) C52H94FN22O14S calculated 1301.7008, found 1302.1126.

4.11.5

H 2N Aoc Gly-Arg(Pbf)-Thr(t-Bu)-Gly-Arg(Pbf)-Arg(Pbf)-Asn(Trt)-Ala-Ile-O

52

Aoc-PKI(14-22)-2-Cl-trityl Resin Synthesis (52).

2-Chlorotrityl Chloride (2-CTC) resin

preloaded with Ile was purchased from ChemImpex (200-400 mesh, Catalog #03472). Peptide
couplings were carried out automatically via standard Fmoc amino acid protection chemistry.
After the final deprotection (Aoc) with 20% piperidine in DMF, the resin-bound product was
taken directly to the next step.
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4.11.6
O
HN

NH
H
N Aoc Gly-Arg(Pbf)-Thr(t-Bu)-Gly-Arg(Pbf)-Arg(Pbf)-Asn(Trt)-Ala-Ile-OH

S
O

53

53. To the peptide on resin was added 49 (6 eq) and TEA (10 eq) in DMF (0.05 M of 35). The
reaction was stirred for 3 h, washed with DMF 5x, then DCM 5x. The resin-bound product was
taken directly to the next step. The Biotin-peptide bound to resin was cleaved under soft
conditions with 2% TFA in DCM. Solvent removed in vacuo. MS (MALDI) C119H172N22O24S4
calculated 2421.1798 found 2422.4553.

4.11.7
O
HN

NH
H
N

S

H
Gly-Arg-Thr-Gly-Arg-Arg-Asn-Ala-Ile-N

O
F

O

54

54. Biotin-Aoc-PKI(14-22)-OH (0.05 mmol, 53) was taken up in DCM (5 mL). PyBOP (0.065
mmol), DIEA (0.2 mmol), and fluoromethyl ketone 47 (0.065 mmol) were added to the solution.
The reaction was stirred for 16 h. Solvent was removed and the purified on a silica gel gravity
column, washed with DCM, and eluted with 20% MeOH/DCM. The solid was then globally
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deprotected with 95:2.5:2.5 TFA:TIS:H2O (5 mL) for 1 hr. Then triturated with ether to afford
the crude product. Product purified on HPLC (95:5 to 75:25 H2O:ACN over 20 minutes). MS
(MALDI) C60H109FN23O15S3+ calculated 1442.8162, found 1442.8860.
4.12 Biology Experimentals:
Overlap of Figure 43.
To overlap the gels, they were saved as .tiff files and inserted into a Microsoft Word
document. Once in the word document the transperancy of the images were adjusted so that both
could be observed when overlapped. By positioning the images such that the reference points in
the C199A mutant lanes were in line (lanes 7 and 8) immediately the predominant species was
identified as the bottom band. This is a curious find in that the upper band always had a more
robust signal intensity, but it is actually present in significantly less quantities than the lower
band. This leads into the hypothesis of the probe having significant isoform selectivity; however,
the differences between the two band at this point were unknown and further characterization
was required.

Overlap of Figure 46.
To overlap the gels, the fluorescence and Coomassie images were saved as .tiff files and
inserted into a Microsoft Word document. Then the transparency of the overlapping images was
adjusted such that both could be observed simultaneously. By positioning the images such that
the reference points in the BSA and PKACα were aligned the predominant species was again
identified as the bottom band. This spurred a return to the literature were this issue had
previously been reported. The two bands differ by phosphorylation at Thr197, the top band is the
phosphorylated form (pThr197) and the bottom is the non phosphorylated species.87,130,131 To
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confirm the new hypothesis that the double banding issue is the same reported in the literature,
recombinant PKACα was exposed to physiologically relevant phosphorylating conditions
detailed below.

Figure 47:
To examine the effect of phosphorylation of Thr197 on labeling with Rh-PKI(14-22)-G-(CMK)
recombinant PKACα was phosphorylated in vitro. To promote phosphorylation at Thr197, the
enzyme that performs this catalytic action in vivo (3-phosphoinositide-dependent protein kinase
1, PDK1) was purchased from Invitrogen. Recombinant PKACα was diluted to 0.1mg/mL in
MOPS buffer (50 mM MOPS, pH 7.4, 100 mM NaCl, 10 mM BME, 10 mM MgCl2, and 1 mM
ATP). To the solution of PKACα was added 6 μL of a 0.33 mg/mL solution of PDK1. The
resulting solution was allowed to react for 90 minutes at ambient temperature. After the reaction
was complete the solution was buffer exchanged back in to phosphate buffer solution (25 mM
PO4 pH 7.2, for labeling reactions). In Figure 47, the labeling characteristics of the probe were
examined against the wild-type recombinant PKACα and with recombinant PKACα that was
treated with PDK1. Both protein solution concentrations were determined by absorbance at 280
nM and diluted to 1 mg/mL in phosphate buffer (25 mM PO4 pH 7.2). Appropriate amounts of
protein were added to reaction vessels (epindorf tubes). The probe was made as a 10 mM stock
solution in DMSO and diluted accordingly for appropriate final concentrations in the gel
experiments. The gel was cast as 1.5 mm thick and the wells were a total volume of 20 μL. The
the samples were incubated with probe for 1 hr. The samples were quenched with a denaturing
sample buffer (made in house and detailed in the biological experimental section) and incubated
at 100°C for 5 minutes. The denaturing sample buffer contained a disulfide reducing agent
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(betamercaptoethanol, BME). Coomassie staining was performed with blue G250 in a
H2O/MeOH/AcOH solution, and destained with a H2O/MeOH/AcOH solution. Images of the
Coomassie stained gel were taken with a galaxy S4 smart phone camera (13 megapixels,
autofocus and default settings).

Bradford assay
Standard solutions of bovine serum albumin (BSA, provided in kit) were prepared at 0.5, 0.25,
0.125, 0.1, 0.05 mg/mL in 25 mM NaPO4 buffer pH 7.2. The BioRad Bradford assay reagent is
5X and must be diluted to 1X in H2O. A 96 well clear bottom plate from Greiner was used. To a
well was added 10 μL of analyte solution and 200 μL Bradford detection solution. The resulting
solution was allowed to incubate for 5 minutes. The absorbance was read on a FlexStation 3 at
595 nM. Absorbance values were graphed in excel and used to determine the concentration of
unknown (linear range of assay is from 0.05 to 0.5 mg/mL).
Preparation of Lysates
MCF7 Lysates. The MCF7 cell line was grown up in T75 flasks in RPMI buffer with 10% FBS
(no antibiotic present). Every second or third day (whichever time the cell line was 75%
confluent) they were passaged at 1:10. Once three consecutive T75 flasks were growing the
MCF7 cell line, they were grown to complete confluence and harvested and gently centrifuged
(1000 rpm for 4 minutes) into a pellet. The pellet was resuspended in 5 mL phosphate buffer (25
mM NaPO4, pH 7.2). The suspension was homogenized with a Dounce homogenizer and the
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debris removed by centrifugation (31,200 rpm for 45 minutes). Supernatant was decanted and
aliquoted. Protein concentration determined by Bradford assay.
Bradford Assay for MCf7 Cell Lysates:

BSA	
  Standard	
  for	
  MCF7	
  
2.5	
  
y	
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Figure 70. Bradford assay graph for MCF7 lysates.

Table 13. Results of Bradford assay for MCF7 cell lysates.

MCF7

Absorbance
0.9692

Concentration
(mg/mL)
0.077

Preparation of MDA-MB-231 Cell Lysates
MDA-MB-231 Lysates. The MDA-MB-231 cell line was grown up in T75 flasks in RPMI buffer
with 10% FBS, and 1% ampicillin. Every second or third day (whichever time the cell line was
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75% confluent) they were passaged at 1:5. Once four consecutive T75 flasks were growing the
MDA-MB-231 cell line, they were grown to complete confluence and harvested and gently
centrifuged (1000 rpm for 4 minutes) into a pellet, cell count was 2,820,000 (89.36% viable).
The pellet was resuspended in 3 mL phosphate buffer (25 mM NaPO4, pH 7.2) with 1X Rouche
Protease Inhibitor Cocktail and 1 mM EDTA. The suspension was homogenized with a Dounce
homogenizer and the debris removed by centrifugation (31,200 rpm for 45 minutes). Supernatant
was decanted and aliquoted. Protein concentration determined by Bradford assay.
Bradford Assay for MDA-MB-231 Cell Lysates:

BSA	
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Figure 71. Bradford assay graph for MDA-MB-231 cell lysates.

Table 14. Results of Bradford assay for MDA-MB-231 cell lysates.

MDA-MB231

	
  

Absorbance

Concentration (mg/mL)

1.2321

0.25
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Preparation of bovine heart lysates.
Bovine heart was obtained from a local butcher shop and immediately cut into equal 10 g
portions and the portions not being used were frozen. One 10g portion was submerged in
phosphate buffer (25 mM NaPO4, pH 7.2) with 1X Rouche Protease inhibitor cocktail with 1
mM EDTA. The tissue was homogenized with a tissue homogenizer and the debris removed by
sequential centrifugation (8,000 rpm for 30 minutes then 31,200 rpm for 45 minutes). The
soluble fraction was collected and aliquoted out. The concentration was determined by Bradford
Assay.

BSA	
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Figure 72. Bradford assay graph for bovine heart lysates.
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Table 15. Results from Bradford assay of bovine heart lysates.

Absorbance (0.1x)
Bovine heart lysates

0.7516

Concentration
(mg/mL)
0.25

Actual (mg/mL)
2.5

Preparation of mouse heart lysates.
Mouse hearts harvested from HEB6 mice were a generous gift from Dr. Jolene Windle. Intact
hearts were submerged in PBS buffer with Roche Protease Inhibitor at 1X concentration (at 0 oC)
immediately after harvesting. The tissue was homogenized with a tissue homogenizer on ice and
cellular debris removed by sequential centrifugation (8,000 rpm for 30 min, then 31,200 rpm for
45 min). The soluble fraction was collected and concentration determined by Bradford assay.

Figure 73. Bradford assay graph for mouse heart lysates.
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Table 16. Results from Bradford assay for mouse heart lysates.
Absorbance
(.01x)

Concentration
(mg/mL)

Actual
(mg/mL)

0.83945

0.26

26

Resolving gel (10%)

1 gel

2 gels

Water
Lower buffer
Glycerol
40% acrylamide
10% APS (freshly prep.)

3.20 ml
2.00 ml
0.80 ml (1.01 g)
2.00 ml
40 μl

6.40 ml
4.00 ml
1.60 ml (2.02 g)
4.00 ml
80 μl

Mouse Heart
Lysates

4.1 Gel Electrophoresis
Gel recipes:
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TEMED

10 μl

20 μl

Stacking gel

1 gel

2 gels

Water
Upper buffer
40% acrylamide
10% APS (freshly prep.)
TEMED

1.95 ml
750 μl
300 μl
30 μl
7.5 μl

3.90 ml
1.5 ml
600 μl
60 μl
15 μl

Lower buffer - 100 ml (pH 8.8)
Final conc.
1.5 M
0.40%

Component
Tris
SDS
Water
Adjust to pH 8.8 with HCl

M.W.
121.14
–
–

Amount (g)
18.171
0.4
–

Volume (ml)
–
–
q.s.

M.W.
121.14
–
–

Amount (g)
6.057
0.4
–

Volume (ml)
–
–
q.s.

Upper buffer - 100 ml (pH 6.8)
Final conc.
0.5 M
0.40%

Component
Tris
SDS
Water
Adjust to pH 6.8 with HCl

General Sample preparation procedure for gel electrophoresis
In vitro labeling of wild type and C199A PKACα. 2.0 mg of protein was diluted into 40 mL
PBS (25 mM NaPO4 pH 7.2), final concentration ~1.2 mM. The proteins were incubated with the
relevant concentration of probe for 1 hr. 10 mL of a 5x SDS-Page Sample buffer was added and
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separated on a 10% SDS-PAGE gel. Fluorescent imaging was performed on an Amersham
Imager 600 (AI600) instrument. The gel was then stained with Coomassie and imaged on the
AI600.

In vitro oxidation and labeling of wild type PKACα. 2.0 mg of protein was diluted into 40 mL
PBS (25 mM NaPO4 pH 7.2), final concentration ~1.2 mM. Wild type PKACα was incubated
with 2 mM Ellman’s reagent for 1 and 4 hours. The oxidized and non-treated proteins were then
incubated with 300 nM probe for 1 hr. 10 mL of a 5x SDS-Page Sample buffer was added and
separated on a 10% SDS-PAGE gel. Fluorescent and Coomassie imaging was performed on an
AI600 instrument.

In vitro saturation of labeling of wild type PKACα. 2.0 mg of protein was diluted into 40 mL
PBS (25 mM NaPO4 pH 7.2), final concentration ~1.2 mM. Wild type PKACα was incubated
with increasing concentrations of PKI(14-22)Amide for 1 hr. The treated and non-treated
proteins were then incubated with relevant concentrations of probe for 1 hr. 10 mL of a 5x SDSPage Sample buffer was added and separated on a 10% SDS-PAGE gel. Fluorescent and
Coomassie imaging was performed on an AI600 instrument.

In vitro labeling of mouse heart lysates. Lysates were diluted in 1X protease inhibitor cocktail
to a concentration of 2.5 mg/mL, with or without cAMP at 100 mM and with or without Probe at
300 nM for 1hr. The resulting proteome solution was concentrated to 25 mg/mL with a 10 kDa
molecular weight cut off spin filter. 10 mL of a 5x SDS-Page Sample buffer was added and
separated on a 10% SDS-PAGE gel. Fluorescent imaging was performed on an Amersham
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Imager 600 instrument. The gel was then transferred to a PVDF membrane and bands detected
by colorimetric HRP reaction with a T197 specific rabbit antibody, image taken on AI600
instrument.

In vitro labeling of bovine heart lysates. Lysates were diluted in 1X protease inhibitor cocktail
to a concentration of 2.5 mg/mL, with or without cAMP at 100 mM and with or without Probe at
300 nM for 1hr. The resulting proteome solution was concentrated to 25 mg/mL with a 10 kDa
molecular weight cut off spin filter. 10 μL of a 5x SDS-Page Sample buffer was added and
separated on a 10% SDS-PAGE gel. Fluorescent imaging was performed on an Amersham
Imager 600 instrument. The gel was then transferred to a PVDF membrane and bands detected
by colorimetric HRP reaction with a T197 specific rabbit antibody, image taken on AI600
instrument.

In vitro labeling of MCF7 lysates. Lysates were used at the concentration harvested, with or
without cAMP at 100 mM and with or without Probe at 300 nM for 1hr. The resulting proteome
solution denatured with 10 μL of a 5x SDS-Page Sample buffer and separated on a 10% SDSPAGE gel. Fluorescent imaging was performed on an Amersham Imager 600 instrument. The
gel was then transferred to a PVDF membrane and bands detected by colorimetric HRP reaction
with a T197 specific rabbit antibody, image taken on AI600 instrument.

In vitro labeling of MDA-MB-231 lysates. Lysates were used at the concentration harvested,
with or without cAMP at 100 mM and with or without Probe at 300 nM for 1hr. The resulting
proteome solution denatured with 10 μL of a 5x SDS-Page Sample buffer and separated on a
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10% SDS-PAGE gel. Fluorescent imaging was performed on an Amersham Imager 600
instrument. The gel was then transferred to a PVDF membrane and bands detected by
colorimetric HRP reaction with a T197 specific rabbit antibody, image taken on AI600
instrument.

Gel Electrophoresis
1) Cast the gel (add reagents in order listed in recipe, TEMED starts the solidifying
reaction)
2) Prepare the electrophoresis setup
3) Prepare the samples
4) Prepare the sample buffer, add 0.1x volume of BME to the amount of sample buffer
required (10uL per well, calculate for a few extra ie. 7 wells you should make 100uL of
buffer)
5) Denature the Samples with 5x Sample Buffer (10uL to 40uL for a total of 50uL)
a. 5minutes at 100oC
6) Spin the samples in microcentrifuge for 30 seconds to collect all volume at bottom
7) Load 40uL of the denatured sample into respective lanes on the gel (50 is max but it does
not all fit properly)
8) Load 2uL undiluted Ladder to lane(s)
9) Place top of gel electrophoresis chamber on
10) Turn on the instrument
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11) Set to constant voltage of 170, for 60 minutes

Western Blot:
Transfer to membrane
1) Collect the gel and wash with tap water 5x, leave in Petri dish submerged in water until
needed
2) Submerge membrane in MeOH for 3 minutes
3) Prepare 1L of transfer buffer (see buffer bottle for dilution instructions)
4) Submerge filter paper and fiber pads in transfer buffer
5) Decant MeOH off the membrane and then immediately submerge in transfer buffer (do
not let dry, if it does and you see white spots, repeat step 2)
6) Follow the setup depicted for the Western blot (ie black side of cartridge down, then in
this order: Fiber pad, filter paper, gel, membrane, filter paper, fiberpad)
7) Place second cartridge into the electrophoresis chamber and fill chamber up with
remaining buffer
8) Place cold pack into electrophoresis chamber
9) Top off chamber to Western blot line with buffer (or water if only a small amount is
required)
10) Set to constant 100 mAmps and run for 60 minutes
Protein Detection (for colorimetric only, for ECL see manufacturer instructions)
1) Collect the membrane and submerge in blocking buffer (5% BSA) for 1hr.
2) Decant blocking buffer off
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3) Incubate with primary antibody for 2hrs (dilute antibody 1:1000 in blocking buffer,
10mL total)
4) Wash with TBS 5x
5) Incubate with secondary antibody for 1hr (dilute antibody 1:1000 in blocking buffer,
10mL total)
6) Wash 5x with TBS
7) Leave submerged in TBS until ready for staining
8) Prepare colorimetric staining solution according to BioRad specifications (ie 9 mL of
H20, 1 mL of 10x buffer, 60 uL of reagent B; then right before adding to membrane 2
mL reagent A)
9) Allow to develop until color change stops
10) Quench with tap water and let dry
11) Image on gel imager
General Procedure for the trypsin digest mass spectrometry
Unmodified PKACα or PKACα incubated with probe was buffer exchanged into a lysis buffer
(25 mM Tris pH 7.6, 1 mM EDTA, 150 mM NaCl, 1% Triton X-100, 0.1% SDS, and 10 mM
DTT). The protein solution was mixed with trypsin at a ratio of 20:1 protein to protease. The
resulting solution was incubated at 37oC for 24 hr. The sample was analyzed by MALDI mass
spectrometry with CHCA matrix (Sigma) on a Voyager DE-ProTM MALDI TOF Mass
Spectrometer.
Procedure for Biotin Pull-Down Experiment.
Streptavidin column and buffers were purchased from BioRad as a complete kit. The column
was washed with biotin solution to block all irreversible binding sites prior to usage. Subsequent
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reactivation of the streptavidin column (stripping of reversible binding sites) with acidic buffer
was then performed according to manufacturers instructions, followed by neutralization with
supplied PBS. Then, 1 mL of mouse heart lysates was incubated with the streptavidin resin for
45 minutes. The lysate solution was eluted with PBS and the appropriate fractions were collected
(determined by absorbance at 280 nm on spectrophotometer). The collected fractions were
pooled and diluted to a final volume of 10 mL with 25 mM PO4 buffer with 1X Rouche Protease
inhibitor cocktail and 1 mM EDTA. To the resulting solution was added biotinylated probe and
allowed to react for 1 hr. The solution was then incubated with the streptavidin column for an
additional 45 minutes. The column was washed with PBS until no absorbance was detected on
the spectrophotometer. Then biotinylated compounds were eluted with a 2 mM biotin solution
provided in the kit. The appropriate fractions were collected (as determined by absorbance at 280
nM) and pooled. Gel electrophoresis experiments and Western blots were conducted to confirm.
Procedure for generation of plasmids
Initial cultures for plasmid isolation were grown up in 10 mL LB buffer at 37 °C for 16 hr with
gentle shaking. The plasmids were collected with a QIA prep Spin miniprep kit w/ centrifuge
according to manufacturers instructions as follows:
1) cell centrifuged to a pellet and solution decanted (1600xG 5 min)
2) cells taken up in 250μL Buffer P1 and transferred to an epindorf tube
3) to the solution was added 250 μL buffer P2 and inverted 5 times (solution turns blue)
4) to the solution was added 350 μL of Buffer N3, inverted 5 times (precipitate forms)
5) centrifuge for 10 minutes at 17,900xG for 3 minutes
6) decant solution into QIA prep spin column
7) centrifuge for 1 minute and discard flowthrough
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8) Add 500 μL of Buffer PB and centrifuge for 1 minute, discard flowthrough
9) Add750 μL of Buffer PE centrifugre for 1 minute, discard flowthrough
10) Centrifuge an additional time for 1 minute and discard flowthrough
11) Place QIAPrep column in new (clean) epindorf tube
12) Add 50 μL Buffer EB and let equilibrate for 1 minute
13) Centrifuge for 1 minute
14) Collect flowthrough and freeze

Procedure for prep scale production of proteins (by day)
Day 1: Initial culture.
To a sterile test tube add 5 mL of LB media (solution of tryptone, yeast extract, and NaCl) with
amp or kan (for dual expression use both antibiotics) selection. Cells directly from the -80 °C
were added, without freezing and as small amount as could be reliably harvested (a pipette tip
was used to scratch the surface of the frozen cells and the end submerged in the test tube media).
Incubated at 37 °C with gentle shaking for 16 hrs.
Day 2: Scale up from initial culture.
Prepared 1 L vessels for growing by adding auto induction media to each (1 L amount) and
autoclaving. To the auto induction media add 20 mL of 50x glyceral, glucose, lactose solution, 1
mL of 1 M MgCl2 salt, and 1 mL of amp solution (50 mg/mL) (and kan solution for dual
expression). From the initial culture on the previous day, extract 1 mL and add to the auto
induction media that has been treated to promote growth. Incubate at 37 °C for 16 hr with gentle
shaking.
Day 3: Isolation and Purification.
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Collect media and spin down at 6000 rpm for 10 minutes. Collect cells in minimal amount of
solvent you wish to lyse into (PBS is fine, but solvent for the Ni column is preferred). Lyse cells.
Spin lysates for 30 minutes at 20,000 RPM to remove debris. Decant onto activated nickel
column. Wash with 1 mM imidazole solution until no absorbance detected. Elute with 100 mM
imidazole. Collect appropriate fractions.

Procedure for moving PDK1 into pRSF Duet vector.
PDK1 initially in pMCSG10 vector and the plasmid was isolated as described above. The pRSF
duet vector (kan resistance) plasmid was simultaneously isolated in the same manner. To a micro
centrifuge tube was added: 10 μL of PDK1 Plasmid, 2 μL Green buffer, 1 μL BglII, 1 μL NdeI,
and 6 μL H2O. To a separate micro centrifuge tube was added: 10 μL of pRSF Plasmid, 2 μL
Green buffer, 1 μL BamHI, 1 μL NdeI, and 6 μL H2O. Digested at 37 °C for 30 minutes. The
resulting solutions were run on agarose gel that was made in house (50 mL stock Tris Acetate
EDTA (TAE) in H2O, 0.5 g agarose, bring to boil then add 5 μL ethidium bromide and pour onto
plate after solution has slightly cooled). Gel was run at 100 V for ~45 minutes with obersvation
until adequate separation for isolation had occurred. Bands excised with scalpel. The appropriate
excised gel fragments were placed in an epindorf tube with a solution of 1:3 isopropanol:buffer
QG (100 mg gel = 100 μL volume). Incubate at 50 °C for 10 minutes (or until dissolved).
Transfer to QIAquick spin column and spin for 1 minute, discard flowthrough. Add 0.5 mL
buffer QG, spin 1 minute, discard flowthrough. Add 0.75 mL buffer PE incubate for 5 minutes,
spin 1 min, discard flowthrough. Spin down an additional 1 minute and discard flowthrough.
Move QIAquick column to a 1.5 mL centrifuge tube and add 30 μL of elution buffer allow to
equilibrate for 1 minute. Spin for 1 minute and collect flowthrough. To a fresh microcentrifuge
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tube add 17 μL DNA mixture, 2 μL of ligation buffer, 1 μL ligase and incubate at room temp for
30 minutes. Competent scarab cells were transformed with the resultant mixture as follows:
200 μL of competent scarab cells were thawed from the -80 °C freezer. To the cells was added
10 μL ligation mixture. Cells made to sit in ice for 30 minutes. Heat shock at 42 °C in water bath
for 1 minute. Plate onto antibiotic plate. Incubate at 37 °C overnight.
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